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Abstract
IV
The unrestrained growth of many cancers is maintained by autocrine and paracrine
loops of neuropeptide growth factors. These growth factor loops present an
important target for therapeutic intervention. Analogues of Substance P are currently
undergoing clinical trials as potential novel therapies for small cell lung cancer
(SCLC). Such analogues have been shown to inhibit mitogenic signal transduction
by a range of neuropeptides, acting in a broad spectrum manner. They inhibit the in
vitro growth of cancer cells within a physiologically obtainable concentration range
and are also capable of inhibiting the growth of tumour xenografts in nude mice.
They also stimulate apoptosis in vitro.
This study explores the range of tumour types which are sensitive to substance P
analogues. It was found that a wider range of tumour types than had been previously
demonstrated were sensitive to growth inhibition by the substance P analogue,
[D-Arg6,D-Trp7'9,NmePhe8]-Substance P (6-11) (antagonist G). Sensitive tumour
types included SCLC, NSCLC, colo-rectal and ovarian tumour cell lines with a mean
IC50 value of 33pM for 11 tumour cell lines of various origins. The mechanism of
action of the growth inhibitory effects of substance P analogues is unclear. Using
RT-PCR this study shows that sensitivity of tumour cell lines to antagonist G is
dependent upon the expression of neuropeptide receptors, in particular the bombesin
/ gastrin releasing peptide receptor, and not dependent on tumour type. This is
confirmed by the demonstration of increased sensitivity of Rat-1 fibroblasts
transfected with the bombesin receptor when compared to the parent cell line.
V
Substance P analogues have been previously thought to act as neuropeptide receptor
antagonists but more recently they have been shown to have some agonist effects
including the activation of c-Jun -N-terminal kinase (JNK). Further studies using
fibroblast cell lines transfected with the bombesin receptor show that substance P
analogues are potent activators of MAPK and that this occurs via activation of the
bombesin / GRP receptor. It was found that the substance P analogue [D-Arg',D-
Phe5,DTrp7'9,Leun]-substance P (6-11) (antagonist D) inhibits bombesin stimulated
calcium flux by preventing the activation of Gq stimulated downstream effectors and
preferentially activates Gi downstream effectors, resulting in MAPK activation. It is
demonstrated that MAPK activation by antagonist D is integral in the pro-apoptotic
effects of this compound. Thus, the combined effects of substance P analogue
stimulated, discordant MAPK and JNK activation, together with the inhibition of
neuropeptide stimulated calcium flux, results in growth inhibition and apoptosis in
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1.1 Neuropeptide Signal Transduction.
The regulation of normal cell proliferation is central to many physiological
processes, including embryogenesis, growth and development, haemopoeisis,
tissue repair and immune responses. Cell proliferation is controlled by a plethora
of growth factors as well as cellular interactions with extracellular matrix
proteins in their immediate environment. Differentiated cells are generally
maintained in a non-proliferating state but can be stimulated by external factors,
to undergo mitosis.
Cancer cells are able to override the normal signals from their surrounding
environment, and acquire complete or partial independence from mitogenic
control signals through different mechanisms(Westermark and Heldin, 1991;
Cross and Dexter, 1991). This process of transformation from a normal cell to a
cancer cell and finally to a cancer cell which is able to metastasise, is a multi-step
process. Tumour cells are characterised by many mutations which are found to
accumulate as the cancer progresses. These mutations appear to occur
sequentially and often, but not always, involve tumour suppressor genes and
oncogenes. They can occur spontaneously or as a result of exposure to mutagens.
In lung cancer, frequent mutations include the genes for the oncogene myc,
tumour suppressor protein p53, retinoblastoma protein and the cell cycle inhibitor
pl6,NK (for review see, Braithwaite et al, 1999).
Several cancer cell types can produce growth factors that stimulate unrestrained
growth via receptors present on the same cells (autocrine) or on adjacent cells
(paracrine). This hypothesis is supported by the observation that cancer cells
require fewer exogenous growth factors than normal cells and are able to
proliferate in serum free medium. Cancer cells may escape normal regulatory
controls by alterations in the number or structure of cellular receptors and
changes in the activity of post-receptor signalling pathways. (Seger, 1989). This
is supported by the discovery of increasing numbers of oncogenes coding for
growth factors, their receptors and post-receptor signalling molecules.
Thus, increased understanding of the growth factors and signal transduction
mechanisms which mediate cancer cell growth and the development of drugs that
can inhibit these processes are vital if we are to succeed in controlling the
disease.
It has become apparent that cell proliferation can be stimulated through multiple,
independent signal-transduction pathways which act synergistically (Rozengurt,
1986). At least two major growth factor mediated signal transduction pathways
initiate cascades of molecular events leading to proliferation of cultured cells:
one involves polypeptide growth factors that bind to receptors with intrinsic
tyrosine kinase activity while the other involves receptors coupled to guanine
nucleotide binding regulatory proteins (G-proteins). The two pathways are
subject to considerable cross talk and transactivation of one pathway by another
is a frequent phenomenon.
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1.1.1 Neuropeptides
In recent years an increasing number of small regulatory peptides or
neuropeptides have been discovered in the neural and neuroendocrine cells of the
gastrointestinal tract and central nervous system (Walsh, 1987). In the central
and peripheral nervous system they are synthesised and stored in presynaptic
neurones and act as fast acting neurotransmitters, while in peripheral
neuroendocrine cells they act both systemically as hormones circulating through
the blood stream and locally in a paracrine or autocrine fashion. Multiple
peptides are found in both neuronal and endocrine cells, and can modulate each
other's effects, e.g. bombesin/gastrin-releasing peptide (GRP), stimulates the
release of other biologically active peptides and galanin inhibits GRP induced
insulin release from the pancreas. The role of these peptides as fast-acting neuro-
hormoral signallers has been expanded by the discovery that they also stimulate
cell proliferation (Zachary et ah, 1987; Rozengurt, 1991). In addition, these
neuropeptides are increasingly implicated as growth factors in human cancer.
Consequently, it is very important to understand in detail the receptors and signal
transduction pathways that mediate the mitogenic action of neuropeptides
because they may provide novel targets for therapeutic intervention.
Swiss 3T3 cells are mouse embryonic fibroblasts that have been used as a model
system to identify the molecular pathways by which neuropeptides stimulate
mitogenesis. These cells readily become quiscent (G]/G0 phase of the cell cycle)
and can be stimulated by serum or mitogenic factors, to reinitiate DNA synthesis
and cell division. Much of the early work of screening neuropeptides for growth
promoting activity was carried out in these cells. The list of neuropeptides that
can act as mitogens has now grown considerably and includes bombesin, gastrin
releasing peptide, galanin, gastrin, cholycystokinin, bradykinin, endothelin and
vasopressin (Woll and Rozengurt, 1989a; Rozengurt, 1990; Rozengurt and
Sinnett-Smith, 1990; Sethi et al., 1992).
1.1.2 G protein couped receptors
Neuropeptides signal via G-protein coupled receptors (GPCRs). Approximately
1-2% of coding regions in the mammalian genome belongs to the superfamily of
G protein coupled receptors (GRCRs) (reviewed in (Probst et al., 1992)). This
family consists of three major sub-types; receptors related to the rhodopsin
receptor (Type A), receptors related to the calcitonin receptor (Type B) and
receptors related to the metabotrophic receptors (Type C). Of these, the
rhodopsin family is the largest and includes (3-adrenergic receptors, dopamine
receptors, seratonin receptors and receptors for several other neuropeptides.
These receptors couple to, and transduce signals via, heterotrimeric GTP binding
proteins. The predicted protein structures contain seven stretches of 20-30
hydrophobic amino acids, which are believed to form membrane spanning a-
helices. These helices are referred to as transmembrane domains 1-7 (TM1-7).
The proteins have extracellular amino termini and cytoplasmic carboxyl termini
(Fig 1.1).
The areas of greatest homology among the GPCRs are in the seven
transmembrane regions. Proline residues in TM 4, 5, 6, and 7 introduce kinks in
the a-helices and may be important in the formation of the binding pocket.
Overall there is little sequence homology among the receptors in the first
extracellular domain. However, GPCRs have single conserved cysteine residues
in each of the first two extracellular loops that are believed to form a disulphide
bond that stabilises the functional protein. The resulting structure is represented
in figure 1.2. Different sub-classes of GPCRs bind ligand by different
mechanisms, but it seems that all involve the ligand interacting with a binding
pocket which is created due to the specific three dimensional arrangement of the
receptor protein within the plasma membrane.
Fig 1.1 Schematic representation of the structure of a G protein coupled receptor. The
receptor consists of a single polypeptide chain containing 7 hydrophobic a-helices, which create
7 membrane spanning segments (TM1-7). The remainder of the polypeptide consists of four
intracellular, cytoplasmic loops and three extracellular loops. The receptors have an extracellular
N-terminal and an intracellular C-terminal.
Fig 1.2 Schematic representation of the 3D structure of a GPCR receptor.
The conformation of the 7 transmembrane domains within the membrane provides a binding
pocket for peptide ligand interaction.
The endogenous ligands for many GPCRs are peptides. Catecholamines and
related biogenic amines are small molecules that bind primarily within the
transmembrane domain of their receptors (Strader et al., 1995) but peptide
ligands are considerably larger and it is thought that their binding sites may
involve extracellular domains in addition to the transmembrane region. Site
directed mutagenisis of the substance P (NK1) and bradykinin receptors has
revealed that the binding site involves residues of both the extracellular and
transmembrane regions (Fong et al., 1992). Electrostatic forces between specific
receptor residues and peptide ligands are thought to initially attract the ligand
towards the receptor, thus increasing the effective concentration of ligand and
therefore increasing the binding probability. Additional interactions occur upon
ligand binding and together result in high affinity interaction of the ligand to
GPCR. The binding of an agonist to a GPCR, results in a conformational change
in the receptor, leading to the formation of a high affinity agonist-receptor-G-
protein complex which initiates downstream signalling.
Agonists induce conformational changes upon their receptors. It has been
proposed that receptor activation involves protonation of amino acid residues. In
many GPCRs, a highly conserved Arg resides in a hydrophilic pocket formed by
TM1,2 and 7. The protonation of an Asp residue causes Arg shift out of the
pocket leading to the exposure of G-proteins, to previously buried sequences in
the second and third intracellular loops. This hypothesis has been backed up by
both experimental data and computer simulations (Scheer and Cotecchia, 1997).
In several receptor types it is apparent that GPCRs are maintained in an inactive
conformation by stabilising intramolecular interactions. It has been proposed that
important conformational restraints maintain the receptor in an inactive state and
that these constraints are released upon agonist binding causing key sequences to
be exposed to the G -protein. There are several theories to further explain the
mechanics of agonist activation of GPCRs. Perhaps the most widely accepted is
the ternary complex model, which accounts for co-operative interactions between
agonist, receptor and G-protein (De Lean et ah, 1980). The model proposes that
a receptor can exist in an equilibrium of functionally distinct states inactive R,
which does not interact with G-proteins, and active R*, which activates G
proteins and initiates signalling events. The level of basal receptor activity, in the
absence of ligand is determined by the equilibrium between R and R*. The
efficacy of ligands is determined by their ability to alter this equilibrium.
Agonists bind to and stabilise the R* form of the receptor, thus increasing its
presence, whereas antagonists bind to and stabilise R, thus reducing the
formation of R* (Fig 1.3).
Figl.3 Ternary complex model of GPCR activation.
Receptors exist in equilibrium between inactive R and active R*. Agonists (A) bind to and
stabilise R* allowing increased interaction with G-Proteins. Antagonists (Ant) bind to and
stabilise R, decreasing interactions with G-Proteins.
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1.1.3 G-PROTEINS
G proteins constitute a large family of highly homologous proteins. The proteins
are heterotrimers consisting of a-, (3- and y-subunits. The a-subunit appears to
be the most diverse and has traditionally been used to define the purified
heterotrimeric proteins. The a-subunit can often account for the primary activity
of the G protein. Thus Gsa stimulates adenylate cyclase and transducin a (Gta)
activates a cyclic GMP-dependent phosphodiesterase. The Gj proteins were
identified as inhibitory regulators of adenylate cyclase. More recently, the Gj and
G0 proteins have been implicated in the regulation of several ion channels and Gi
has been associated with activation of MAPK pathways and tyrosine kinase
pathways. The Gt, Gi and G0 proteins are substrates for pertussis toxin induced
ADP-ribosylation; attenuation of hormone action by this toxin implicates the
participation of one or more of these proteins. In the basal state the a-subunit
contains bound GDP, and association of a- and Py-subunits is highly favoured.
Stimulation of the G protein results when it binds GTP rather than GDP.
Receptors interact most efficiently with the heterotrimeric form of the G protein
and accelerate activation by increasing the rate of dissociation of GDP and
potentially enhancing association of GTP. When activated, the affinity between
the a and Py-subunits of the G protein is decreased. This increases the likelihood
of dissociation of subunits and the generation of two potential pathways (a(GTP)
and free Py-subunits) for downstream regulation. Finally, the G protein a-
subunit has an intrinsic hydrolytic activity that converts GTP to GDP and returns
the G protein to it's inactive form (Fig 1.4)
A mutation has been characterised that interrupts this GTP-driven cycle in the a-
chain of Gs, the G-protein that stimulates adenyl cyclase. The mutation inhibits
GTPase activity and results in a constitutively activated adenyl cyclase mediated
cyclic adenosine monophosphate (cAMP) production. These mutations are
commonly found in growth hormone secreting pituitary adenomas (Landis et al.,
1989).
GDP
Fig 1.4 Schematic Representation of the Activation of G-proteins by Ligand-Bound
Receptor.
A) Without agonist stimulation the receptor state favours no interaction with the G-protein.
B) Binding of the agonist (A) induces a conformational change in the receptor which presents
previously unexposed residues to the G-protein and promotes G-protein receptor coupling.
C) This event promotes the catalytic exchange of GDP for GTP on the a subunit of the G-protein
and results in the dissociation of the heterotrimer into a and (3/y subunits. The free subunits can
then interact with various downstream effectors.
D) Intrinsic GTPase activity of the a subunit reverts the a subunit back to its GDP bound form
and promotes re-association of the heterotrimer.
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1.1.4 BOMBESIN
As discussed, studies in murine Swiss 3T3 fibroblasts have identified many
neuropeptides as mitogens. Neuropeptides have been shown to stimulate colony
formation in semi-solid media and can induce DNA synthesis and mitogenic
signal transduction in various cell types.
The first neuropeptide to be identified as a mitogen was bombesin/GRP. GRP
has 9/10 N-terminal amino acids identical to bombesin. Studies with synthetic
bombesin-like peptides have demonstrated that full biological activity requires
more than 7 but no more than 9 N-terminal amino acids (Heimbrook et al., 1988).
Further bombesin-like peptides have been isolated from porcine brain and spinal
cord, designated neuromedins (Table 1.1). The human GRP gene is located on
chromosome 18 at 18q21 (Naylor et al., 1987), whereas the human neuromedin B
gene lies on the long arm of chromosome 15 (Krane et al 1988).
Bombesin-like peptides function both as neurotransmitters and gut hormones
(Moody et al., 1983). They are localised to neurones and neuroendocrine cells in
the central and peripheral nervous systems (Panula, 1984), although
autoradiographic studies in gut suggest that their receptors have a wider
distribution.
Infused GRP has a plasma half-life of 2.8 minutes (Knigge et al., 1984). It causes
secretion of gastrin, pancreatic polypeptide, insulin, glucagon, cholecystokinin
and gastric inhibitory peptide, leading to amylase and gastric acid secretion
(Knigge et al., 1984). GRP and its receptor are abundant in the hypothalamus,
and this has lead to speculation that it may regulate pituitary hormone secretion.
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In support of this, GRP infusion has been shown to stimulate the secretion of
ACTH, Cortisol and endorphin in normal subjects (Knigge et al., 1987).
Table 1.1 Amino-acid sequence of bombesin like peptides.
MAMMALIAN
GRP(l-27) Human Pro Leu Pro Ala Gly Gly Gly Thr Val Leu Thr Lys —
Met Tyr Pro Arg Gly Asn His Irp Ala Val Gly His Leu Met NH?
GRP(l-27) Porcine Ala Pro Val Ser Val Gly Gly Gly Thr Val Leu Ala Lys —
Met Tyr Pro Arg Gly Asn His Trp Ala Val Glv His Leu Met Nib
GRP( 14-27) Porcine Met Tyr Pro Arg Gly Asn His Trp Ala Val Gly His Leu Met NH?
GRP 10 (NeuromedinC) Gly Asn His Irg Ala Val Glv His Leu Met NLb
Neuromedin B Gly Asn Leu Irp Ala Thr Glv His Leu Met NH?
AMPHIBIAN
Bombesin pGlu Gin Arg Leu Gly Asn Gin Irp Ala Val Glv His Leu Met NH?
Bombesin(8-14) Irp Ala Val Glv His Leu Met NH?
Ranatensin pGlu Val Pro Gin Trp Ala Val Glv His Leu Met NH?
Litorin pGlu Gin Trp Ala Val Glv His Leu Met NH?
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1.1.5 BOMBESIN/GRP SIGNAL TRANSDUCTION.
In serum-free medium bombesin stimulates DNA synthesis and cell division in
the absence of other growth-promoting agents. The ability of bombesin, like
platelet-derived growth factor (PDGF), to act as a sole mitogen for these cells
contrasts with other neuropeptide growth factors which are active only in
synergistic combinations (Rozengurt, 1986). The mitogenic effects of bombesin
are markedly potentiated by insulin, which both increases the maximal response
and reduces the bombesin concentration required for half-maximal effect
(Rozengurt and Sinnett-Smith, 1983). The cause-effect relationships and
temporal organisation of the early signals and molecular events induced by
bombesin provide a model for the study of other mitogenic neuropeptides and
illustrate the activation and cross talk of a variety of signalling pathways
(Rozengurt, 1998).
1.1.5.1 Bombesin/GRP Receptors
Bombesin and GRP bind to a single class of high affinity receptors. The
bombesin/GRP receptor has been cloned and sequenced (Battey et al., 1991). The
deduced amino acid sequence predicts a polypeptide core of Mr 43000 and
demonstrates that it belongs to the super-family of G protein coupled receptors.
1.1.5.2 Inositol Phospholipid Turnover, Ca^+ Mobilisation and Activation of
Protein Kinase C.
Binding of bombesin/GRP to its receptor initiates a cascade of intracellular signals
(Fig 1.5) culminating in DNA synthesis 10-15 h later. One of the earliest events to
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occur after the binding of bombesin to its specific receptor is the activation of the
heterotrimeric G-protein, Gq. The released GTP bound Gqa subunit activates
phospolipase C (3 (PLC-(3) which catalyses the hydrolysis of the membrane
phospholipid phosphatidyl inositol 4,5 bisphosphate (PIP2) to produce the second
messengers, inositol 1,4,5- triphosphate (IP3) and diacylglycerol (DAG) (Exton,
1996). IP3 stimulates the release of calcium from intracellular stores in the
endoplasmic reticulum via the binding of ligand-gated Ca2+ channels (Mikoshiba,
1997) and DAG directly activates several isoforms of protein kinase C (Nishizuka,
1995). These two events are implicated in the stimulation of DNA synthesis in
several cell types (Charlesworth and Rozengurt, 1994). Both the mobilisation of
intracellular calcium and the production of DAG activate PKC and as a result,
bombesin stimulates the translocation of the PKC substrate myrisolated alanine rich
C kinase substrate (80K/MARCKS) from the membrane to the cytoplasm (Zachary
and Rozengurt, 1986). 80K/MARCKS binds calmodulin in a Ca2+ dependent
manner, which can be prevented by PKC phosphorylation of 80K/MARCKS (the
calmodulin-binding domain turned out to be identical to the phosphorylation site
domain). Activation of PKC and increases in [Ca2+]i could regulate the interaction of
80K with both the cytoskeleton and the plasma membrane, and 80K/MARCKS may
play a suppressor role in the control of cell proliferation, (reviewed in (Blackshear,
1993). Bombesin stimulation of PKC also results in the activation of the PKC
substrate, protein kinase D (PKD) (Matthews, 1997). The activation of PKD































Fig 1.5 Bombesin Mediated Mitogenic Signal Transduction Pathways. See text for details
and abbreviations.
1.1.5.3 Activation of MAPK by Bombesin.
PKC plays a role in transducing neuropeptide signals into activation of
serine/threonine protein kinase cascades including p42MAPK/p44MAPK and
protein kinase D (PKD)
The activation of the MAPK cascade relays mitogenic signals to the nucleus
(Khokhlatchev et ah, 1998) resulting in the activation of transcription factors and
cell cycle progression. The activated MAP kinase directly phosphorylates
transcription factor regulators which results in the increased expression of c-fos
and c-myc (Treisman, 1992). However, neither direct activation of PKC by
phorbol esters nor addition of vasopressin stimulate a maximal increase in c-fos
mRNA levels. It is likely that the induction of c-fos by bombesin is mediated by
the co-ordinated effects of PKC activation, Ca^+ mobilisation and an additional
pathway dependent on arachidonic acid release (Rozengurt, 1991).
P42 (Erk2) and P44 (Erkl) mitogen activated protein kinases (MAPK) are
activated by phosphorylation of both tyrosine and threonine residues by the
cytoplasmic dual specific kinase, MEK (Seger and Krebs, 1995). The MAPK
cascade can be activated by a wide range of mitogenic stimuli including the
activation receptor tyrosine kinases and the activation of G-protein coupled
receptors. Bombesin has been shown to potently stimulate MAPK via its Gq
coupled receptor in several cell types. In Swiss 3T3 cells this MAPK activation
has been shown to be via the activation of PKC and does not appear to involve
Ras (Mitchell et ah, 1995; Seufferlein and Rozengurt, 1996b). This distinguishes
bombesin mediated MAPK activation from that via Gi and tyrosine kinase
receptors. The mechanisms by which MAPK is activated by GPCRs is
dependent more so, upon cell type than on the nature of the stimuli (Delia Rocca
et ah, 1997). Accordingly, it has been found that in Rat-1 fibroblasts transfected
with the bombesin receptor, MAPK is activated by bombesin via a PKC
independent and Ras dependent pathway (Charlesworth and Rozengurt, 1997).
This demonstrates that the same GPCR can activate MAPK via different
pathways depending on cellular context.
In addition to the above pathways leading to MAPK activation, it has also been
shown that GPCRs are able to transactivate EGF receptor tyrosine kinases which
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leads to the Ras dependent activation of Raf and subsequent MAPK
stimulation(Daub et al., 1997).
1.1.5.4 Bombesin stimulation of p70 S6 Kinase.
The activation and phosphorylation of the serine, threonine kinase, p70 S6 kinase
occurs in response to many mitogenic stimuli. Bombesin stimulates the
activation of p70 S6 kinase via a PKC dependant pathway (Withers et al., 1997)
although the precise mechanism is unknown. It is thought that the activation of
p70 S6 Kinase by bombesin is dependent upon the activity of the
RAFTl/FRAP/mTor complex (Thomas and Hall, 1997). RAFT1 shares
homology with the catalytic domain of PI3K and is implicated in the regulation
of mitogenisis. The drug rapamycin, blocks the activity of the RAFT1 containing
complex and inhibits DNA synthesis by bombesin in Swiss 3T3 cells (Withers et
al., 1997).
1.1.5.5 Bombesin Stimulation of Arachidonic Acid Release and
Prostaglandin Synthesis.
While bombesin/GRP stimulates DNA synthesis in the absence of other factors,
vasopressin is mitogenic for Swiss 3T3 cells only in synergistic combination with
other factors e.g. insulin (Rozengurt et al., 1979; Rozengurt and Sinnett-Smith,
1983). Binding of vasopressin to its G-protein coupled receptor in quiescent
cultures of Swiss 3T3 cells, causes a rapid production of Ins(l,4,5)P3,
mobilisation of Ca^+ from intracellular stores and sustained activation of PKC
(Rozengurt, 1991). Independent signal-transduction pathways act synergistically
in the initiation of DNA synthesis, hence, the ability of bombesin to act as a sole
mitogen could be due to activation of a signalling pathway not stimulated by
vasopressin.
Bombesin, but not vasopressin, has been shown to induce a marked, biphasic
release of arachidonic acid into the extracellular medium (Millar and Rozengurt,
1990). A first phase involves rapid activation of phospholipase A2 (PLA2). The
major phase of arachidonic acid mobilisation begins 20 min after the addition of
ligand. The stimulation of arachidonic acid release by bombesin is likely to
contribute to bombesin-induced mitogenesis because arachidonic acid has been
shown to potentiate mitogenesis induced by agents that stimulate
polyphosphoinositide breakdown but not arachidonic acid release, e.g.
vasopressin. Arachidonic acid released by bombesin is converted into E-type
prostaglandins which enhance cAMP accumulation in the cell (Millar and
Rozengurt, 1990). Since elevated cAMP levels constitute a mitogenic signal for
Swiss 3T3 cells (reviewed in (Rozengurt, 1991)) it is likely that part of the
mitogenic effects of bombesin are mediated via this pathway.
1.1.5.6 Bombesin Stimulation of Tyrosine Kinase Activity
The receptor for peptides of the bombesin family does not possess intrinsic
tyrosine kinase activity. However, bombesin has been shown to rapidly increase
tyrosine phosphorylation of multiple substrates in intact quiescent Swiss 3T3
cells (Zachary et al., 1991). Vasopressin bradykinin, gastrin, CCK and
endothelin elicit a similar response (Seufferlein and Rozengurt, 1995).
One of the prominent tyrosine phosphorylated proteins in bombesin and other
neuropeptide stimulated Swiss 3T3 cells is the non-receptor protein tyrosine
kinase focal adhesion kinase (pl25FAK) (Zachary and Rozengurt, 1992).
Phosphorylated pl25FAK presents a high affinity binding site for the SH2
domains of the Src family kinases which further activates pl25FAK and results
in the binding of other signalling or scaffolding molecules (Parsons and Parsons,
1997). The focal adhesion proteins paxillin and pl30cas (Sakai et al., 1994) are
adapter proteins which promote the assembly of, pl25FAK containing, signalling
complexes. Neuropeptides have been shown to induce the phosphorylation of
paxillin and pl30cas and promote the formation of a complex between pl30cas
and the proto-oncogene c-Crk (Zachary et al., 1993). This event may be integral
in the mitogenic effects of neuropeptides as c-Crk can activate a number of
signalling molecules, including Rap-1, which is a small GTP-binding protein
which can stimulate mitogenisis in Swiss3T3 cells (Casamassima and Rozengurt,
1997). Accordingly it has been shown that inhibitors of tyrosine kinases can
inhibit bombesin stimulation of DNA synthesis in Swiss 3T3 cells by 60% (Seckl
and Rozengurt, 1993).
Neuropeptides stimulate the tyrosine phosphorylation of FAK via a pathway that
is largely independent of PKC and intracellular calcium flux (Sinnett-Smith et al.,
1993). This suggests that bombesin stimulation of tyrosine phosphorylation
occurs via a pathway which is independent of the Gq mediated PLC pathway.
The prevention of focal adhesion assembly via disruption of the actin
cytoskeleton by cytochalesin D, prevents bombesin mediated phosphorylation of
pl25FAK (Rozengurt et al., 1995) indicating that focal adhesion assembly is
upstream of bombesin mediated pl25FAK phosphorylation. GPCR agonists
promote the formation of actin stress fibres and focal adhesions and this is
thought to be via the small G protein, Rho (Tapon and Hall, 1997). Inhibition of
Rho by treatment with C. botulinum C3 exoenzyme inhibits bombesin
stimulation of pl25FAK, paxillin and pl30Cas (Rankin et al., 1994; Zachary et
al„ 1993).
It has been suggested that the mechanism by which GPCRs stimulate the
formation of focal adhesions and subsequent tyrosine phosphorylation of focal
adhesion proteins, involves the coupling of the receptor to the G12 family of
heterotrimeric G-proteins (Buhl et al., 1995). In other words, the bombesin
receptor couples to both a Gq mediated PLC pathway involving calcium
mobilisation and PKC activation, and to a G12 mediated pathway which
stimulates focal adhesion formation via the activation of Rho.
In addition to the stimulation of tyrosine kinases via focal adhesion associated
proteins, bombesin and other neuropeptides have been shown to modulate
tyrosine kinase receptor activity. Classical receptor tyrosine kinases (RTKs) such
as the epidermal growth factor (EGF) receptor are single transmembrane proteins
that dimerise and transphosphorylate upon ligand binding. The mechanisms by
which GPCRs transactivate are unclear but it has been suggested that the
resulting phosphorylated EGFR, recruits SHC to the plasma membrane where
this adaptor protein is tyrosine phosphorylated by Src family kinases resulting in
the activation of the MAPK cascade (Zwick et al., 1999). It has been shown that,
in COS7 cells, bombesin is capable of stimulating the tyrosine phosphorylation
of SHC via EGF receptor activation (Daub et al., 1997).
20
1.1.6 Other Neuropeptide Growth Factors.
1.1.6.1 Vasopressin.
Vasopressin or antidiuretic hormone (ADH) is a cyclic nonapeptide synthesised in
the supra-optic nucleus of the hypothalamus, ADH containing vesicles pass down the
neural axons to the posterior pituitary before being secreted into the circulation.
Vasopressin is thus found in the brain and peripheral organs. Two types of
vasopressin receptor have been distinguished functionally and pharmacologically
(Huffman et al., 1988). Stimulation of the renal V2 receptor by vasopressin results in
H20 reabsorption and induction of cAMP in collecting ductules. The majority of the
other functions of vasopressin are mediated via the VIA receptor. These functions
include blood vessel constriction, liver glycogenolysis, platelet adhesion and various
brain functions. The V1B receptor mediates stimulation of pituitary corticotrophin
release. Reviewed in (Zingg, 1996)
The Vi receptors mediate their vascular and hepatic effects of vasopressin by
activating inositol phosphate turnover. The V2 receptors are coupled to
adenylate cyclase and mediate antidiuretic responses of the kidney. Vasopressin
has been demonstrated to act as a mitogen for Swiss 3T3 cells (Rozengurt et al.,
1979). It has been shown, in this context, to bind to specific high affinity
receptors (Collins and Rozengurt, 1984) of the Vi type (Zachary and Rozengurt,
1986). Although vasopressin alone does not stimulate cell proliferation in serum
free medium, it acts synergistically with insulin, serum, EGF and PDGF at
nanomolar concentrations. Like bombesin, vasopressin causes a rapid production
of Ins(l,4,5)P3, mobilisation of Ca-+ from intracellular stores and sustained
activation of PKC via a G-protein linked transduction pathway (reviewed in
(Rozengurt, 1991). Vasopressin has also been shown to rapidly increase tyrosine
phosphorylation of multiple substrates including pl25FAK, in quiescent Swiss
3T3 cells (Zachary et al., 1991).
1.1.6.2 Bradykinin.
The nonapeptide bradykinin is generated in the plasma or tissues from large
molecular weight precursors (kininogens) by the action of kallikreins, which are
activated during proteolysis and clotting. Bradykinin is usually present in plasma
at very low concentrations, due to its rapid degradation by carboxypeptidase N
and angioconverting enzyme. Bradykinin is one of the most potent pain
producing substances and receptors have been localised to the nocioceptive
sensory pathways, where it acts as a neurotransmitter (Steranka et al., 1989).
Bradykinin is implicated in smooth muscle contraction, vasodilatation and
vascular permeability. There are at least two bradykinin receptor subtypes: Bi
and B2- Bradykinin in the presence of insulin is mitogenic for Swiss 3T3 cells
and this is mediated through a B2 receptor (Woll and Rozengurt, 1988).
Bradykinin rapidly mobilises [Ca^+Jj and stimulates phosphorylation of
80K/MARCKS. However, in contrast to bombesin and vasopressin the
stimulation of 80K/MARCKS phosphorylation by bradykinin is slower, reaching
a maximum after 1 min of incubation, and then rapidly decreases to almost basal
levels. Furthermore, bradykinin does not induce PKC mediated events or
enhancement of cAMP accumulation. Bradykinin induces rapid accumulation of
total inositol phosphates, but in contrast to bombesin and vasopressin which
stimulates a linear increase in inositol phosphate accumulation over a 10-min
period (Issandou and Rozengurt, 1990). In neuronal cells, bradykinin has been
shown to induce transactivation of the EGF receptor and subsequent Ras/MAPK
activation via a calcium dependent mechanism (Zwick et al., 1997).
1.1.6.3 Neurotensin.
Neurotensin is a 13 amino acid polypeptide which is present in the hypothalamus
and in the mucosal endocrine cells of the ileum. It is a neuromodulator of
dopamine transmission and of anterior pituitary hormone secretion. It exerts
potent hypothermic and analgesic effects in the brain (Vincent et al., 1999).
Neurotensin, in the presence of EGF, stimulates DNA synthesis in hepatocytes
(Carr et al., 1992) and has been implicated as a growth factor in several cancers
(discussed later).
1.1.6.4 Gastrin and Cholecystokinin.
Gastrin and cholecystokinin (CCK) share a common C-terminal pentapeptide and
bind to at least two different receptors (Jensen et al., 1989). The CCKB/Gastrin
receptors, which are found mainly in the central nervous system and in the
gastrointestinal tract, bind both CCK and gastrin with equal affinity whereas the
CCKA receptors preferentially bind CCK, with a 400 fold increase in affinity for
CCK than for gastrin (Jensen et al., 1989).
CCK exerts trophic effects on normal pancreas and human pancreatic cancers via the
mobilisation of intracellular calcium (Smith et al., 1991) and has mitogenic effects in
other cell types. Gastrin exists in multiple forms including penta-gastrin (G14), big-
gastrin (G34) and the most common gastrin -1 (G17). Gastrins are found in the
proximal duodenum and gastric antrum where they are secreted by neuroendocrine
G-cells. Gastrin release stimulates gastric acid secretion, gastric motility and
contraction of the lower oesophageal sphincter. In addition gastrin is found in the
hypothalamus and pituitary where it may act as a neurotransmitter (Walsh, 1987).
Gastrin exerts growth promoting effects in the digestive tract and exocrine pancreas
(Johnson, 1984). Gastrin has been identified as a growth factor for several cancers
(discussed later).
1.1.6.5 Galanin
Galanin is a 29 amino acid peptide first isolated from porcine intestine (Tatemoto
et al., 1983) and is widely distributed in central and peripheral neurones
(Rokaeus, 1987). Its biological responses include the modulation and release of
several hormones (Fisone et al., 1987), the stimulation of smooth muscle
contractility and inhibition of neuronal excitation (Ekblad et al., 1985). In the
endocrine pancreas, galanin inhibits the release of insulin (Ahren et al., 1988) and
blocks the mobilisation of intracellular calcium via a pertussis sensitive G-protein
(Dunne et al., 1989). It has been shown that galanin receptors couple negatively
to adenylate cyclase through this G protein (Ahren et al., 1988). Galanin can also
act as a mitogen. This was demonstrated by its ability to stimulate the
mobilisation of intracellular calcium and proliferation in SCLC cells (Woll and
Rozengurt, 1989b; Sethi and Rozengurt, 1991b; Sethi and Rozengurt, 1991a).
Galanin has subsequently been shown to activate MAPK in SCLC cells
(Seufferlein and Rozengurt, 1996a).
24
1.1.6.6 Tachykinins.
Table 1.2 Amino Acid sequences of tachykinins.
Substance P Arg Pro Lys Pro Gin Gin Phe Phe Glv Leu Met nh2
Substance K: His Lys Thr Asp Ser Phe Val Glv Leu Met nh2
(neurokinin A)
Neurokinin K: Asp Met His Asp Phe Phe Val Glv Leu Met nh2
(neurokinin B)
The three mammalian tachykinins illustrated above (Table 1.2) have similar
biological activities associated with their shared carboxy-terminal sequence, but
bind to distinct receptors. Substance P and substance K are derived from the
same gene by alternative splicing. The tachykinins are widely distributed in the
brain (hypothalamus, trigeminal ganglion, caudate nucleus and olfactory bulb),
the spinal cord and gut neurones. The best studied is the undecapeptide substance
P, which is synthesised in the dorsal root ganglia and transported axoplasmically
to be stored in the sensory nerve endings. A variety of stimuli lead to its release,
causing local pain, smooth muscle spasm and vasodilatation (Payan, 1989).
The tachykinin receptors have been characterised pharmacologically (Regoli et
ah, 1989; Snider et ah, 1991). The receptors for substance P, substance K and
neuromedin K have been designated as NK-1 (substance P), NK-2 (substance K)
and NK-3 (neuromedin K).
Substance P has been shown to have mitogenic effects on T lymphocytes, at
concentrations as low as lOOpM, mediated through it's specific receptor (Payan et
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al., 1984). Tachykinins have been shown to stimulate growth of human skin
fibroblasts, arterial smooth muscle cells and keratinocytes (Nilsson et al., 1985)
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1.2 Neuropeptides as Cancer Growth Factors
1.2.1 Neuropeptides as Growth Factors in Lung Cancer
The neuroendocrine nature of SCLC has been long recognised on morphological
grounds (presence of neurosecretory granules), as well as biochemical grounds.
The first peptide documented to be produced by SCLC was bombesin/GRP. The
current list is extensive (Table 1.3) and can explain the many symptoms of
ectopic hormone production that small cell lung cancer patients suffer.
In addition many of these bioactive peptides can be produced by normal lung
(Becker, 1985). Many of these peptides are synthesised as pro-hormones that
acquire biological activity only after specific post-translational modifications
(Quinn et al., 1991).
The effects of a range of peptides were investigated by (Woll and Rozengurt,
1990). The ability of 32 neuropeptides and hormones to stimulate mobilisation
of intracellular calcium was examined in 5 small cell lung cancer cell lines.
(Table 1.4)
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Table 1.3: Peptides and Hormones Secreted by SCLC.
ACTH (Becker et al., 1984)
Atrial natriuretic peptide (Bliss et al., 1990; Gross et al., 1993)
Calcitonin gene related product (Bepler et al., 1988)
CCK (Moody et al., 1988; Rehfeld et al., 1989)
Chorionic gonadotrophin (Sorenson et al., 1981; Gazdar and Carney,
1984)
FSH (Sorenson et al., 1981)
GRP (Moody et al., 1981; Erisman et al., 1982)
Gastrin (Gazdar and Carney, 1984; Rehfeld et al., 1989)
GMCSF (Abe et al., 1984)
Growth hormone (Sorenson et al., 1981)
Glucagon (Sorenson et al., 1981; Bepler et al., 1988)
IGF-I (Macaulay et al., 1990; Reeve, 1991)
Lipotrophin (Sorenson et al., 1981; Abe et al., 1984)
Neuromedin B (Giaccone et al., 1992; Cardona et al., 1991)
Neurotensin (Bepler et al., 1988; Moody et al., 1985a)
Opioid peptides (Roth and Barchas, 1986)
Oxytocin (Maurer, 1985; Sorenson et al., 1981)
Parathyroid hormone (Yoshimoto et al., 1989; Sorenson et al., 1981)^
Physalaemin (Lazarus and Hernandez, 1985)
Prolactin (Sorenson et al., 1981)
Serotonin (Sorenson et al., 1981)
Somatostatin (Woodet al., 1981)
Vasopressin (North et al., 1980; Gross et al., 1993)
28
Table 1.4: The effect of multiple peptide hormones and neuropeptides on























Willey et al (Willey et al., 1984) reported that bombesin and GRP acted as
growth factors for cells derived from explants of normal human bronchial
epithelium cells. Embryonic mouse lungs express bombesin receptors during
branching morphogenesis. Treatment with bombesin increases lung branch
formation and can be inhibited by [Leu13-psi(CH2N2)Leu14]-bombesin, a specific
bombesin antagonist (Wang et ah, 1996; Aguayo et ah, 1994). In a rhesus
monkey model of lung development GRP mRNA was detected in embryos
between 63 and 80 days of gestation. Immunoreactivity for bombesin-like
peptides is usually localised to neuroendocrine cells but during this stage of
gestation GRP was also detected in cells of budding airways. In this study
treatment with bombesin resulted in increased size and number of airways and
cultured airway epithelial cells could be stimulated to undergo DNA synthesis by
bombesin treatment (Li et ah, 1994).
In the normal, adult lung, secretion of GRP by pulmonary neuroendocrine cells
occurs in response to alterations in pulmonary oxygenation, such as those
associated with birth (increased oxygenation) or with chronic obstructive airways
disease (decreased oxygenation) (Schuller et al., 1991). Many of these
pulmonary diseases are associated with smoking. Increased secretion of GRP is
accompanied by pulmonary neuroendocrine cell hyperplasia (Schuller, 1994).
Siegfried et al (Siegfried et al., 1993) investigated the responses of human
bronchial epithelial (HBE) cells from 13 donors. It was found that
GRP/bombesin stimulated colony formation in 8 of the cell lines. The same
group later investigated expression of bombesin receptor subtypes in HBE cells
and found that increased expression of these receptors correlated to a history of
cigarette smoking. Cell lines from donors that smoked for more than 25 pack-
years (number of years smoking multiplied by the number of packs smoked per
day) could be stimulated to proliferate in response to bombesin (Siegfried et al.,
1997). In support of this hypothesis, transfection of GRP-R into a human
bronchial epithelial cell line resulted in the ability of bombesin to stimulate
mitogenesis (al Moustafa et al., 1995). Elevated levels of GRP have been found
in broncho-alveolar lavages of normal smokers compared to non-smokers
(Aguayo et al., 1990). The high incidence of SCLC in smokers with a history of
chronic obstructive lung disease, and the induction of bombesin-producing
carcinoids in hamsters by simultaneous exposure to hyperoxyia and carcinogenic
nitrosamines (Schuller et al., 1991), implies a role for GRP and abnormal
oxygenation in the initiation of smoking related tumours. Curiously, in a study of
schizophrenic patients, who are often very heavy smokers, it was found that
plasma bombesin levels in smokers were significantly lower than levels found in
non-schizophrenic smokers. In fact schizophrenic patients had lower serum
bombesin levels than non-schizophrenic patients, irrespective of smoking history.
These findings may help explain the lower incidence of lung cancer seen in
schizophrenic smokers (Olincy et al., 1999).
Bombesin-like peptides were first detected in SCLC in the early 1980s (Moody et
al., 1981). Demonstration of pre-pro GRP mRNA, pro-bombesin C-terminal
peptide and multiple GRP gene associated peptides in SCLC confirm that the
GRP and related peptides originate in these tumours (Sunday et al., 1991;
Sausville et al., 1986; Cuttitta et al., 1988). GRP secretion by SCLC can be
stimulated by treatment with secretin or vasoactive intestinal peptide (Korman et
al., 1986).
Currently a major factor in diagnosis of SCLC is detection of bombesin-like
immunoreactivity as well as other markers of neuroendocrine differentiation. In
a recent study an enzyme immunoassay was developed to detect ProGRP, the
more stable precursor of GRP. Sera of 87 SCLC patients were tested for the
presence of proGRP. Using this assay 45% of SCLC samples were correctly
identified with no false positives in a reference group of 75 sera samples of
patients with benign lung disease (Stieber et al., 1999).
In addition to secreting bombesin-like peptides, SCLC also express bombesin
receptors, as demonstrated by specific binding of [125j_jyr4] bombesin to SCLC
(Moody et al., 1985a). This was the first suggestion that GRP may act as an
autocrine growth factor for SCLC. Subsequently, several studies have confirmed
the presence of bombesin receptors on SCLC cells. The presence on lung cancer
cells of three structurally and pharmacologically distinct bombesin receptor
subtypes has been demonstrated. These subtypes are GRPR, neuromedin B
receptor (NMB-R) and the bombesin receptor subtype 3 (BRS-3) (Fathi et al.,
1996; DeMichele et al., 1994b). Toi-scott et al (Toi-Scott et al., 1996) showed
the presence of GRP-R in 17/20 SCLC cell lines. 11/20 cell lines expressed
Neuromedin B receptor and 5/20 expressed bombesin receptor subtype-3. The
various subtypes of this family of receptors shall be further discussed in another
section.
In a recent study by Shriver et al the authors compared GRP-R expression in
airway cells and tissues of males and females. They discovered that GRP-R
expression was significantly higher in samples from non-smokers and short term
smoking females than in corresponding males (75% compared to 20%).
Additionally, female smokers showed expression of GRP-R earlier in their
smoking history than male smokers (37 compared to 59 pack-years). This may
be due to the fact that the gene for GRP-R is located on the X chromosome and is
not susceptible to X inactivation. This means that females possess 2 copies of the
gene whereas men only have one. These findings may explain the increased
incidence of smoking related lung cancer in women (Shriver et ah, 2000).
GRP/bombesin has been shown to act as growth factors in SCLC in vitro and in
vivo. Weber et al (Weber et ah, 1985) reported that GRP enhanced DNA
synthesis in 2 SCLC cell lines. In another study, colony formation in 9/10 SCLC
cell lines was stimulated up to 150-fold by GRP, with maximal effects at 50nM
(Carney, 1987). However, there was no correlation between amounts of GRP
secreted, response to exogenous GRP, and the number of binding sites in
individual cell lines. Growth of SCLC xenografts (NCI-H69) was reported to be
increased 77% above control in nude mice treated three times daily with
intraperitoneal injections of bombesin (Alexander et al., 1988).
The hypothesis of autocrine growth stimulation by GRP in SCLC was tested by
Cuttitta et al. (Cuttitta et al., 1985), using a monoclonal antibody to [Lys^]
bombesin (2A11). It inhibited the clonal growth of 2 SCLC cell lines in serum
free medium, and retarded the growth of one growing as xenografts in nude mice.
This antibody has recently been in a phase 1 clinical trial and showed no dose
limiting toxicity and tumour uptake in 11/12 patients (Chaudry et al., 1999).
GRP has been shown to activate PLC in SCLC, both in metabolically labelled
whole cell and membranous preparations (Trepel et al., 1988). This activation is
accompanied by an elevation of [Ca^+jj (Heikkila et al., 1987). GRP stimulation
of InsP3 and increase in [Ca^+Jj were inhibited by prior treatment with PKC
activator phorbol 12-myristate 13-acetate, suggesting that PKC might exert
negative feedback regulation on this response. Because non-hydrolysable GTP
analogues could modulate PLC activation in response to GRP (Sharoni et al.,
1990; Trepel et al., 1988), it was concluded that the GRP receptor in SCLC was
coupled to PLC by a G-protein. The GRP receptor and neuromedin B receptors
have been cloned from SCLC cells and two consensus PKC phosphorylation sites
are conserved in these receptors (Corjay et al., 1991). Bombesin has been shown
to potently activate MAPK in SCLC with maximal activation at 6 minutes
(Seufferlein and Rozengurt, 1996). Draoui et al showed that stimulation of 2
SCLC cells with lOnM bombesin induced expression of c-fos and c-jun
transcription factors indicating that bombesin can regulate nuclear oncogene
expression (Draoui et al., 1996). It has also been shown that bombesin can
stimulate tyrosine phosphorylation and tyrosine kinase activity in SCLC cell lines
(Tallett et al., 1996). Phosphorylation of a 120kd protein which was identified as
focal adhesion kinase (FAK) was observed. The same effects were observed
with stimulation using other neuropeptides (bradykinin, gastrin and neurotensin)
indicating a common signalling pathway in SCLC which is utilised by multiple
neuropeptides. (Tallett et al., 1996).
It seems likely that SCLC may be stimulated to grow by the normal intracellular
signals evoked by ligand-dependent activation of bombesin peptide receptors.
However, in a study by Woll and Rozengurt (Woll and Rozengurt, 1989b) GRP
did not stimulate an increase in [Ca^+h in all SCLC cell lines, which suggests
that in some SCLC cell lines, unrestrained growth is due to other factors and not
a GRP mediated autocrine growth loop.
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1.2.1.2 Vasopressin.
In 1985 vasopressin, in addition to bombesin, was identified as a chemoattractant
of SCLC (Ruff et al., 1985) suggesting a role for vasopressin in SCLC
metastasis. Subsequent work suggested a role for vasopressin as a growth factor
for SCLC cells. Vasopressin does not seem to be a growth factor for human
bronchial epithelial (HBE) cells. In a study by Franknell et al 0/6 HBE cells
responded by mobilisation of intracellular calcium to vasopressin stimulation
(Frankel et al., 1994).
Vasopressin is secreted by up to 65% of SCLC (North et ah, 1980; Sorenson et ah,
1981) although some studies have suggested a lower frequency of expression.
Verbeeck et al (Verbeeck et ah, 1992) detected vasopressin mRNA in only 3/26
SCLC lines and only one expressed both vasopressin and vasopressin receptor
mRNA suggesting that autocrine growth loops involving vasopressin may not be
as common as those involving bombesin/GRP. Vasopressin at nanomolar
concentrations increased [Ca^+Jj, in all SCLC cell lines tested, through Vi
receptors (Woll and Rozengurt, 1989b; Bunn et ah, 1992). The presence of VIA
receptors in SCLC has been confirmed recently by North et al (North et ah, 1997)
and in addition, V1B and V2 receptors were detected. The presence of multiple
subtypes of vasopressin receptors indicates a multifaceted role for this peptide in
SCLC.
Vasopressin has been shown to stimulate mobilisation of intracellular calcium in
SCLC cells. This calcium mobilisation can be blocked by specific vasopressin
antagonists. Vasopressin activates MAPK and promotes colony formation in
responsive SCLC cells (Sethi and Rozengurt, 1991a; Sethi et ah, 1992b; Bunn et
al., 1992; Seufferlein and Rozengurt, 1996). This can be blocked by the MEK
antagonist PD098059 and the PKC antagonist GF109203X (Bunn et al., 1994;
Seufferlein and Rozengurt, 1996).
Interestingly, variant SCLC cell lines do not seem to proliferate in response to
vasopressin but functional, structurally normal receptors have been detected on
both classical and variant cell lines. Stimulation of these receptors in both cell
types produce an increase in inositol phosphate production but in variant lines, no
corresponding calcium mobilisation is seen. This indicates regulation of the
cellular response to vasopressin at a post receptor level (North et al., 1997).
As discussed, both mitogenic vasopressin and vasopressin receptors are present
in SCLC tumours indicating that this neuropeptide is an autocrine growth factor
for SCLC cells.
1.2.1.3 Bradykinin.
Bradykinin is usually present in plasma at very low concentrations, due to its
rapid degradation by carboxypeptidase N and angioconverting enzyme.
However, lung tumours are frequently surrounded by areas of tissue and tumour
necrosis and local concentrations of bradykinin may be significantly higher.
Bradykinin is indeed present in normal lung (Said et al., 1980). In a study by
Franknel et al, 6/6 human bronchial epithelial cells were able to mobilise
intracellular calcium in response to bradykinin stimulation (Frankel et al., 1994).
Thus bradykinin was identified as having a potential role in lung physiology and
may also play a role in the growth of lung tumours. Bradykinin at nanomolar
concentrations increases [Ca2+]j in all SCLC cell lines tested through B2
receptors (Woll and Rozengurt, 1989a). In a panel of 18 human lung cancer cell
lines BK caused calcium mobilisation and DNA synthesis in more cell lines than
any other neuropeptide tested and the responses were of a greater magnitude than
those achieved with any other neuropeptide (Bunn et ah, 1992; Bunn et al.,
1992). Bradykinin has been shown to stimulate colony growth in SCLC cell
lines (Sethi and Rozengurt, 1991b), activate MAPK (Seufferlein and Rozengurt,
1996) and stimulate both tyrosine kinase activity and tyrosine phosphorylation
(Tallett et al., 1996).
Although the presence of both bradykinin and bradykinin receptors has never
been demonstrated on the same SCLC cell line or tumour sample, it is fair to
hypothesise that bradykinin may be an autocrine growth factor for SCLC.
1.2.1.4 Galanin.
In the mammalian lung the distribution of galanin seems to be confined to
smooth muscle, seromucous glands and blood vessels as well as airway nerves
(Cheung et al., 1985; Ghatei et al., 1987; Luts et al., 1989). It elicits a variety of
rapid biological responses including modulation of the release of several
hormones (Fisone et al., 1987), stimulation of smooth muscle contractility and
inhibition of neuronal excitability (Ekblad et al., 1985). Galanin also inhibits
neurokinin stimulated airway mucous production (Wagner et al., 1995; Wagner
et al., 1995).
In several contexts galanin opposes the Ca-+ signals and modulates the action of
other neuropeptides in various cell systems (see previous chapter), it is
interesting that in SCLC cells, galanin can stimulate mobilisation of intracellular
calcium at nanomolar concentrations (Woll and Rozengurt, 1989a).
Subsequently this calcium mobilisation was found to be via a pertussis toxin
insensitive G protein and was precluded by accumulation of inositol phosphates.
Activation of PKC by phorbol esters attenuated the ability of galanin to stimulate
calcium mobilisation (Sethi et al., 1992b). In several separate studies galanin
was found to stimulate colony formation in SCLC cell lines. It was found that
the mitogenic capacity of galanin was dependant upon the activation of MAPK
and in one study, dependant upon the activation of PKC (Sethi and Rozengurt,
1991a; Sethi et al., 1992b; Seufferlein and Rozengurt, 1996).
There is therefore considerable evidence implicating galanin as a potential
growth factor in SCLC however, there is little evidence to suggest that it is an
autocrine growth factor. It has not been detected in SCLC tumour samples or cell
lines, in fact, in a panel of 35 endocrine tumours of the lung, pancreas and
gastrointestinal tract, there was no expression of galanin whereas expression was
more prevalent in tumours of various brain regions (Sano et al., 1991).
1.2.1.5 Gastrin and Cholecystokinin
Low level CCK immunoreactivity has been detected in pulmonary
neuroendocrine cells (Wang and Cutz, 1993) and trace levels of gastrin has been
demonstrated in non-neoplastic lung tissue (Rehfeld et al., 1989), although in a
study by Frankel et al 0/3 human bronchial epithelial cells responded to gastrin or
CCK by mobilising intracellular calcium (Frankel et al., 1994). In a study by
Flansen et al (Hansen et al., 1980) serum gastrin levels were found to be
marginally elevated in 20% of patients with SCLC and in another study the
presence of gastrin was detected in one SCLC tissue sample (Hattori et al., 1979).
A significant increase in the presence of gastrin was found between limited and
extensive stage SCLC (Dowlati et al., 1996). The expression of gastrin and CCK
peptides has been demonstrated in SCLC cell lines (Rehfeld et al., 1989; Geijer et
al., 1990; Denyer et al., 1994). Other studies have reported receptors for CCK
and gastrin in some ,but not all ,SCLC cell lines (Yoder and Moody, 1987; Lin et
al., 1989; Sethi and Rozengurt, 1992; Sethi et al, 1993; Denyer et al., 1994).
Gastrin receptor has been detected on between 42% and 100% of SCLC cell lines
in various studies (Matsushima et al., 1994; Matsumori et al., 1996; Reubi et al.,
1997).
The presence of both gastrin/CCK peptides and corresponding receptors in SCLC
cells implicated these neuropeptides as potential autocrine growth factors in
SCLC. Stimulation of SCLC cells with gastrin or CCK induces mobilisation of
intracellular calcium (Staley et al., 1989b; Woll and Rozengurt, 1989b; Bunn et
al., 1992; Sethi and Rozengurt, 1992; Sethi et al., 1993) This mobilisation of
calcium was found to be via a G protein (Kaufmann et al., 1995). CCK and
gastrin were also shown to stimulate clonal growth of various SCLC lines (Sethi
and Rozengurt, 1992; Sethi et al., 1993). It was found that the activities of CCK
and gastrin could be blocked by both specific CCK and Gastrin receptor
antagonists indicating that CCK and gastrin are both capable of acting at the
same receptor in SCLC cells (Staley et al., 1990; Sethi et al., 1993). More
recently, stimulation of SCLC cells with gastrin has been shown to stimulate
tyrosine kinase activity and tyrosine phosphorylation (Tallett et al., 1996).
There is considerable evidence suggesting that CCK and gastrin may be autocrine
growth factors in SCLC. Receptor expression, particularly of the gastrin
receptor, is frequent in SCLC tissue and cell lines however tissue expression of
gastrin and CCK peptides seem to be of relatively low occurrence so this
autocrine growth loop may be of less importance than those involving other
neuropeptides.
1.2.1.6 Neurotensin.
Neurotensin is found at relatively low concentrations in the normal lung (Goedert
et al., 1984) but there is responsiveness to neurotensin in some human bronchial
epithelial cells (Frankel et al., 1994). Neurotensin immunoreactivity has been
demonstrated in benign pulmonary carcinoid tumours (Farhangi et al., 1987)and
neurotensin has been shown to stimulate calcium mobilisation in embryonic lung
fibroblasts (Gupta et al., 1994). It is apparent that neurotensin may play a role in
normal lung physiology but more interestingly neurotensin and neurotensin
receptors are upregulated in some lung neoplasms. High neurotensin
immunoreactivity has been detected in SCLC cell lines in comparison to normal
lung tissue (Goedert et al., 1984) and in other studies up to 50% of SCLC cell
lines have been shown to produce neurotensin (Wood et al., 1981; Luster et al.,
1985; Moody et al., 1985b). Neurotensin binding sites have also been
demonstrated in SCLC cells (Allen et al., 1988; Reubi et al., 1999). Neurotensin
is now known to stimulate mobilisation of intracellular calcium in SCLC cell
lines (Woll and Rozengurt, 1989b; Davis et al., 1989; Staley et al., 1989a; Sethi
and Rozengurt, 1991b; Sethi et al., 1992a; Bunn et al., 1992) and induce clonal
growth of SCLC cells in semi-solid media (Davis et al., 1989; Sethi and
Rozengurt, 1991b; Sethi et al., 1992a). Subsequent studies have shown that
neurotensin activates MAPK via a PKC dependent pathway (Seufferlein and
Rozengurt, 1996) and stimulates tyrosine kinase activity (Tallett et al., 1996).
Thus, it is extremely likely that neurotensin acts as an autocrine growth factor for
some SCLC tumours.
It is evident that multiple autocrine and paracrine growth stimulatory loops
involving several neuropeptides and their receptors, exist in SCLC and
potentially fuel the growth of this aggressive cancer. Some of these neuropeptide
autocrine loops, in particular those involving bombesin/GRP, seem to be
upregulated as normal lung undergoes the multistep process of carcinogenisis.
Neuropeptides and neuroendocrine cells are common throughout the body and
neuropeptide growth loops are therefore not confined to tumours of pulmonary
origin. The remainder of this section shall discuss the importance of
neuropeptides in other tumour types.
1.2.2 Neuropeptides as Growth Factors for Non-Small Cell Lung Cancer.
There is considerable evidence that bombesin/GRP is a potent growth factor for
NSCLC tumours, as it is for SCLC tumours. Positive immunoreactivity for
bombesin-like peptides has been demonstrated in 21% of NSCLC tumour samples
(Kiriakogiani-Psaropoulou et al., 1994) and it has been shown that GRP stimulates
colony formation in NSCLC cells in semi-solid media (DeMichele et al., 1994a). In
another study it was found that bombesin treatment significantly increased the
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growth rate in 1/3 NSCLC xenografts (Kruczynski et al., 1993). Several subsequent
studies have detected the presence of bombesin/GRP receptors on NSCLC cell lines
and tissues. The GRP receptor was detected by RT-PCR in 84% of NSCLC cell
lines (Toi-Scott et al., 1996) and using the same technique, Siegfried et al showed
that the GRP receptor was expressed in 9/14 (64%) NSCLC cell lines and receptors
for the bombesin-like peptide Neuromedin B (NMB) were expressed in 14/14
(100%) of the same NSCLC cell panel. Using an HPLC assay to detect bombesin-
like peptides in conditioned media, it was found that 7/9 NSCLC cell lines produced
NMB and 7/9 produced GRP. Interestingly, in the cells that produced both peptides,
7-15 times the amount of NMB was produced in comparison to GRP. In the same
study, Siegfried et al showed that stimulation of three NSCLC cell lines with GRP or
NMB increased colony formation and increased BRDU incorporation - an indicator
of DNA synthesis (Siegfried et al., 1999). Bombesin has been shown to stimulate
mobilisation of intracellular calcium in NSCLC cells and in addition causes
translocation of PKC from the cytoplasm to the membrane. In this study it was also
shown that bombesin stimulated increased colony formation in semi-solid media in a
NSCLC cell line (Moody et al., 1996). It has also recently been shown that
stimulation of a NSCLC cell line with bombesin results in the phosphorylation of
MAPK (Koh et al., 1999).
It is apparent that bombesin/GRP and neuromedin B can both act as autocrine growth
factors in NSCLC cells and that the expression of this autocrine loop is not
uncommon in this type of pulmonary tumour.
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Neuropeptides as Growth Factors for Gastric Cancer and Colonic Cancer.
There is considerable evidence implicating gastrin as an autocrine growth factor in
gut cancers. The major physiological roles of gastrin include stimulation of acid
secretion, proliferation of gastric mucosa and regulation of the mucosal cell lineage
(Kidd et al., 1998).
Gastrin precursor mRNA has been detected in several gastric and colonic cancer cell
lines (Baldwin et al., 1990; Baldwin and Zhang, 1992; Baldwin, 1995; Kelly et al.,
1998) and the expression of the gastrin receptor (CCKB-R) has been demonstrated.
In one study, gastrin was expressed by 5/5 gastric and 7/8 colonic cell lines and it
was found that in the same cell panel, 3/5 gastric and 5/8 colonic cell lines co-
expressed the truncated gastrin receptor, delta CCKB (McWilliams et al., 1998).
Gastrin/CCK specific antagonist L365,260 inhibited DNA synthesis and proliferation
of a gastric adenocarcinoma cell line which had been shown to express gastrin
(Remy-Heintz et al., 1993). Additionally, inhibition of a gastric cancer cell line has
been demonstrated using the non-selective gastrin/CCK receptor antagonists
proglutamide and benzotript, thus providing more evidence implicating gastrin as an
autocrine growth factor for such cancers (Baldwin, 1994).
Colorectal and gastric tumour cell lines, when grown as xenografts in nude mice can
be stimulated to proliferate in response to exogenously administered human gastrin
(Watson et al., 1989). In a study by Baldwin et al, gastrin was shown to stimulate the
growth of 50% of gastric and colorectal tumours, but consistent proliferative effects
on cell lines were not shown. (Baldwin and Whitehead, 1994).
Gastrin is synthesised and secreted mostly by neuroendocrine calls of the gastric
antrum. Transcriptional regulation of gastrin is positively regulated by transforming
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growth factor alpha (TGFa) and inhibited by somatostatin. Gastrin precursors must
undergo several post-translational processing steps and aberrations in the processing
steps may produce incompletely processed forms including glycosylated progastrin
which has been implicated as an autocrine growth factor for gut neoplasms (Kidd et
al., 1998). Gastrin release is stimulated by luminal aromatic amino acids, a decrease
in luminal pH and other factors including gastrin releasing peptide (GRP).
Hypergastrinemia is a condition characterised by increased serum presence of gastrin
and its precursors. It is often caused by an increase of luminal pH caused by
pharmacological agents or excessive gastrin release resulting from helicobacter
infections (Konturek et al., 1997). This increase in gastrin levels has been shown to
cause proliferation of gastrin dependant fundic enterochrommaffin-like (ECL) cells
in some cases resulting in the formation of hyperplastic lesions which may evolve
into neoplastic lesions (Baldwin, 1995) (reviewed in (Bordi et al., 1997)). It has
been shown that gastrin has a promoting but not transforming role in the
development of gastric cancers and is likely to require genetic changes such as loss
of the MEN-1 suppressor gene or over-expression of BCL-2 for transformation to
occur. Indeed, in humans, ECL cell dysplasia and gastric carcinoids have only been
demonstrated in patients who show loss of the MEN-1 suppressor gene from
chromosome llql3. Gastric dependence of gastrointestinal adenocarcimona has not
been proven and epidemiological evidence does not support gastrin dependence of
carcinomas of the stomach, pancreas or colon (reviewed in (Creutzfeldt, 1994)).
Gastrin releasing peptide (GRP) has also been implicated as an autocrine growth
factor in gut cancers. High affinity binding sites for GRP have been identified on
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gastric and colonic cell lines (Bold et al., 1998b; Halmos et al., 1994; Preston et al.,
1994). Bombesin binding to these binding sites was both saturatable and reversible.
Stimulation of these receptors result in activation of a G-protein and mobilisation of
intracellular calcium (Qin et al., 1994). In addition, bombesin stimulation of several
colonic tumour cell lines results in accumulation of inositol phosphates, and
increased DNA synthesis (Narayan et al., 1992; Williams and Schonbrunn, 1994). It
has been shown that, in a gastric cancer cell line, bombesin increased the expression
of transcription factors c-Jun and JunB as well as increasing the binding affinity of
API transcription factors (Kim et al., 1996). In another gastric cancer cell line
(S11A) bombesin stimulated both intracellular calcium mobilisation and tyrosine
phosphorylation. Specific bombesin antagonists blocked calcium mobilisation but
not tyrosine phosphorylation. Bombesin caused proliferation in this cell line but this
was unaffected by the bombesin antagonist and blocked by tyrphostin, an antagonist
of tyrosine phosphorylation (Bold et al., 1994).
Resected gastric and colonic tumours have been shown to express GRP receptors. In
one study 12/13 gastric tumours expressed binding sites for GRP and only one
uninvolved mucosal sample was found to contain GRP binding sites. This patient
suffered from Menetrier's disease which is a pre-malignant disease of mucosa
(Preston et al., 1993). Another study demonstrated GRP receptors in 27/29 colon
cancer cell lines but no expression in normal colonic epithelium. High expression of
GRP receptor correlated with tumours that had undergone lymphatic vessel invasion
(Saurin et al., 1999). Carroll and colleagues have shown that in an extensive panel of
resected tumour samples, 84% of colon cancers expressed GRP or its receptor.
Interestingly 62% expressed both GRP and GRP receptors and this group showed
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high expression of proliferating cell mitogenic antigen indicating that GRP is indeed
an autocrine growth factor and has important clinical relevance in cancers of the
colon (Carroll et ah, 1999).
Receptors for other neuropeptides have been detected on colonic and gastric cancer
cell lines but the physiological significance of these findings are not clear. It is
apparent that gastrin and GRP play an important role in these cancers and that the
clinical use of antagonists of these peptide growth factors may be an important step
in finding novel therapies.
Neurotensin is a product of gastrointestinal endocrine cells (Solcia et al., 1987) and
its release is stimulated by intraluminal fats. It is trophic for normal bowel and
colonic mucosa. Expression of neurotensin is localised to the mucosa of the adult
small bowel but is expressed in foetal colon. Ectopic neurotensin expression is
found in colon cancers suggestion a reversion to foetal phenotype (Evers et al.,
1996). Neurotensin may function as an autocrine growth factor in colon cancers..
This hypothesis has been confirmed by other studies. In one study, mRNA for
neurotensin was detected in 4/4 cell lines, 2/6 freshly resected human colon tumours
and 1/9 human colon cancer xenografts in nude mice. No neurotensin expression
was detected in normal colonic mucosa. Neurotensin receptor was identified in 2/3
cell lines and elevates [Ca^+Jj in 2/3 cell lines (Evers et al., 1992). In a study of 19
human colon carcinoma cell lines and normal colon epithelia, over 40% of the
tumour cell lines expressed neurotensin in comparison with 0% of the normal
epithelia (Maoret et al., 1994). This work strongly suggested that neurotensin
expression occurs in colonic cells upon the development of malignancy. Neurotensin
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also stimulated the growth of a mouse colon cancer and human colon cancer cell line
in vivo (Yoshinaga et al., 1992). Two recent studies have provided more evidence
implicating neurotensin as an autocrine growth factor. Maoret et al found that
neurotensin stimulated the growth of 5/6 colon cancer cell lines in culture. Further
experiments with one of these cell lines showed that neurotensin stimulated colony
growth in semi-solid media and xenograft growth in nude mice (Maoret et al., 1999).
A study by Ehlers et al noted that stimulation of a colon cancer cell line with
neurotensin resulted in the mobilisation of intracellular calcium and the activation of
MAPK. Neurotensin also increased cellular levels of c-fos in the same cell line
(Ehlers et al., 1998).
It is highly likely therefore, that neurotensin plays an important role as a paracrine
and autocrine growth factor in colon cancers and also perhaps in other gut cancers
too.
1.2.4 Neuropeptides as Growth Factors for Breast Cancer
Bombesin-like immunoreactivity and the expression of bombesin/GRP has been
demonstrated in several breast cancer cell lines (Burns et al., 1999) and the plasma
concentration of bombesin in breast cancer patients has been shown to be
significantly higher than normal control patients (Milewicz et al., 1994). Various
studies have attempted to determine the importance of bombesin as a growth factor
in breast cancer. Bombesin/GRP receptors have been detected in resected tissue
from breast cancer patients. In three studies the frequency of bombesin receptor
expression in breast cancer tissue ranged from 33-61% and in one study, high GRP
receptor expression correlated with high expression of receptors for the sex steroids,
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oestrogen and progestin. Lymph node metastasis biopsy samples were also positive
for GRP receptor expression. No receptor expression was demonstrated in non¬
neoplastic breast samples or in normal lymphoreticular tissue surrounding lymph
node metastases (Giacchetti et al., 1990; Halmos et al., 1995; Gugger and Reubi,
1999). In one study, the level of bombesin receptor expression was seen to increase
following cell line exposure to radiotherapy (Aalto et al., 1998).
In oestrogen independent and dependent breast cancer cell lines, bombesin signals
through a pertussis toxin insensitive G protein (Schrey et al., 1992) resulting in
intracellular calcium mobilisation(Bold et al., 1998a) via production of inositol
phosphates (Patel and Schrey, 1990). Interestingly bombesin has also been shown to
stimulate endothelin release in a breast cancer cell line via a pertussis toxin sensitive
G protein (Schrey et al., 1992). Bombesin has been shown to stimulate DNA
synthesis in breast cancer cell lines and this can be inhibited by the specific
bombesin antagonist RC3095 (Yano et al., 1992).
Several groups have investigated the effects of bombesin antagonists on the growth
of breast cancer xenografts in nude mice. Treatment with specific bombesin
antagonists RC3095 and RC3940II significantly inhibited xenograft growth in
several studies (Yano et al., 1994; Szepeshazi et al., 1992; Miyazaki et al., 1998).
The current success in breast cancer therapy is largely due to the sensitivity of these
cancers to the drug tamoxifen. Unfortunately, tamoxifen is a successful treatment
only in oestrogen dependent breast cancers. The prognosis for patients suffering
from oestrogen independent breast cancer is still unsatisfactory. It is apparent that
bombesin/GRP plays an important role as a growth factor for both oestrogen
dependant and independent breast cancer and the development of drugs that can
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block the mitogenic effects of bombesin are important in the search for new
therapies.
It has been demonstrated that vasopressin level in the neoplastic breast are higher
than level of vasopressin in normal circulation (Taylor et al., 1990). In a study by
North et al, it was found that 12/12 breast cancer tissue samples contained
vasopressin gene related products, including vasopressin and its pre-cursors (North et
al., 1995). The same author then demonstrated the presence of all three subtypes of
the vasopressin receptor, including an abnormal "diabetic" form of the V2 receptor,
on a breast cancer cell line (North et al., 1999). It is highly likely, especially as it
seems that at least the majority of breast cancers produce vasopressin peptide, that
vasopressin is an autocrine growth factor for breast cancer cells and it is surprising
that more research has not been carried out to further clarify the situation.
1.2.6 Neuropeptides as Growth Factors for Ovarian Cancer
Ectopic gastrin production by ovarian cancers was previously considered to be
unusual and was associated with rare cases of, ovarian neoplasm induced, Zollinger-
Ellison syndrome (Primrose et al., 1988; Maton et al., 1989). More recently gastrin
secretion by ovarian tumours has been shown to be commonplace. In a study by
Vansolinge et al it was shown that 16/16 ovarian tumours secreted forms of gastrin
(amidated gastrin, glycine extended gastrin and progastrin) and that peptide levels
were higher than levels found in benign tumours and normal ovarian tissue
suggesting that the synthesis and processing of progastrin increases during the
progression of ovarian malignancy (Van Solinge et al., 1993). In another gastrin
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expression was demonstrated in 1/5 ovarian cancer cell lines and in this cell line
gastrin stimulated mobilisation of intracellular calcium (Kim et al., 1998). The
presence of gastrin receptors in ovarian cancer tissues has been confirmed by Reubi
et al. In this study 100% of stromal ovarian tissues were found to express gastrin
receptors (Reubi et al., 1997).
In addition, ovarian cancers have been shown to express gastrin-releasing peptide
(GRP). 49/100 ovarian mucinous tumours showed immunoreactivity to the N-
terminal epitope of GRP (Tenti et al., 1992) and an ovarian cancer cell line has been
shown to express GRP receptors which were shown to be linked to a intracellular
calcium mobilising pathway (Kim et al., 1998).
It is probable that gastric type differentiation is common in ovarian tumours but there
has been no work carried out to show that either gastrin or gastrin releasing peptide
act as growth factors in ovarian cancers. However, in light of these peptides
mitogenic activity in other tumour types, this possibility is not unlikely.
1.2.6 Neuropeptides as Growth Factors for Prostate Cancer
Prostate cancer cells are most often androgen dependent and can be successfully
treated with current therapies. Relapsed prostate cancer is often androgen
independent and resistant to treatment. Several studies have shown that as these
tumours progress from androgen dependence to androgen independence, they gain
increased neuroendocrine differentiation. This increased expression of
neuroendocrine markers, such as chromogrannin A and neuron specific enolase, is
associated with poor prognosis and tumour progression (Abrahamsson, 1996;
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Abrahamsson, 1999). Cussenot et al found that 50% of malignant prostate tumours
contain neuroendocrine cells (Cussenot et al., 1996). It can be postulated that, as
neuroendocrine cells do not express androgen receptors, these cells will be selected
for during anti-androgen therapy and form the basis of the relapsed tumour.
Elevated bombesin levels have been noticed in the serum of prostate cancer patients
(Cussenot et al., 1996). It has also been shown that bombesin can stimulate the
mobilisation of intracellular calcium in prostate cancer cell lines (Aprikian et al.,
1996; Wasilenko et al., 1996). The presence of bombesin receptors of prostate
cancer cell lines and tissues has been established by several groups (Aprikian et al.,
1996; Bartholdi et al., 1998). In a recent study, GRP receptors were detected in
30/30 invasive prostatic carcinomas, 26/26 cases of pre-malignant prostatic intra¬
epithelial neoplasias and 4/7 androgen independent bone marrow metastasis. In this
study, well differentiated tumours had higher GRP receptor expression than poorly
differentiated tumours. GRP receptors were detected at a much lower density and
frequency in hyperplastic and normal prostate. This study strongly suggests that
GRP receptor expression is increased during malignant progression of prostate
cancer (Markwalder and Reubi, 1999).
Treatment with bombesin stimulates mobilisation of intracellular calcium via a G-
protein in prostate cancer cell lines (Reile et al., 1994). In addition, bombesin was
shown to stimulate the growth of two prostate carcinoma cell lines in culture
(Bologna et al., 1989). Stimulation of in vivo growth by bombesin has not yet been
demonstrated but several studies have shown that specific bombesin antagonists,
including the compound Hca6,Leu13T/[CH2N]Tac14-Bombesin(6-14) (RC3904-II),
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inhibit the growth of various prostate cancer xenografts in nude mice (Pinski et al.,
1993; Pinski et al., 1994; Jungwirth et al., 1997). Bombesin has also been shown to
enhance migration of an androgen-independent prostate cancer cell line. This
phenomenon was dependent upon the activation of PKC, protein tyrosine kinases and
focal adhesion kinase (FAK). It was also noted that bombesin stimulated the
tyrosine phosphorylation of integrin associated proteins in prostate cancer cells
(Aprikian et al., 1997). Another group demonstrated that bombesin increased the
invasion of a prostate cancer cell line through a reconstituted basement membrane
(Hoosein et al., 1993).
It is likely therefore, that bombesin has both autocrine mitogenic effects on cancers
of the prostate and can mediate the migration and invasion of these tumour cells.
Bombesin seems to be an important growth factor in androgen-independent prostate
cancer. Development of compounds, which target the actions of bombesin in these
cancers, may provide novel therapies for relapsed prostate cancer, which currently
has a very poor prognosis.
Several studies have demonstrated the presence of neurotensin receptors on both
androgen dependent and androgen independent prostate cancer cell lines (Sehgal et
al., 1994; Seethalakshmi et al., 1997; Carraway and Mitra, 1998). Neurotensin
production by prostate cancer cell lines has also been demonstrated (Moody et al.,
1998; Seethalakshmi et al., 1997). Neurotensin can stimulate calcium mobilisation
and DNA synthesis in prostate cancer cell lines (Carraway and Mitra, 1998;
Seethalakshmi et al., 1997; Mitra and Carraway, 1999). In a study by Sehgal et al it
was shown that, in androgen sensitive LNCaP prostate cancer cells, neurotensin
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secretion followed androgen withdrawal. This cell line expressed neurotensin
receptors but a growth response to neurotensin could only be demonstrated when the
cells were deprived of androgens. This group found that androgen stimulation of
LNCaP cells induced the production of a metalloprotease that was active towards
neurotensin (Sehgal et al., 1994). This work provides a potential mechanism
whereby anti-androgen therapy can produce cells which are stimulated to growth by
an alternative, neuropeptide growth stimuli.
1.2.7 Neuropeptides as Growth Factors for Pancreatic Cancer
It has long been known that bombesin can stimulate the growth of normal pancreas
in vitro and in vivo (Evers et al., 1990; Hajri et al., 1992). The production of
bombesin by pancreatic cancer cells has been demonstrated in a study by Wang et al
who found that 4/4 ductal pancreatic carcinoma cell lines secreted bombesin (Wang
et al., 1996). Numerous studies have detected bombesin/GRP high affinity binding
sites on pancreatic tumour cell lines and tissues (Logsdon et al., 1987; Singh et al.,
1990; Avis et al., 1993; Wang et al., 1996; Farre et al., 1994). It has been shown that
bombesin stimulation of receptor bearing pancreatic carcinoma cell lines causes
increased mobilisation of intracellular calcium (Simeone et al., 1995), accumulation
of inositol phosphates (Avis et al., 1993) activation ofMAPK (Douziech et al., 1999)
and increased DNA synthesis (Avis et al., 1993). Bombesin stimulation of growth in
pancreatic cancer cell lines in vitro, has been demonstrated (Avis et al., 1993; Wang
et al., 1996; Douziech et al., 1999) but the evidence for bombesin stimulated growth
in vivo is somewhat conflicting. Hajri et al showed that bombesin treatment
stimulated the growth of pancreatic cancer xenografts in rats (Hajri et al., 1992).
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However, in a study by Alexander et al, it was found that chronic bombesin
treatment of a human ductal pancreatic cancer xenograft, reduced tumour growth but
stimulated pancreatic growth in the same animals (Alexander et al., 1988). Similar
results have been obtained in other studies. Meijers et al found that bombesin
treatment reduced the formation of N-nitrosobis(2-oxoproply)amine (BOP) induced
pre-neoplastic pancreatic lesions in hamsters (Meijers et al., 1991). In another study,
the growth of a bombesin receptor expressing pancreatic cancer xenograft was
reduced by bombesin treatment. Again, normal pancreatic growth was observed
(Farre et al., 1994). Studies using specific bombesin antagonists, such as RC3095
and RC3940-II, showed that these compounds inhibit the growth of pancreatic cancer
xenografts iti vivo (Szepeshazi et al., 1991; Qin et al., 1994; Qin et al., 1995) but
interestingly, in one study both bombesin and the bombesin antagonist RC-3095
reduced the growth of BOP induced pancreatic carcinomas and treatment with
bombesin and RC3095 together had a synergistic effect on tumour inhibition.
It is clear that in some circumstances bombesin can act as growth factor for
pancreatic cancer cells but it seems that the in vivo situation is considerably more
complex. The mechanisms of action of bombesin in pancreatic cancer are unclear
and it is apparent that there is heterogenicity in the cellular response to bombesin.
Gastrin and CCK have been implicated as growth factors for pancreatic cancer cells.
Gastrin production by pancreatic cancer cells has been demonstrated in vivo (Smith
et al., 1996). Receptors for these neuropeptides have been demonstrated on
pancreatic cancer cell lines in vitro (Smith et al., 1993). It is thought that both
gastrin and CCK stimulate pancreatic cancer cells via the CCKB/gastrin receptor and
not the CCKA receptor (Smith et al., 1995). The growth promoting activity of
54
gastrin/CCK in pancreatic cancer is controversial. In several studies these peptides
have been shown to produce a proliferative response in cell lines and in tumour
xenografts in nude mice (Smith et al., 1995). The growth of pancreatic tumour
xenografts can be blocked by the addition of anti-sense oligonucleotides to gastrin
(Smith et al., 1999) and by specific gastrin antagonists (Smith et al., 1996). However
in one study it was shown that in two pancreatic cell lines transfected with the gastrin
receptor, the addition of gastrin produced a growth inhibitory effect (Detjen et al.,
1997) which raises the possibility that gastrin/CCK have a more complex role in
pancreatic tumours that simply acting as autocrine growth factors.
1.3 Lung Cancer
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Cancer is diagnosed in over a quarter of a million people each year in the UK and
is the cause of one in four deaths. Lung cancer is the most common fatal
malignancy in the developed world and over 40,000 cases were diagnosed in the
UK alone in 1995. In men, lung cancer is the most common form of malignancy
and caused 22,760 UK deaths in 1996. Lung cancer mortality in UK women is
approaching the mortality levels caused by breast cancer. However, in Scotland
and Northern England lung cancer mortality in women now exceeds that from
breast cancer and may soon do likewise in the rest of the UK (Fig 1.6) (Cancer
Research Campaign cancer statistics 1999). World wide, the incidence of
pulmonary cancer is expected to rise over the next twenty years with an
increasing number of cases unrelated to smoking (Osann, 1991).
The survival figures for lung cancer are extremely low in comparison to other
tumour types. Figure 1.7 shows the age-standardised 5 year survival rates for
lung cancer to be 5% in both men and women. Apart from cancer of the
pancreas, this is the lowest survival rate for any cancer type.
Several genetic mutations are required to complete the transformation of normal
lung cells into lung cancer cells. These genetic changes cause the activation of
oncogenes and the deletion of tumour suppressor genes and result in pathological
changes which, although the early stages are reversible, generally result in
neoplastic progression. The resulting tumour arises from cells which have an
increased proliferation rate which is often unchecked due to defects in their
ability to initiate apoptosis (programmed cell death).
Lung tumours are carcinomas originating from respiratory epithelium and are
classified on the basis of histological type (W.H.O. report 1982). The two main
types are small cell lung cancer (SCLC) and non-small cell lung cancer
(NSCLC). NSCLC includes squamous cell carcinoma, adenocarcinoma and
large cell carcinoma, and collectively accounts for 75% of all new cases. SCLC
accounts for the remaining 25% of lung tumours and includes several subtypes
which shall be discussed at length.
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Fig 1.6 Mortality figures for men and women in the UK due to various types of cancer.
Data from the Cancer Research Campaign Cancer Statistics 1999 (available on CRC website).
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Fig 1.7 Five-year relative survival of adults diagnosed during 1986-1990 in England and
Wales, (adapted from Cancer survival trends in England and Wales 1971-1995: deprivation and
NHS Region)
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1.3.1 Causative agents of Lung Cancer.
All types of bronchial carcinomas can be related to smoking with the exception
of bronchial carcinoids. The association with smoking and bronchoalveolar
carcinomas, a subgroup of adenocarcinomas, which arise from the terminal
bronchioles and alveoli, is not as strong as that of the other carcinoma types.
Smoking accounted for 91% of male lung cancer deaths in the USA in the 1970's
(W.H.O. report 1982) and accounts for 30% of all cancer deaths in the UK.
Further avoidable causes of lung cancer include exposure to occupational hazards
such as asbestos, arsenic, bischloromethyl ether, chromium, mustard gas, nickel,
polycyclic hydrocarbons and ionising radiation. Although asbestos has now been
removed from most work places it is still the UK's biggest cause of newly
diagnosed occupational cancers because asbestos induced cancers can take a
considerably longer time to develop. Radon is a naturally occurring radioactive
gas which can seep into houses, especially in Cornwall and Devon. The National
Radiological Protection Board estimate that Radon exposure may account fori in
20 lung cancer cases in the UK.
There are synergistic interactions between different carcinogens, e.g. smoking
and asbestos or radiation exposure.
1.3.2 Classification of Lung Cancers.
Bronchogenic carcinomas arise from the mucosa of the tracheo-bronchial tree
(Gazdar and McDowell, 1988). Squamous cell carcinomas (SQCC) arise from
metaplastic squamous epithelial cells. Cell lines demonstrating ultrastructural
features of squamous differentiation include well and poorly differentiated
SQCC, adenosquamous and mucoepidermoid carcinomas. All these tumour types
demonstrate upregulation of EGF receptor expression and markers characteristic
of squamous differentiation (involucrin, transglutaminase activity, higher
molecular weight keratins and cornified envelope formation).
Adenocarcinomas appear to arise from several cell types including surface
epithelium (ciliated and mucus producing cells), giving rise to mucin-containing
or mucin-secreting tumours, and the progenitor cells of the peripheral airways
(Clara cells and Type II pneumocytes ) giving rise to peripheral airway cell
tumours (Gazdar and McDowell, 1988). The latter types often demonstrate
morphological features of lepidic and papillary growth, and include the
adenocarcinoma subtypes bronchioloalveolar and papillary.
Large cell carcinomas are predominantly undifferentiated tumours, which may
represent their basal or stem cell origin.
SCLC were previously thought to arise from pulmonary neuroendocrine cells
(Gazdar et al., 1985), however it now seems more likely that they arise from a
common stem cell (see below).
Bronchial carcinoid tumours are a minor category of lung cancers which have
neuroendocrine features. These tumours are thought to arise from submucosal
glands and are not highly malignant. Atypical carcinoids lie between the SCLC
and the carcinoid tumours.
As mentioned above each of the four major types of lung cancer reflects
phenotypic features of the cell types that make up the normal bronchial
epithelium. A new hypothesis that is becoming increasingly accepted is that the
four types of lung cancer are related through a common differentiation pathway
in the bronchial epithelium (reviewed in (Mabry et al., 1991)). This proposal is
supported by clinical evidence that demonstrates potential for transitions between
the different tumours, in other words, tumours in patients can be mixtures of
different phenotypes. Neuroendocrine (NE) features can be found in NSCLC
tumours. This occurs in about 25% of adenocarcinomas and confers an initial
sensitivity to chemotherapy and radiotherapy, but these tumours with NE features
are faster growing and have a worse prognosis compared to adenocarcinomas
without NE features. Furthermore, individual cells have been observed to
manifest features of the SCLC and NSCLC phenotypes simultaneously. It is
proposed that these transitions mimic normal cellular transitions in bronchial
mucosa and are mediated by the consistent genetic abnormalities now being
described for lung cancer. A cell culture model system for one of these
transitions, SCLC to the large cell undifferentiated phenotype has been
developed. In this in vitro model, the combination of two genetic abnormalities
that can occur in lung cancer results in a transition of phenotype, where there are
losses of NE markers, acquisition of drug resistance patterns typical of NSCLC.
There is a concomitant fall in cellular production of GRP, and an increase in
expression of EGF receptor on their surface and production of TGF-a. This
model has been extended linking differentiation of adult normal bronchial
epithelial cells and transitions between the lung cancer phenotypes (Mabry et al.,
1991).
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1.3.3 Small Cell Lung Cancer
SCLC constitutes 25% of all primary pulmonary cancers hence it is the sixth
most common malignancy and the fourth leading cause of death from cancer.
Without treatment, SCLC has a more aggressive clinical course than any other
pulmonary tumour with median survival from diagnosis only 2-4 months. SCLC
is usually widely metastasised at the time of presentation and because of this,
localised forms of treatment such as surgical resection and radiation therapy
rarely result in long term survival (Prasad et al., 1989).
SCLC is usually initially responsive to cytotoxic chemotherapy, but survival is
only prolonged for more than two years in less than 5% patients as it almost
invariably relapses and is resistant to further treatment (Smyth et al., 1986). For
those patients who survive in excess of 2 years from initial diagnosis, there is an
increased risk of mortality from other types of lung carcinoma (Minna et al.,
1985). This dismal prognosis has fuelled interest in SCLC pharmacology and
encouraged research with the aim of providing a more detailed understanding of
the fundamental biology of SCLC. It is hoped that this research will serve as a
basis for developing urgently required, novel therapeutic approaches.
1.3.3.1 Cellular Classification of SCLC sub-types
The current classification of SCLC subtypes are : (Hirsch et al., 1988)
• Small cell carcinoma
• Mixed Small cell / large cell carcinoma.
• Combined small cell carcimoma (SCLC with neoplastic squamous or
glandular components)
Neuroendocrine carcinomas represent a spectrum of disease. At one extreme is
SCLC, which has a poor prognosis. At the other extreme are bronchial
carcinoids which have a promising prognosis following surgical resection
(Harpole et ah, 1992). Between these two extremes is a sub-type called well-
differentiated neuroendocrine carcinoma of the lung. Like SCLC it occurs
primarily in smokers but it metastasises less frequently and the 5-year survival
rate is often greater than 50%. The pathological diagnosis of well-differentiated
neuroendocrine tumours from SCLC is difficult because both cell types are very
similar.
The characteristics of classic SCLC cells are the presence of sparse cytoplasm
and indistinct or absent nucleoli. Cells are 2-3 times the size of mature
lymphocytes and their nuclei are darkly stained. Small dense-core granules are
seen in the cytoplasm, and are a manifestation of the peptide secretion that is the
hallmark of the neuroendocrine properties observed in SCLC, but relatively
infrequently in other types of lung cancer.
SCLC cell lines grow in culture as tightly clustered spheroids in suspension, form
colonies in soft agarose and can form tumours in nude mice. They have a
doubling time ranging from 32-72 hours. In contrast NSCLC cell lines grow as
attached monolayer cultures. They are also tumourigenic in nude mice and will
form colonies in soft agarose.
SCLC has distinct neuroendocrine biochemistry, and the cells express several
bio-markers of neuroendocrine differentiation including:
• L-Dopa decarboxylase
• Neuron Specific Enolase,
• The BB isoenzyme of Creatine Kinase,
• Chromogrannin A
Interestingly, 25% of NSCLC adenocarcinomas express endocrine markers L-
Dopa Decarboxylase and Neuron specific enolase. These cells are faster
growing, have a worse prognosis and are chemosensitive in contrast to other
adenocarcinomas (Gazdar and McDowell, 1988). SCLC cells also express many
peptide hormones (discussed in section 1.2) which are responsible for many
clinical symptoms of SCLC and also stimulate the unregulated growth of these
tumours.
In studies of a large number of SCLC cell lines it is clear that there is
considerable heterogeneity of neuroendocrine marker expression, allowing sub-
classification of SCLC into two distinct types (Carney et ah, 1985): Classic cell
lines, which express high levels of all 4 biomarkers and variant cell lines, in
which there is selective loss of some of these biomarkers. In vitro studies have
shown that variant cell lines have a more rapid growth rate and a higher cloning
efficiency in soft agar and higher tumourgenicity in nude mice than classic cell
lines. Variant cell lines have larger cell morphology, are more undifferentiated
and are relatively chemo and radio resistant. Variant cell lines have been
proposed to represent the in vitro counterpart of the poor prognosis, mixed Small
cell/large cell SCLC subtype. 10% of SCLC cell lines are biochemical variants
which lack DDC and other biochemical markers, another 20% are morphological
variants which grow as loose aggregates or monolayers with short doubling times
and high cloning efficiencies. Although conversion from classic to variant
phenotype might explain the clinical development of resistance to chemotherapy
in some cases, other mechanisms are also likely to be operative in the change
from responsive to non-responsive in SCLC, this is because only 10% of SCLC
patients have tumours showing histology in which large cell admixtures are
present. At post-mortem this figure has moderately increased to 13-28%, despite
the majority of these tumours being resistant to treatment (Sehested et al., 1986).
Several longitudinal studies show that the more extensive the disease the higher
the incidence of positivity of endocrine markers (Johnson et al., 1991) and
reviewed in Carney et al.(1991). Neuron Specific Enolase (NSE), is a highly
specific marker for neurones. Its levels are more elevated in extensive disease.
Sequential determinations of NSE levels are of value in monitoring the response
to chemotherapy and the detection of relapse. Levels of Chromogrannin A, BB
isoenzyme of Creatine kinase and Carcinoma embryonic antigen are also of
prognostic value and showed a significant correlation with tumour response to
cytotoxic therapy and relapse after therapy. Brambilla and his colleagues
(Brambilla et al., 1991) have also showed in a longitudinal study (before and
after the acquisition of resistance to chemotherapy and radiotherapy) involving
20 patients, an increase in neurosecretory granules in SCLC cells and these cells
appear more differentiated after chemotherapy. However, these results though in
agreement with those of Bepler et. al. (Bepler et al., 1987), are in contradiction
with other observations of cell lines and biopsies from treated patients
(Berendsen et al., 1988) and with long-term untreated SCLC cultures, in which it
has been shown that large cells exhibited a dedifferentiated phenotype with loss
of NE markers. On balance it seems most likely that in the majority of cases of
SCLC cells are of the classic phenotype and maintain this classic phenotype
during chemotherapy and the acquisition of chemoresistance , in a minority of
cases there may be conversion from classic to variant phenotype or a
maintenance of variant phenotype during the course of the disease.
1.3.3.2 Clinical features of SCLC.
SCLC tends to infiltrate the submucosa. This causes bronchial obstruction with
consequent cough, wheezing, chest discomfort, haemoptysis or post-obstructive
pneumonia. Two-thirds of patients will have evidence of distant metastases,
most often to the liver, bone, bone marrow, or brain, at the time of original
diagnosis.
There are many paraneoplastic syndromes associated with SCLC and which may
be confused with symptomatic metastases (Bunn and Ridgway, 1989). These
syndromes are often due to the synthesis and release by the tumour of various
hormones and peptides. Adrenocorticotrophic factor (ACTH) secretion causes
ectopic Cushing's syndrome. Arginine vasopressin (AVP) and atrial natriuretic
(ANF) (Bliss et al., 1990; Gross et al., 1993) release causes hyponatraemia and
the syndrome of inappropriate antidiuretic hormone secretion.
Immune reactions to tumour antigens, often result in neurological syndromes
such as the Eaton-Lambert myaesthenic syndrome, in which the presence of
circulating antibodies react with voltage-gated calcium channels (de Aizpurua et
al., 1988). Visual deficits produced by retinal degeneration and sensory
neuropathy are two other syndromes most commonly found in SCLC, in which
serum antibodies reacting with both tumour and neuronal tissue are also observed
(Bunn and Ridgway, 1989).
1.3.4 Treatment of Lung Cancer
1.3.4.1 Treatment of Small Cell Lung Cancer
The majority of patients present with extensive disease. That is thoracic disease
involving more than one hemithorax or with metastatic spread. The presentation of
limited disease involving only one hemithorax is less common.
Because of the frequency of metastatic disease, chemotherapy is the treatment of
choice for SCLC patients. The majority of SCLC tumours show good sensitivity
to cytotoxic drugs and initial response rates are high although tumours nearly
always relapse and are subsequently often resistant to chemotherapy.
A variety of chemotherapy regimens (Table 1.5) have been used with response
rates of up to 80% in unselected patients, and complete response rates of 50-60%
in patients with limited disease (Minna et al., 1985).
In limited SCLC, combination chemotherapy produces results that are superior to
single agent treatment and intensive doses are more effective than doses that only
produce mild toxic effects. Randomized trials have suggested a modest but
significant improvement in survival when chemotherapy is used in combination
with radiotherapy (Murray et al., 1993). Combined etoposide and cisplatin
chemotherapy with con-current chest radiation has achieved a 40-50% 2-year
survival in pateints with limited disease (McCracken et al., 1990; Johnson et al.,
1996).
The relative effectiveness of 2-5 drug regimens and different schedules of chest
radiation therapy appear to be similar and the use of alternating chemotherapy
regimens have not proven more effective than consistent administration of a
single regimen. The optimum duration of chemotherapy for patients with limited
stage SCLC is not clear, however, there is no improvement in survival after drug
administration exceeds 3-6 months (Murray et ah, 1993; Johnson et ah, 1996).
Treatment for extensive stage SCLC, as for limited stage disease is multiple
agent chemotherapy at moderate-high doses. At this stage of disease, chest
irradiation does not improve survival compared with chemotherapy alone
however radiation therapy is important in control of the symptoms from the
primary tumour and of metastatic disease particularly brain, epidural and bone
metastasis (Twelves et al., 1990). Many patients with extensive disease have a
much poorer performance status at the time of presentation than limited stage
patients. Such patients have a poorer prognosis and tolerate aggressive treatment
regimens poorly. Low dose, single agent regimens have been developed for
these patients although this is not as effective as normal treatment (James et al.,
1996; Souhami et al., 1997).
The prognosis for SCLC that has progressed despite chemotherapy is extremely
poor. Median survival is 2-3 months. However patients who are initially
sensitive to chemotherapy and then relapse are more likely to respond to
additional chemotherapy. Chemotherapeutics that have shown some limited
success as second line treatments include; oral etoposide, etoposide/cisplatin,
cylclophosphamide/doxorubicin/vincristine, lomustine/methotrexate and
topotecan (Greco, 1993; Johnson et al., 1990; Evans et al., 1985).
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Biological response modifiers are another form of treatment for SCLC. SCLC
cells have reduced expression of specific cell surface antigens, specifically the
class 1 major histocompatability antigens. These lack of these molecules may be
relevant in the escape of SCLC cells from immune surveillance. Treatment of
SCLC cells with leukocyte A interferon and y-interferon can induce expression of
these antigens and preliminary results show greater survival for patients receiving
interferon maintenance therapy than those not receiving such therapy (Mattson et
Unfortunately the outlook for patients with SCLC is bleak. Relapse and
chemotherapy resistance is usually the outcome irrespective of the treatments
used. Over the last twenty years there has been no significant improvements in
overall success of the available treatments for SCLC. It is obvious that novel
approaches to the treatment of the disease are urgently required.


















1.3.4.2 Treatment of Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) consists of at least 3 distinct histological types
of lung cancer including epidermoid or squamous carcinoma, adenocarcinoma, and
large cell carcinoma. These histological types are often classified together because,
when localized, all have the potential for cure with surgical resection. Systemic
chemotherapy can produce partial responses and short term relief of symptoms in
patients with advanced disease. Local control can be achieved with radiation in a
large number of patients with un-operable disease. Unfortunately a cure is seen only
in a small minority of patients as NSCLC tumours are less sensitive to chemotherapy
than untreated SCLC tumours . Patients with good performance status, women, and
patients with distant metastases confined to a single site appear to live longer than
others (Albain et ah, 1991).
Currently no single chemotherapy regimen is recommended for routine use. For
operable patients, large tumour size and presence of the erbB-2 oncoprotein are
negative prognostic factors (Albain et ah, 1991).
Other factors that have been identified as adverse prognostic factors in non-small
cell lung cancer include mutation of the K-ras gene, vascular invasion, and
increased numbers of blood vessels in the tumor specimen (Harpole et ah, 1995).
Treatment is not satisfactory for almost all patients with NSCLC.
1.3.5 Mechanisms ofDrug Resistance in Lung Cancer.
Clinical drug resistance is defined according to W.H.O. criteria which state that if
a tumour shows less than a partial response to chemotherapy then it is classified
as being resistant. SCLC is initially sensitive to chemotherapy but almost
invariably relapses and is resistant to further treatment. There are few drugs
which show even a modest activity against NSCLC tumours. There are several
mechanisms by which tumours can exhibit resistance to chemotherapeutic
treatments. Several of these mechanisms shall be discussed.
Cellular drug accumulation can be modified by alteration of the influx or efflux
of drugs. Most drugs enter the cell via passive diffusion but mechanisms of
active transport also exist (Ishikawa, 1992). Typical multi-drug resistance is
caused P-glycoprotein, encoded by the MDR-1 gene, which is a cell surface ATP-
binding cassette transporter which transports anti-tumour agents out of the cell.
Overexpression of the MDR-1 gene does not seem to correlate with clinical
resistance in lung cancer so it is thought that this is not the major mechanism of
drug resistance in such tumours (Lai et ah, 1989). Other transporter proteins
have been associated with clinical drug resistance in lung cancer, namely the
non-P-glycoprotein, multidrug resistance protein-1 (MRP-1) which, like P-
glycoprotein, actively transports drugs out of the cancer cell (Cole et al., 1992).
It has been reported that in doxorubicin and cisplatin resistant cell lines, changes
in the intracellular distribution of anticancer drugs, contribute to clinical
resistance. This mechanism is thought to be P-glycoprotein independent and
results in the accumulation of drugs in extranulear vesicles as opposed to a
nuclear distribution in chemotherapy sensitive cells (Takeda et ah, 1991). This
phenotype is reversible in vitro by tyrosine kinase inhibitors (Takeda et ah,
1994). Lung resistance protein (LRP) is protein located in the cytoplasm and
nuclear membrane and is though to induce drug resistance by acting on nuclear
transport.
Another mechanism of drug resistance in lung cancer is thought to involve
overexpression of glutathione-S-transferase (GST). This enzyme plays a role in
the detoxification of free radical damage such as that caused by doxorubicin
derivatives (Shen et al., 1997).
Metallothioneins have been shown to react with heavy metals and scavenge free
radicals and are candidates drug resistance compounds (Kasahara et al., 1991).
Some lung cancer cells, which show resistance to cadmium chloride treatment,
have increased expression of metallothioneins (Endresen et al., 1983).
DNA topisomerase I and II inhibitors such as etoposide and doxorubicin are used
to treat lung cancer patients. Increased expression of topoisomerases correlates
with sensitivity to these drugs (Kasahara et al., 1992). Decreased expression or
mutation in the topoisomerases is a mechanism of resistance to such drugs.
1.4 Blocking Growth Factor Action
73
The majority of currently used cancer therapies, are untargeted cytotoxic drugs
which have devastating effects on all rapidly dividing cells. Side effects of these
chemotherapeutics are expected but it is generally considered that the benefits of
such treatments marginally outweigh the risk to the patient. Despite recent advances
in cytotoxic drug development, it is a universal goal to develop novel cancer
therapies, which are more specific to cancer cells, and produce minimal damage to
non-malignant cells. One approach to realising this goal is the development of drugs
that are able to block the growth promoting effects of cancer cell mitogens. As
discussed earlier, small cell lung cancer cells, in addition to several other tumour
types, proliferate in response to a range of neuropeptide growth factors and in many
cases these neuropeptides are involved in autocrine and paracrine growth loops, that
fuel the unrestrained proliferation of cancer cells. There has been considerable
research carried out in order to identify compounds that are capable of breaking these
growth loops. The most accessible methods of intervention are to neutralise the
ligand or to prevent its interaction with the receptor. It is widely accepted that
bombesin is an important growth factor for SCLC and several groups have designed
specific bombesin antagonists with the aim of preventing bombesin mediated
autocrine growth loops. Monoclonal antibodies have been developed against
circulating bombesin and one such antibody, 2A11 has been shown to inhibit the
growth of SCLC in vitro and also as xenografts in nude mice (Chaudry et al., 1999).
This antibody has recently completed a phase 1 clinical trial that showed no dose
limiting toxicity and produced a clinical remission of one patient with relapsed small
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cell lung cancer. Although one patient had a complete response during treatment
with A211, it is not clear how suitable this approach is for general clinical use.
Antibodies are costly to manufacture and have relatively low tissue penetration
compared to small peptide drugs. Peptide receptor antagonists have been the main
focus of research in this drug development strategy. One such antagonist is [Leu13-
psz'(CH2NH)Leul4]Bombesin, a pseudopeptide analogue of bombesin. It was shown
to be a potent inhibitor of bombesin stimulated growth in Swiss 3T3 cells and blocks
bombesin stimulated calcium mobilisation and clonal growth in soft agar (Mahmoud
et al., 1991). Another bombesin antagonist [D-Phe6'13 psiu,CH2-
NH,Cys14]Bombesin-(6-14) (RC-3950-I) and a series of similar analogues have
shown anti-tumour activity against a wide range of bombesin receptor expressing
tumour types (Tablel.6). Recently these bombesin antagonists have been used to
target conjugated cytotoxic drugs such as doxorubicin to tumour sites with some
evidence of anti-tumour activity (Kiaris et al., 1999).
Bombesin is only one of several neuropeptide tumour cell growth factors and it is
likely that for maximal anti-tumour effect, the actions of more than one neuropeptide
growth factor must be inhibited simultaneously. The following section will discuss
the development of substance P analogues as broad spectrum neuropeptide
antagonists.
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Table 1.6: Tumour types sensitive to growth inhibition in xenograft models by
RC3095 and related bombesin antagonists
Tumour Type Reference
Small Cell Lung Cancer (Halmos and Schally, 1997)
Prostate Cancer (Milovanovic et al., 1992; Pinski et al., 1993;
Jungwirth et al., 1997b; Jungwirth et al., 1997a)
Renal Adenocarcinoma (Jungwirth et al., 1998)
Breast Cancer (Yano et al., 1992; Szepeshazi et al., 1992;
Shirahige et al., 1994; Miyazaki et al., 1998)
Colo-Rectal Cancer (Radulovic et al., 1991; Radulovic et al., 1992)
Pancreatic Cancer (Qin et al., 1994; Qin et al., 1995; Szepeshazi et
al., 1999)
Gastric Cancer (Pinski et al., 1994; Qin et al., 1994)
Malignant Glioblastoma (Pinski et al., 1994; Kiaris et al., 1999b)
1.4.1 Substance P Analogues as a Novel Cancer Therapy
Substance P is an 11 amino acid peptide (Arg Pro Lys Pro Gin Gin Phe Phe Gly Leu
Met NH2) of the tachykinin family. Synthetic analogues of substance P (Tablel.7)
were initially identified as antagonists of various, substance P mediated, cellular
effects and were subsequently found to also antagonise the cellular effects of
structurally unrelated bombesin (Jensen et ah, 1984). When tested in SCLC cell
lines, it was found that several of these substance P analogues were able to inhibit the
mobilisation of calcium stimulated by the neuropeptides; bombesin, bradykinin,
gastrin, galanin, vasopressin, cholecystokinin and neurotensin (Woll and Rozengurt,
1988; Woll and Rozengurt, 1990; Langdon et ah, 1992). They were also found to
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inhibit mitogenisis by the same range of neuropeptides in both Swiss 3T3 cells and
SCLC cells (Everard et al., 1992; Woll and Rozengurt, 1990; Woll and Rozengurt,
1988; Bepler et al., 1989). All neuropeptides which were sensitive to inhibition by
substance P analogues, mediate their effects via receptors coupled to Gq. In contrast
substance P analogues had no effect on the mitogenic effects of the neuropeptide,
vasoactive intestinal peptide (VIP) which activates cAMP accumulation via Gs or on
the signals stimulated by PDGF which signals through a receptor tyrosine kinase
(Seckl and Rozengurt, 1998). Substance P analogues inhibit multiple mitogenic
signals emanating from neuropeptide receptors. They have been shown to inhibit
ligand binding at vasopressin, bradykinin and bombesin receptors (Woll and
Rozengurt, 1988; Bepler et al., 1989) and in addition to inhibiting agonist stimulated
mobilisation of intracellular calcium by these neuropeptides, they also inhibit PKC
mediated 80K/MARCKS phosphorylation, PLC(3 activation, MAPK activation
(Seckl et al., 1996) and FAK tyrosine phosphorylation (Tallett et al., 1996) by
bombesin. In addition to the inhibition of bombesin stimulated signalling events,
substance P analogues also inhibit vasopressin stimulated 80K/MARCKS
phosphorylation and tyrosine phosphorylation and both vasopressin and bradykinin
stimulated DNA synthesis and MAPK activation (Seckl et al., 1996). It has been
demonstrated that the inhibition of the above downstream signalling pathways by
substance P analogues is reversible by the addition of high concentrations of
neuropeptide agonists (Seckl et al., 1997).
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Table 1.7: Comparison of structure/inhibitory activity of multiple substance P
analogues on the growth of the H69 SCLC cell line in liquid culture on dayl2
(adapted from (Seckl and Rozengurt, 1998)).
% Growth
Substance P Analogue Structure inhibition at 25pM


















(a) Antagonist G - currently entering a Phase II clinical trial.
(b) Most effective analogue at inhibiting SCLC growth.
(c) This analogue inhibits vasopressin but not bombesin stimulated signalling and mitogenisis.
(d) Antagonist D - (Woll and Rozengurt, 1990)
(e) Substance P
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In addition to the in vitro growth inhibitory effects of substance P analogues, it has
also been shown that these compounds can inhibit the growth of tumours in
xenograft models in nude mice. Both antagonist D and antagonist G have been
shown to inhibit the growth of the SCLC cell line WX332 in vivo (Langdon et al.,
1992) and antagonist G inhibits the growth of the H69 cell line in vivo (Jones et al.,
1997). Unpublished data from our laboratory has shown that other tumour cell lines
including HT29 (colorectal cancer) and PE04 (ovarian cancer) are sensitive to
growth inhibition by antagonist G in vivo.
The nature of the growth inhibition by these peptides has recently been shown to be
at least partly via the induction of apoptosis. In three SCLC cell lines, antagonist G
induces apoptosis at similar concentrations to which it causes growth inhibition
(Tallett et al., 1996; MacKinnon et al., 1999).
The exact mechanism by which these compounds exert their anti-tumour effects have
been subject to considerable debate over the last decade. The fact that substance P
analogues can reversibly inhibit agonist binding and subsequent signalling from
multiple, structurally unrelated, neuropeptides lead to the hypothesis that they were
acting as competitive antagonists of ligand binding, perhaps acting at a common
domain shared by all the sensitive receptor types. Interestingly, the pro-apoptotic
and growth inhibitory effects of substance P analogues are not reversible by
exogenous neuropeptides (Mitchell et al., 1995; MacKinnon et al., 1999) which may
point towards a mechanism which is independent of competitive neuropeptide
antagonism. An alternative hypothesis suggested is that as these compounds are
small hydrophobic peptides, they may insert into membranes and either disrupt
membrane integrity in a non-specific manner or influence receptor / G-protein
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coupling. The parent peptide, substance P, can insert into cell membranes and
directly activate G-proteins in a receptor independent fashion resulting in the release
of histamine from mast cells (Mousli et al., 1990). An argument against the proposal
that substance P analogues can directly modulate G-protein activity involves the
ability of two substance P analogues to differentially modulate the same signalling
pathways from bombesin and vasopressin receptors. [D-Arg1, D-Phe5, D-Trp7'9,
Leun]Substance P inhibits both bombesin and vasopressin binding and signal
transduction. A truncated version of this peptide, [D-Arg1, D-Phe5, D-
Trp7'9]Substance P, showed activity against vasopressin but not against bombesin
(Seckl and Rozengurt, 1998). This suggests that the truncated peptide acts as a
vasopressin antagonist but not a bombesin antagonist which implies that these
compounds block neuropeptide signal transduction at the receptor level.
However, several recent papers have highlighted the fact that the mechanism of
action of substance P analogues may be more complex than was previously
appreciated. Mitchell et al showed that at low bombesin concentrations (l-10nM)
antagonist D blocked the activation of MAPK by bombesin, however, at higher
bombesin concentrations (>10nM), antagonist D enhanced bombesin stimulated
MAPK activation. Thus antagonist D is capable of differentially modulating
neuropeptide signal transduction rather than simply acting as a competitive
antagonist (Mitchell et al., 1995). Furthermore, our group have demonstrated that
antagonist G can induce the sustained activation of c-Jun-N-terminal kinase (JNK) in
SCLC cells and this JNK activation occurs in the absence of exogenously added
neuropeptides. This JNK activation does not appear to be dependant upon
competitive neuropeptide antagonism as it is not reversible by high concentrations of
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neuropeptides (MacKinnon et al., 1999). Thus, antagonist G has neuropeptide
independent agonist activity in addition to its previously described antagonist effects.
The agonist activities of substance P analogues were further investigated by Jarpe et
al. It was shown that antagonist D could also activate JNK, and that this JNK
activation was dependent upon the presence of neuropeptide receptors - in this case
the GRP receptor. JNK activation by GPCRs has been shown to be via the G12
family of G-proteins (Prasad et al., 1995). Jarpe et al proposed the novel
terminology "biased agonism" to explain the receptor mediated effects of antagonist
D. They suggested that antagonist D is capable of differentially activating some
downstream signalling pathways (via G12) from a neuropeptide receptor whilst
simultaneously inhibiting others (via Gq) (discussed in more detail in chapter 6).
Antagonist G has recently completed a phase I clinical trial and will be entering a
phase II clinical trial in the near future. The phase I trial was carried out on
volunteer cancer patients and evaluated the effects of dose escalation up to
400mg/m2. Patients received a 6hr infusion of the peptide every three weeks for up
to 12 cycles. No dose limiting toxicity was found. Pharmacokinetic analysis of
patient plasma showed that the mean plasma concentration of antagonist G at the
maximum dose, was 40pM. This concentration is well within the expected range for
growth inhibition in vitro. A phase II clinical trial is now being planned for post
chemotherapy SCLC patients.
In conclusion, the combined research into the mechanism of action of substance P
analogues over the last decade, has provided conflicting and confusing evidence
which must be clarified if these compounds are to be developed into a successful
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therapeutic tool. Understanding both, the exact manner in which these peptides
modulate neuropeptide mediated and neuropeptide independent signalling, and
pinpointing which of these effects are clinically relevant, will allow the rational
design of more potent analogues and aid the clarification of the potential clinical
setting of this group of compounds.
1.5 PLAN OF STUDY
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It is becoming increasingly evident that neuropeptides are important mitogens for a
range of tumour types including lung cancer, breast cancer, prostate cancer,
pancreatic cancer and gastric cancers. The presence of autocrine / paracrine
neuropeptide growth loops in cancers presents an obvious target for therapeutic
intervention and the development of antagonists of these systems is a major step in
controlling these diseases.
Analogues of substance P have been developed as broad-spectrum neuropeptide
antagonists and one substance P analogue, Antagonist G, is entering a phase II
clinical trial as a potential therapy for small cell lung cancer. In order to further the
development of substance P analogues as a cancer therapy it is necessary to define
their mechanism of action and to increase their therapeutic potential it is necessary to
define their clinical placement.
In order to investigate these issues the following work will be carried out.
1) The sensitivity of a panel of tumour cell lines will be assessed to establish
against which tumour types substance P analogues may be useful.
2) The importance of neuropeptide receptors in the mechanism of action of
substance P analogues will be investigated: The expression levels of
neuropeptide receptors in a panel of tumour cell lines will be assessed in
order to detect any correlation with sensitivity to substance P analogues.
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3) In order to clarify the clinical setting of substance P analogues, small cell
lung cancer cell lines from longitudinal follow ups from single patients
will be assessed for sensitivity to substance P analogues and
responsiveness to neuropeptides. These cell lines and others will be used
to assess the relationship between sensitivity or resistance to conventional
chemotherapy and responsiveness to growth inhibition by substance P
analogues.
4) Mechanistic studies will be carried out to further investigate the agonist
effects of substance P analogues. Signal transduction pathways involved
in the mechanism of action of substance P analogues will be clarified and
the relevance of these pathways in terms of growth inhibition will be
investigated.
Sections 1 and 2 will be carried out using the substance P analogue, antagonist G.
This analogue was chosen because it is currently undergoing clinical trails as an anti¬
cancer drug and thus is the most appropriate analogue with which to investigate
tumour cell sensitivity. Section 3 will be carried using both antagonist G and related
substance P analogue, antagonist D. Finally, section 4 will investigate the
mechanism of action of antagonist D. Historically, most of the mechanistic work on
this group of compounds has been carried out using antagonist D. To make this
work directly comparable to previous research it was decided to concentrate on





A panel of cancer cell lines was assembled for in vitro experiments. Cell lines
included small cell lung cancer lines, non-small cell lung cancer lines, colo-rectal
tumour lines, pancreatic tumour lines and ovarian tumour lines (Table 2.1). All
SCLC cell lines grew as non-adherent aggregates. All other cell lines grew as
adherent monolayers in culture.
Investigations into the mechanism of action of substance P analogues were carried
out using non-tumour, fibroblast cell models (Table 2.2). Wild type and transfected
Rat-1 fibroblasts were a gift from Dr. E. Rozengurt. Wild type and transfected Balb-
3T3 fibroblasts were a gift from Dr. J Battey. All other cell lines used in this project
were from ICRF.
For experimental purposes all cell lines were used at the lowest possible passage
number and regularly screened for mycoplasma infection. All lines were
consistently negative.
2.2 Cell culture
Stocks were maintained in RPMI 1640 (tumour cell lines) or DMEM (non-tumour
cell lines)(both from Sigma) medium supplemented with 10% (v/v) foetal bovine
serum (Gibco Lifetech) (heat-inactivated at 57°C for 1 h) in a humidified atmosphere
of 5% CC>2:95% air at 37°C. Cells were passaged as required. For experimental
purposes, cells were either grown in SITA which consists of RPMI 1640 medium
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supplemented with, Insulin -Transferrin-Sodium Selenite (SIT) media supplement
(Sigma) and 0.25% bovine serum albumin (essentially fatty-acid and globulin free,
(Sigma) (Simms et al., 1980) or in quiescent media which consists of 0% FCS
(tumour cell lines) or 0.1% FCS (non-tumour cell lines) and 0.25% bovine albumin
in either RPMI or DMEM.
Table 2.1 Characteristics of Tumour Cell Lines












H510 SCLC BM M yes - C
WX330 SCLC PE - no no C
GLC4 SCLC PE - no - V
GCL4ADR SCLC
In vitro CR
PE In vitro V
LS274 SCLC PE - no - C
LS310 SCLC PE - yes - C
GLC14 SCLC LN F no no c









HCT116 Colorectal Colon - - - NA
PE04 Ovarian Ascites - Yes (resistant) - NA
PANC1 Pancreatic - - Yes - NA
(Abbreviations: PE - pleural effusion, BM - bone marrow, LN - lymph node, C-classical, V-variant,
M-male, F-female, CR - chemotherapy resistant.)
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Table 2.2 Characteristics of Non-tumour cell lines
Cell Line Type Modifications
Rat-1 Rat Fibroblast None
Borl5 Rat fibroblast Stable transfection with bombesin
receptors
Balb bl Mouse fibroblast Re-clone of Balb 3T3
5ET4 Mouse fibroblast Balb bl stable transfection with
mouse GRP-R (106 receptors /cell)
R288H Mouse fibroblast Balb bl stable transfection with
mouse GRP-R with mutated ligand
binding site.
CHO-K1 Chinese hamster ovary
epithelium.
Sub-clone of CHO cell line.
2.3 Liquid Growth Assay:
SCLC cells were grown in SITA for 3-5 days, then centrifuged at 2,000 rpm for 30s,
washed and resuspended in SITA at a density of 5 x 10^ cells per ml, in the presence
or absence of antagonists in triplicate.
Adherent cells were grown in SITA for 3-5 days then plated at a density of 2 x 10
cells per ml of SITA, in the presence or absence of antagonists in triplicate.
Cell number was determined using a Coulter Counter (model Zl, Coulter). Prior to
counting cell clumps were disaggregated by passing the cell suspension through 19
and 21 gauge needles.
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2.4 Determination of intracellular Ca^+ concentration:
Aliquots of 4-5 x 10^ SCLC cells cultured in SITA for 3-5 days, were washed and
incubated for 2 h at 37°C in 10 ml fresh SITA medium. Then, lpM fura-2-
tetraacetoxymethylester AME (FURA-2-AM) (Calbiochem) from a stock of ImM in
dimethyl-sulphoxide was added and the cells were incubated for a further 10
minutes. The cell suspension was centrifuged at 2000 rpm for 15 seconds, then the
cells were resuspended in 2ml of electrolyte solution (140 mM NaCl, 5 mM KC1, 0.9
mM MgCl2, 1.8 mM CaCh, 25 mM glucose, 16 mM Hepes, 16 mM Tris and a
mixture of amino acids at pH 7.2), transferred to a quartz cuvette, and stirred
O
continuously at 37 C.
Adherent cells were grown in DMEM containing 10% FCS until confluent, in
100mm petri dishes then quiesced overnight in DMEM containing 0.1% FCS and
0.25% bovine albumin. Cells were trypsinised to remove them from the dishes then
lmg/ml soya bean trypsin inhibitor was added to the cell suspension. The cells were
washed in Hanks balanced salt solution (HBSS without calcium, Sigma) and then
incubated with lpM FURA-2-AM in HBSS (without calcium) for 10 minutes. The
cell suspension was centrifuged at 2000 rpm for 15s and the cells resuspended in 2ml
HBSS (with calcium), transferred to a cuvette and stirred continuously at 37°C.
Fluorescence was recorded in a Model F2000 fluorescence spectrophotometer
(Hitachi). Alternate dual wavelength excitation at 380nm and 410nm allowed
ratiometric analysis of bound and unbound FURA-2AM when measured at 505nm
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[Ca2+]i was calculated using the formula:
Rmin = Fmin (Ai)-Zi / Fmin (A2)-Z2
Rmax = Fmax / Fmax (A2)-Z2
R = F(A,)-Z,/F(A2)-Z2
Concentration C = K (R - Rmin / Rmax - R x Fmin (A2) / Fmax (A2))
Where;
Fmax (AO: F(A|) at saturated Ca concentration.
Fmin (A]): F(Ai)-at Ca concentration 0.
Fmax (A2): F(A2) at saturated Ca concentration.
Fmin (A2): F(A2) at Ca concentration 0.
Z\\ F(Aj) of sample alone (auto-flourescence).
Z2: F(A2) of sample alone (autoflourescence)
K: Constant (dissociation constant of FURA2 = 224nM)
(Further details available in "Measurement of Intracellular Cation Concentration Using a Rapid
Scanning Fluorescence Spectrophotometer" Hitachi Scientific Instruments, application notes.)
Fmax was determined by fracturing cell membranes with 0.1% tritonX to release all
intracellular calcium. Fmin was determined by chelating all released calcium with
0.25mM EGTA.
2.5 Clonogenic assay
SCLC cells, 3-5 days post-passage, were washed and resuspended in SITA. Cells
were then disaggregated into an essentially single cell suspension by two passes
through a 19 gauge needle and then through a 20 p.m pore size nylon gauze. Viability
was judged by trypan blue exclusion on a standard haemocytometer. Cell number
was determined using a Coulter Counter. 10^ viable cells were mixed with SITA
containing 0.3% agarose in the presence or absence of antagonists, and layered over
a solid base of 0.5% agarose in SITA with antagonists at the same concentration, in
35mm plastic dishes. The cultures were incubated at 37°C for 21 days, then stained
with lmg/ml of the vital stain nitro-blue tetrazolium (NBT, Sigma) overnight at 37°C
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Colonies of >120 pm diameter were counted using a microscope with a X4
objective. Colonies from at least 10 different fields were counted for each well.
2.6 Determination of Protein Concentration in Cell Lysates
Samples for analysis of proteins were adjusted to equal protein concentrations using
BCA protein assay reagent (Pierce). A standard curve of protein concentration was
produced using various dilutions of bovine serum albumin (0.1-0.5 mg/ml) diluted in
lysis buffer and protein concentrations of test samples were determined from this
curve. Briefly, 200pl of BCA reagent was mixed with lOpl of test or standard
sample in a 96 well plate and incubated at 37°C for 30 min. Protein concentration
was determined using a 96 well plate reader (MRXII, Dynex technologies) (read at
562nm).
2.7 SDS-PAGE and Western Blotting
Cells were lysed in buffer containing 25mM Hepes (Na salt), 0.3M NaCl, 1.5mM
MgCl2, 0.2mM EDTA, 0.5% Triton X-100, 20mM (3-glycerophoshate, 0.5mM
dithiothreitol and ImM orthovanadate (pH 7.4). One Complete™ protease inhibitor
tablet (Boehringer Manheim) was added per 50ml of lysis buffer. Lysates were
cleared by centrifugation at 13000 rpm for 10 minutes at 4°C. Lysates were boiled at
99°C for 5 minutes in sample buffer containing (for 4X stock) 50mM Tris, 10%
glycerol, 2% SDS, 0.1% bromophenol blue and 10% mercaptoethanol (pH 7.4).
Samples were loaded onto SDS-polyacrylamide mini-gels (12%) comprised of a
stacking gel and a separating gel. Separating gels were prepared from a solution
containing H20 (10ml), 30% acrylamide (8.3ml), 1.5M Tris pH8.8 (6.3ml), 10%SDS
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(0.25ml), 10% ammonium persulphate (APS) (0.25ml) and TEMED 0.01ml).
Stacking gels were prepared from a solution containing H2O (6.8ml), 30% acrylamide
(1.7ml), 1M Tris pH 6.8 (1.25ml), 10% SDS (0.1ml), 10% APS (0.1ml) and TEMED
(0.01ml). Gels were run at 160V for lhr then transferred onto nitrocellulose
membrane for lhr at 400mA.in buffer containing 210mM glycine, 24.7mM Tris base
and 20% methanol.
Nitrocellulose membranes were stained with Ponceau S (Sigma) to confirm equal
protein loading then blocked for lhr at room temperature in PBS containing 5%
marvel non-fat dried milk powder and 0.02% tween20. Blocked membranes were
incubated for l-2hrs, with primary antibodies, at various concentrations (table 2.3),
diluted in blocking solution then washed several times in PBS containing 0.02%
tween20. Membranes were then incubated with horseradish peroxidase (HRP)
conjugated secondary antibodies (1:1000) diluted in blocking solution. Following
further washes, antibody bound proteins were detected using ECL western blotting
detection reagent (Amersham Pharmacia Biotech).
Table2.3. Antibodies used for probing western blots.
Primary Antibody Source Working Cone Supplier
pMAPK
(pERKl & pERK2)
Mouse Monoclonal IgGj 1:2000 Sigma
Pan-Ras (AB1) Mouse Monoclonal IgG2t>K 1:20 Oncogene
H-Ras (C-19) Rabbit Polyclonal 1:200 Santa Cruz
P21 WAF1 (AB-4) Mouse Monoclonal IgGiK 1:200 Oncogene
P27 (F-8) Mouse Monoclonal IgGi 1:500 Santa Cruz
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2.8 MAPK (ERK2) activity assays
Samples were lysed on ice as for SDS-PAGE in 0.5ml lysis buffer. Lysates were
cleared by centrifugation at 13000 rpm for 10 min. Cleared lysates were equilibrated
for protein concentration (500pg/ml) then vortexed for 2-4hrs at 4°C with 3pg of
agarose conjugated ERK2 pAB (Santa Cruz). Agarose beads were washed three
times at 4°C in a buffer containing 20mM Hepes, 50mM NaCl, 2.5mM MgC^ and
O.lmM EDTA and once in kinase buffer containing 20mM Hepes, 0.5mM NaF,
7.5mM MgCb, 0.2mM EGTA, 2mM dithiothreitol, lOmM (3-glycerophosphate and
0.5mM Na3V04. One protease inhibitor tablet was added per 50ml of kinase buffer.
Each sample was incubated at 30°C for 20 minutes in 20|il of kinase buffer
containing 10pg myelin basic protein, lOOpM ATP and lpCi Redivue [33P]-ATP
(500Ci/mmol) (Amersham Pharmacia Biotech). Samples were spotted onto p81
paper and washed three times in 500ml 0.5% phosphoric acid and once in acetone
then allowed to dry before counting radioactivity in a Liquid scintillation analyser
(1900TR, Packard).
2.9 Measurement of Thymidine Incorporation.
Confluent quiescent cells in 24 well trays were stimulated with various agonists /
antagonists in DMEM (0.1 % FCS) for 24hrs at 37°C. During the last 5hrs 250|il of
a mixture containing 40pM [6-3H] thymidine (lmCi/ml. 25Ci/mmol) (Amersham
Pharmacia Biotech) and 400mM unlabelled thymidine in DMEM was added to each
well. Cells were washed twice in ice cold PBS then twice in 5%TCA and finally
twice in 70% ethanol. Cells were then solubilised in 250pl base solution containing
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2% Na2 CO3, 0.1N NaOH and 1%SDS which was then transferred to scintillation
vials and incorporated radioactivity counted on a liquid scintillation analyser.
2.10 Semi-Quantitative RT-PCR for Neuropeptide Receptors.
RNA was extracted using Tri-Reagent (Sigma) from exponentially growing cells,
which had been in SITA medium for 3-5 days and was subsequently treated with
DNasel to remove any DNA contamination. cDNA was produced from this RNA
using a 1st strand synthesis kit (Boehringer Manheim).
PCR primers were designed using Gene Jockey software and synthesised by ICRF
(table 2.4). All primer sequences were screened against Genbank database to check
for any mismatches. None were found.
PCR reactions were standardly optimised for MgCl2, dNTPs and PCR cycling
parameters (table 2.5). Taq polymerase was produced by ICRF. By measuring
product production over a range of cycles it was ensured that the chosen cycle
number for each primer pair, was within the linear phase of product production (Fig
2.1 and table 2.5).
PCR products were run on a 1.5% agarose gel containing lpg/ml ethidium bromide
to enable UV visualisation. Stored images of the gels were analysed by densitometry
using Gel Base/ Gel Blot software.
y-Actin levels were measured as an internal control (Fig 2.2). To compensate for
variation in cDNA synthesis efficiency and PCR reagent pippetting accuracy, levels
of each product was expressed relative to the levels of y-actin for the same cDNA
batch and for each PCR reaction.
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The following PCR protocol was followed for each primer pair:
Step 1: 94°C for 2min 1 cycle
Step 2: a) 92°C for 30sec
b) various annealing temperatures
c)72°C for 45 sec various cycle numbers
Step 3: 72°C for 5 min 1 cycle.
Table 2.4: Primers for RT-PCR Detection of Neuropeptide Receptors.
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Fig 2.1: PCR Cycle Optimisation for semi-quantitative RT-PCR PCR cycles were optimised for
each primer pair to ensure that product production was in a linear phase. Product production was
measured by densitometry between 20 and 45 reaction cycles. Each primer pair was optimised in a
cell line which was expected to have a mid-range expression level of a particular receptor. Table (2.5)
shows the optimal number of cycles for each set of primers.
Table 2.5: Optimisation of PCR cycles
cDNA Detected RNA source Optimal number of
PCR cycles
GRP-R HT29 40














H69 H510 WX330 NX002 HT29 HRT18 HCT116 PANC1 PE04
*MP240bp
H69 H510 WX330 NX002 HT29 HRT18 HCT116 PANC1 PE04
Fig2.2. y Actin mRNA levels across tumour cell panel, y actin mRNA levels were similar across
all nine cell lines. Chart shows desitometrical analysis of a representative RT-PCR gel (shown below).
The mean y-actin level in arbitrary units, was 34250 (+/- 4396).
2.11 Detection of Apoptosis
2.11.1 Morphological detection.
Cells were quiesced in media containing 0% (SCLC cells) or 0.1%FCS (all other
cells) in the presence or absence of test agents for 24hrs. The cells were harvested,
and aliquots were cytocentrifuged onto glass slides and stained with May-Grunwald-
Giemsa stain. Slides were examined by light microscopy and cells displaying
apoptotic morphology (cell shrinkage, chromatin condensation) were counted from
>400 cells from random fields.
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2.11.1 Annexin V binding
Cells were quiesced in media containing 0% or 0.1%FCS in the presence or absence
of test agents for 24hrs. Cells were harvested and washed twice in cold PBS then re-
suspended in 250pl of annexin V (Bonder Medsystems) diluted 1:250 in binding
buffer (5mM CaC^ in Hanks balanced salt solution). Cells were incubated in the
dark at 4°C for lOmin then annexin V positive cells were detected by flow cytometry
(Coulter Profile II).
2.11.2 Analysis of caspase activation
CPP32 (caspase 3) activity, as an indicator of apoptosis, was measured using an
ApoAlert™ kit (Clontech). SCLC cells were grown in SITA for 3 days prior to
experimentation. lxlO6 cells were treated with antagonist G or a positive control for
24hrs at 37°C. Cells were lysed using the provided lysis buffer. All samples were
incubated with DEVD -AFC, a CPP32 substrate. Upon activation of CPP32, this
substrate is cleaved to form a fluorescent complex which was detected at 505nm
using a fluorescence spectrophotometer (Model 2000 -Hitachi). Parallel samples
were incubated with a caspase inhibitor (DEVD-CHO) to ensure that the increased
fluorescence at 505nm was due to caspase activity. Further samples were analysed
without incubation with DEVD-AFC to determine background fluorescence
emissions.
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2.12 Transformation of Bacteria and Extraction of Plasmid DNA.
The VIA receptor cDNA was a gift from Professor. M Threbonnier and was
provided in a pcDNA3 plasmid. The GRP receptor cDNA was a gift from Dr. J
Battey and was provided in a modified pcDII plasmid.
Plasmid DNA was sub-cloned into DH5a™ competent bacterial cells (Life
Technologies) and following overnight growth of the bacterial culture, media
containing appropriate antibiotic for selection of plasmid expression, the plasmid
DNA was extracted using Wizard plus SV Miniprep / Maxiprep kits (Promega). To
check for efficient transformation, some extracted plasmid DNA was digested using
appropriate restriction enzymes to release the insert, and ran on a 1% agarose gel
containing ethidium bromide to enable UV visualisation.
2.13 Stable Transfection of Rat-1 Fibroblasts.
Cells were transfected using Lipofectamine PLUS™ reagent (Life Technologies).
lxlO6 Rat-1 fibroblasts were plated in 100mm petri dishes in 10%FCS DMEM until
70% confluent (overnight). The following day, 10pg of cDNA for either the GRPR
or the VIAR was pre-complexed with PLUS reagent in serum free DMEM.
Lipofectamine reagent was diluted in serum free DMEM and then combined with the
pre-complexed cDNA for 15min at room temperature. The media on the cells was
replaced with 4ml of serum free DMEM and the DNA-PLUS-Lipofectamine
complexes were then added gently to the petri dishes and incubated for 3hrs at 37°C.
After this period the media was topped up to normal volume and serum
concentration. The following day the cells were trypsinised and distributed into 5 x
100mm petri dishes, containing 10ml of 10%FCS DMEM, and incubated overnight
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at 37°C. 24 hrs later, 800pg/ml geneticin (G418) (Promega) was added and the
media changed every three days until isolated colonies were visible. The cell
suspension was diluted in 10% FCS DMEM containing 800pg/ml G418 to a density
of 1 cell/200pl and 200pl was added to each well of a 96 well plate. Individual wells
were trypsinised following clonal growth and 24 clones from each transfection were
expanded. The clones were screened for the presence of transfected receptors by
testing their ability to mobilise intracellular calcium in response to the receptor
ligands and also by their ability to bind radiolabeled ligand.
2.14 Radio-Ligand Binding Assay using [125I]GRP.
Rat-1 fibroblasts were transfected with cDNA encoding the Gastrin Releasing
peptide receptor (above) and screened for their ability to bind radiolabeled GRP.
Cells were grown to confluence in 6 well plates and quiesced overnight in DMEM
containing 0.1%FCS. The following day, the cells were washed twice in serum free
DMEM then incubated at 37°C in 750(il of binding medium (30mM HEPES, 5mM
MgCl2 (pH8)) containing [l25I]GRP (Amersham) at a final concentration of InM.
Non- specific binding was measured by incubating the cells with the above binding
medium in the presence of both InM radiolabelled GRP and lpM unlabelled GRP.
Binding was measured after 30 minutes by washing the cells with ice-cold phosphate
buffered saline (PBS) containing 0.1% bovine serum albumin (BSA), then
solubilising the cells with 500pl NaOH containing 0.1% sodium dodecyl sulphate
(SDS) and 2% Na2C03. Samples were transferred to scintillation vials and
radioactivity was counted in a (3 scintillation counter. Total binding was calculated
by subtracting the non-specific binding value from the test samples.
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2.15 Detection of Active Ras using c-Raf-l:GST Pull-outs.
Active Ras was measured by its ability to bind to the Ras binding domain of Raf-1
and detected by western blotting. Plasmid encoding the 42kDa fusion protein clone
(Ras binding domain of human c-Rafl - amino acids 1-149) was a gift from Dr. J
Downward (ICRF) and were provided in BL-21 bacteria.
Bacteria were grown overnight in a shaking incubator at 37°C in liquid broth (LB)
containing lOOpg/ml ampicillin and the following day this culture was used to
inoculate a 500ml flask of LB/Amp. The culture was grown to an OD of 0.35-0.6
(measured at 600nm) and then induced with ImM Isopropylthio-(3-D- galactoside
(IPTG) for 2hrs at 37°C. The bacteria were centrifuged at 4000rpm for 15min at 4°C
and the pellet was resuspended in 5ml of lysis buffer containing lOOmM NaCl,
50mM HEPES (pH 7.5) 1% Triton X-100, ImM EDTA (pH8) ImM EGTA (pH 8),
ImM Na3V04, 20mM Na , 12mM MgCl2 and one protease inhibitor tablet per 50ml.
The suspension was sonicated in a water bath. The lysate was cleared by
centrifugation at 13000rpm for lOmin at 4°C and incubated on a wheel for lhr at 4°
with 1ml of glutathione agarose (Sigma, 1:1 slurry in PBS). The beads were washed
4 times in buffer A containing 20mM HEPES (pH 7.5), 120mM NaCl, 10%
Glycerol, 0.5% triton X-100, 2mM EDTA and 1 protease inhibitor tablet per 50ml
and then stored as a 1:1 slurry in buffer A.
Cell lysates were prepared from stimulated or non stimulated cells grown to
confluency in 100mm petri-dishes using 500|il of the above lysis buffer. 60jil of the
above fusion protein preparation was added to cleared lysates and incubated at 4°C
on a rotating wheel for 30min. The beads were then washed three times with cold
PBS containing 5mM MgCl2 and 0.1% triton X-100. Following the final wash, 40pl
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of IX sample buffer was added and samples boiled for 5 min at 99°C before running
on SDS-PAGE (12%).
Nitrocellulose membranes were probed with either anti-Pan-Ras (AB-1, mouse
monoclonal, diluted 1:200. Oncogene research products ) or anti-R-Ras (C-19, rabbit
polyclonal, diluted 1:20. Santa Cruz).
2.16 HPLC Analysis of Antagonist G and its Metabolites
High performance liquid chromatography was carried out on a liquid chromatograph
consisting of a Model 500 solvent delivery system, a Model 680 controller, a Wisp
autosampler (all from Waters), a Model5100A Coulochem electrochemical detector
with a pre-column Model 5020 guard cell (GC) and a twin electrode (D1 and D2)
Model 5011 high sensitivity analytical cell (ESA inc). The stationary phase was p-
Bondpack C18 packed in a 30cm x3.9mm I.D. stainless steel column (Waters) and
the mobile phase consisted of 0.15% TFA in lOmM ammonium acetate (pH2.75)-
acetonitrile: 60:40 (v/v).
Samples of antagonist G for HPLC analysis were prepared in 1ml volumes in various
media then frozen at -20°C until analysed. Prepared samples were kindly analysed
by Alex McLellan (ICRF).
2.17 Statistical Analysis and Curve Fitting.
Statistical analysis and curve fitting were carried out using Prism software
(GraphPad Prism version 3.00 for windows, GraphPad software, Santiago USA).




3.1 Investigation into the Sensitivity of a Panel of Tumour Cell
Lines to Antagonist G
Antagonist G is entering a phase II clinical trial for the treatment of small cell lung
cancer. Autocrine loops of neuropeptide growth factors are central in maintaining the
unregulated growth of small cell lung cancer cells. Thus, the use of broad spectrum
neuropeptide antagonists as a therapy for SCLC is an exciting development in cancer
therapy.
It is well known that neuropeptides can stimulate the growth of many other types of
cancers including pancreatic cancer, colo-rectal cancer, prostate cancer, ovarian cancer,
breast cancer and non-small cell lung cancer. The aim of this work was to determine
whether cell lines from various tumour types are sensitive to antagonist G and to
investigate the range of sensitivities within a panel of 11 cancer cell lines.
The nature of the growth inhibition will be discussed. It has been previously reported
that broad-spectrum neuropeptide antagonists can induce apoptosis and this will be
confirmed using the H69 SCLC cell line.
Finally, HPLC analysis of the rates of metabolism of antagonist G will be investigated.
This work was carried out in order to determine the stability of antagonist G in SITA
media and also to examine whether differential metabolism rates of sensitive and
resistant cells is a factor determining the potential of antagonist G to cause growth
inhibition. The presence of antagonist G in cells will be examined over a time course to
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determine how long the drug is associated with the cells in the tissue culture
environment.
3.1.1 Determination of Sensitivity to Antagonist G in Liquid Culture
A panel of 11 tumour cell lines was assembled representing a spectrum of tumour types
(Table 3.1). The sensitivity of each cell line to antagonist G was determined in liquid
growth assays. IC50 values (the concentration of drug required to reduce cell growth by
50% of the control growth level) for growth inhibition were calculated using a non¬
linear regression, curve fitting application in Prism data analysis software.














IC50 values were calculated during the exponential growth phase of each cell line. This
was between day 6 and day 10 in each case.
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Fig 3.1 A-Proliferation of SCLC cell line H69 in the presence or absence of various concentrations of
Antagonist G. Cell number was determined using a coulter counter at the intervals indicated. Graph is
representative of at least two independent experiments. Data points represent the mean of triplicate
samples.
B- IC50 determinations for two independent experiments. Day 8 cell counts were used to plot curves.
Curve fitting was carried out using non-linear regression curve fitting in Prism software.
Mean IC50for the H69 cell line =10.5pM (+/-2.1pM)
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Fig 3.2 A-Proliferation of SCLC cell line H510 in the presence or absence of various concentrations of
Antagonist G. Cell number was determined using a coulter counter at the intervals indicated. Graph is
representative of at least two independent experiments. Data points represent the mean of triplicate
samples.
B- IC50 determinations for two independent experiments. Day 9 cell counts were used to plot curves.
Curve fitting was carried out using non-linear regression curve fitting in Prism software.
Mean IC50 for the H510 cell line =29^M (+/-1.4pM)
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Fig 3.3 A-Proliferation of SCLC cell line WX330 in the presence or absence of various concentrations of
Antagonist G. Cell number was determined using a coulter counter at the intervals indicated. Graph is
representative of at least two independent experiments. Data points represent the mean of triplicate
samples.
B- IC50 determinations for two independent experiments. Day 6 cell counts were used to plot curves.
Curve fitting was carried out using non-linear regression curve fitting in Prism software.
Mean IC50 for the WX330 cell line =42p,M (+/-1.4pM)
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Fig 3.4 A-Proliferation of NSCLC cell line NX002 in the presence or absence of various concentrations
of Antagonist G. Cell number was determined using a coulter counter at the intervals indicated. Graph is
representative of at least two independent experiments. Data points represent the mean of triplicate
samples.
B- IC50 determinations for two independent experiments. Day 7 cell counts were used to plot curves.
Curve fitting was carried out using non-linear regression curve fitting in Prism software.
Mean IC5o for the NX002 cell line =33.5pM (+/- 4.9pM)
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Fig 3.5 A-Proliferation of Colo-rectal carcinoma cell line, HT29, in the presence or absence of various
concentrations of Antagonist G. Cell number was determined using a coulter counter at the intervals
indicated. Graph is representative of at least two independent experiments. Data points represent the
mean of triplicate samples.
B- IC50 determinations for two independent experiments. Day 7 cell counts were used to plot curves.
Curve fitting was carried out using non-linear regression curve fitting in Prism software.
Mean ICS0 for the HT29 cell line =18pM (+/-2.8p.M)
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Fig 3.6 A-Proliferation of Colo-rectal carcinoma cell line, HRT18, in the presence or absence of various
concentrations of Antagonist G. Cell number was determined using a coulter counter at the intervals
indicated. Graph is representative of at least two independent experiments. Data points represent the
mean of triplicate samples.
B- IC50 determinations for two independent experiments. Day 7 cell counts were used to plot curves.
Curve fitting was carried out using non-linear regression curve fitting in Prism software.
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Fig 3.7 A-Proliferation of Colo-rectal carcinoma cell line, HCT116, in the presence or absence of various
concentrations of Antagonist G. Cell number was determined using a coulter counter at the intervals
indicated. Graph is representative of at least two independent experiments. Data points represent the
mean of triplicate samples.
B- IC50 determinations for two independent experiments. Day 7 cell counts were used to plot curves.
Curve fitting was carried out using non-linear regression curve fitting in Prism software.
IC50 for the HCT116 cell line ~129ptM
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Fig 3.8 A-Proliferation of SCLC cell line, GLC4, in the presence or absence of various concentrations of
Antagonist G. Cell number was determined using a coulter counter at the intervals indicated. Graph is
representative of at least two independent experiments. Data points represent the mean of triplicate
samples.
B- IC50 determinations for two independent experiments. Day 10 cell counts were used to plot curves.




Mean IC50 for the GLC4 cell line =18pM (+/- 1.4pM)
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Fig 3.9 A-Proliferation of SCLC cell line, CORL51, in the presence or absence of various concentrations
of Antagonist G. Cell number was determined using a coulter counter at the intervals indicated. Data
points represent the mean of triplicate samples.
B- IC50 determination. Day 8 cell counts were used to plot curves. Curve fitting was carried out using
non-linear regression curve fitting in Prism software.
IC50 for the CORL51 cell line =79pM
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Fig 3.10 A-Proliferation of pancreatic carcinoma cell line, PANC1, in the presence or absence of various
concentrations of Antagonist G. Cell number was determined using a coulter counter at the intervals
indicated. Graph is representative of at least two independent experiments. Data points represent the
mean of triplicate samples.
B- IC5o determinations for two independent experiments. Day 9 cell counts were used to plot curves.
Curve fitting was carried out using non-linear regression curve fitting in Prism software.
Mean IC50 for the PANC1 cell line = ~58p.M
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Fig 3.11 A-Proliferation of ovarian carcinoma cell line, PE04, in the presence or absence of various
concentrations of Antagonist G. Cell number was determined using a coulter counter at the intervals
indicated. Data points represent the mean of triplicate samples.
B- IC50 determination. Day 7 cell counts were used to plot curve. Curve fitting was carried out using
non-linear regression curve fitting in Prism software.
IC50 for the PE04 cell line =31|iM
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Fig 3.12 Sensitivity of 11 tumour cell lines to growth inhibition by antagonist G.
The above figure summarises IC50 values from figures (3.1-3.11). The cell panel includes small cell lung
cancer cell lines (H69, H510, WX330, GLC4 and CORL51), a non-small cell lung cancer cell line (NX002),
colo-rectal carcinoma cell lines (HT29, HRT18 and HCT116), a pancreatic carcinoma cell line (PANC1) and
an ovarian cell line (PE04). The IC50 value for the cell line HCT116 is an estimation as high concentrations of
antagonist G (80p.M) did not produce a sufficient growth inhibition to calculate an accurate IC50 value. IC50
values were determined from two independent experiments, except for CORL51 and PE04, which are the
results of single determinations.
The dotted line represents mean plasma levels of Antagonist G achievable in patients, with no dose limiting
toxicity.
Within the cell panel of 11 tumour cell lines, the IC50 values ranged from lOpM to
>100[tM. The mean IC50 value was 42.7p,M.
The sensitivity of the cell panel to growth inhibition by antagonist G, was not confined
to tumour type. The three most sensitive cell lines were the H69 SCLC cell line (IC50 -
10.5pM), the GLC4 SCLC cell line (IC50-18pM) and the HT29 colo-rectal cell line
(IC50 18p.M). 4/6 lung cancer cell lines had IC50 values below the mean IC50 value.
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The most resistant SCLC cell line was CORL51 with an IC50 value of 79pM, however,
this cell line grew in extremely tight aggregates and this may have affected the cell
number determinations and subsequent IC5o calculations. The colo-rectal cell line,
HCT116 was the most resistant with an estimated IC50 of ~115pM. Both the ovarian
carcinoma and the non-small cell carcinoma were sensitive to growth inhibition by
antagonist G, with IC50 values of 31juM and 31.5pM respectively.
During the phase 1 clinical trial of Antagonist G, plasma levels of up to 40pM were
achievable with no dose limiting toxicity. Interestingly, 75% of all cancer cell lines
tested had IC50 values near or below this concentration.
Information as to the nature of the growth inhibition by antagonist G can not be gained
from the above liquid growth assays. Although, in the majority of cases, the final cell
number of treated samples was not below the initial plating density, this does not
necessarily mean that antagonist G acts as a cytostatic drug. Cytotoxicity, resulting in
cell death, may also be occurring but the ratio of mitosis versus apoptosis/necrosis may
mask any observable cytotoxic effect. Further experiments are required to determine
the nature of growth inhibition by antagonist G. These experiments will be discussed
next.
3.2 Detection of Apoptosis Induced by Antagonist G
Three methods of detection of apoptotic cells were employed to confirm previous
findings which suggested that substance P analogues could induce apoptosis in SCLC
cells (Reeve and Bleehen, 1994). The H69 cell line was chosen to investigate
antagonist G induced apoptosis.
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3.2.1 Annexin V Binding in H69 Cells
During the early stages of apoptosis, plasma membrane alterations occur which cause
the membrane phospholipid, phosphatidyl-serine, to translocate from the inner to the
outer leaflet of the membrane. Annexin V is a calcium dependent phospholipid binding
protein which can be flourescently conjugated and used as a probe to detect
phosphatidyl-serine by flow cytometry.
The incubation of H69 cells with annexin V was performed at 4°C as there were
concerns that antagonist G may be able to insert into membranes and expose
phosphatidyl-serine in a non-specific manner. By reducing incubation temperature it
was unlikely for this non-specific movement of membrane phospholipids to occur.
It was found that antagonist G dose dependently increased annexin V binding to H69
cells. Antagonist G, at physiologically relevant concentrations, increased basal annexin
V binding by up to 50% of control. Etoposide (25pg/ml) was used as a positive control
and increased annexin V binding by approximately 100% of control. (Fig 3.13).
Phosphatidyl-serine can also be exposed on necrotic cells so in order to confirm the
presence of apoptosis, alternative methods of detection were also employed.
It was unknown whether antagonist G could induce apoptosis in a non-specific manner
by, for example, disrupting membrane integrity, or whether its pro-apoptotic effects
were specific to a certain type of cell. To investigate this question we attempted to
induce apoptosis with Antagonist G in Chinese hamster ovary (CHO) cells, which are
non-cancerous, non-neuroendocrine cells. It was found that antagonist G did not
significantly increase annexin V binding in CHO cells whereas cyclohexamide, a non¬
specific cytotoxic drug, increased annexin V binding by over 150% of control (Fig3.16).
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3.2.2 Caspase 3 Activation in H69 Cells
CPP32, or caspase 3, is an ICE family cysteine protease, which is activated in the early
stages of apoptosis. The ICE proteases initiate cellular breakdown by specific
structural, regulatory and DNA repair proteins and their activation is a marker of
apoptosis. Activation of caspase 3 was investigated in response to antagonist G, in the
H69 cell line, using the ApoAlert™ caspase 3 activation kit. The assay measures the
activation state of caspase 3 in treated and untreated cell lysates by detecting the
cleavage of a caspase 3 substrate Asp-Glu-Val-Asp (DEVD) -pNA. Upon cleavage of
the substrate, pNA is released and can be detected colourimetrically. Background
readings are determined by incubating an induced sample with the caspase inhibitor
DEVD-flouromethylketone (fmk) and subtracting these values from each test sample.
It was found that antagonist G induced caspase 3 activation in a dose dependant fashion
and at 30pM caspase activation was increased by 50% of control levels. Etoposide
(25pg/ml) was again used as a positive control. This concentration produces sub-
maximal pro-apoptotic effects thus making any additive effects with antagonist G
treatment apparent. Interestingly it was found that incubation of H69 cells with
25pg/ml etoposide together with 30pM antagonist G had an additive effect when
compared with either treatment alone (Fig3.14).
3.2.3 Morphological Detection of Apoptosis
Finally, it was decided to confirm the above findings by morphological examination of
H69 cells treated with antagonist G. Cytocenrifuged cells were stained with May-
Grunwuld-Giemsa stain and examined by light microscopy. It was found that
antagonist G induced a dose dependant increase in the presence of the morphological
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characteristics of apoptosis (cell shrinkage and nuclear condensation). Maximal
concentration of cyclohexamide was used as a positive control. (Fig3.15)
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Fig 3.13: Annexin V binding in H69 SCLC cell line (top). Cells were quiesced overnight then treated
with drugs for a further 24 hrs. Antagonist G was used at the concentrations indicated. Etoposide was
used at 25pg/ml. Annexin V binding was assayed as described in materials and methods. Data represents
the mean of three independent experiments performed in triplicate. (* Significantly different from control
P<0.05)
Flow cytometry histograms of annexin V binding in H69 cells (bottom). Antagonist G produces a
dose dependent shift in FL1 detection, which represents increased annexin V binding.
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Fig 3.14) Caspase 3 activation in H69 SCLC cell line. 5x10 s cells were quiesced overnight then treated
with drugs for a further 24 hrs. Antagonist G was used at the concentrations indicated. Etoposide was
used at 25(ig/ml. Caspase 3 activation was assayed as described in materials and methods. Data
represents the mean of three independent experiments performed in triplicate. (* = Significantly different
from control P<0.05)
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Fig 3.15 ) Morphological Detection of Apoptosis in H69 SCLC cell line. Cells were quiesced
overnight then treated with drugs for a further 24 hrs. Antagonist G was used at the concentrations
indicated. Cyclohexamide was used at 100pM. Apoptosis was detected on cytocentrifuged samples as
described in materials and methods. Data represents the mean of three independent experiments
performed in triplicate. (* = Significantly different from control *P<0.05, ** P<0.01)
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Control 30 [jM antagonist G
Fig 3.16. Morphological detection of apoptosis in H69 SCLC cells. H69 cells were treated for 24hrs
with 30(iM Antagonist G. Samples were cytocentrifuged onto glass slides and then stained with May-
Grunwald-Giemsa stain as described in materials and methods. Apoptotic cells (arrows) show cell














Fig 3.17 Annexin V binding in CHO cells. Cells were quiesced overnight then treated with drugs for a
further 24 hrs. Antagonist G was used at 50pM. Cyclohexamide was used at 100pM. Annexin V
binding was detected using flow cytometry as described in materials and methods. Data represents the
mean of three independent experiments performed in triplicate.
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3.3 Investigation into the Metabolism of Antagonist G in Tissue Culture.
The growth inhibition demonstrated by antagonist G was investigated in liquid growth
assays (SITA media) as discussed earlier. It was unclear as to the stability of antagonist
G in SITA over the time course of these experiments. In order to address this question,
various concentrations of antagonist G were incubated in media at 37°C and the levels
of both intact antagonist G and the three main metabolites of antagonist G were
determined by HPLC. It was found that over an initial 4 day period, levels of intact
antagonist G were reduced by an average of 40% and then remained stable for the
remainder of the 16 day time course. This reduction of intact antagonist G was
accompanied by an increase of metabolites 2 and 3 over an initial 7 day period,
however, the increases in metabolites were very small and did not account for the
reduced presence of antagonist G. Levels of metabolite 1 did not alter throughout the
16 day period (Fig3.18)
The sensitivity of individual cell lines to substance P analogues varies from 10p,M-
100pM as discussed earlier in this chapter. To determine whether the differences in
sensitivity was due to the difference in the cell lines ability to metabolise antagonist G,
the ability of the HT29 cell line (IC5o-21.5pM) and the PANC1 cell line (IC50-57[xM) to
metabolise antagonist G were compared. These cell lines were chosen as they
represented two different sensitivities and also because they were adherent cell lines and
therefore easier to wash off non-associated drug. Both cell lines were incubated with
40|iM antagonist G and levels of intact drug in the media were determined by HPLC on
days 4 and 7. There were no significant differences in media levels of antagonist G
between the two cell lines on either day (Fig 3.19).
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It is unclear whether the association of antagonist G with cells was a transient event or
whether the drug remains associated with cells over a longer time course. To determine
the length of time antagonist G could remain associated with cells, the HT29 and
PANC1 cell lines were incubated with the drug for either 24hrs, 4 days or continually
for 7 days. HPLC analysis of cell associated antagonist G was performed on day 7 in
each case. It was found in both cell lines that after both 24hr and 4 day exposures to
antagonist G, significant levels of intact drug was detectable on day 7. However, these
levels were lower than levels found in cells continually exposed to the drug (Fig3.20).
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Fig 3.18 A: HPLC analysis of Antagonist G in cell free SITA media. Four initial concentrations of
Antagonist G (90pM, 30p.M, 15|LM and 7.5pM) in SITA were incubated for 0-16 days at 37°C. Aliquots were
frozen at the indicated time points for HPLC analysis of antagonist G content as described in materials and
methods. Data points represent the means of duplicate samples.
B: HPLC analysis of metabolites 1,2 and 3 in cell free SITA media. 40pM antagonist G in SITA was
incubated as above. At the indicated time points, aliquots were frozen and subsequently analysed by HPLC for
the presence of metabolites 1,2 and 3 as described in materials and methods.
Antagonist G in SITA
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Fig 3.19 HPLC analysis of antagonist G in media containing HT29 or PANC1 Cells. HT29 cells
(sensitive to Antagonist G) and Panel cells (resistant to antagonist G) were incubated with 40pM antagonist G
in SITA on day 0. On day 4 and day 7, media was removed then levels of antagonist G present in the media
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Fig 3.20 HPLC analysis of cell associated antagonist G on day 7 following either a 24hr, 4 day or 7 day
exposure to antagonist G. 40|iM antagonist G in SITA was added to PANC1 cells and HT29 cells on day 0.
Following either 24hr, 4 days or 7 days, samples were washed twice in PBS and fresh media was added. The
drug free cells were left to continue growing until day 7 when all cells were harvested. Cell samples were
washed twice in PBS and then antagonist G content was determined by HPLC as described in materials and
methods. Parallel samples were counted to determine cell number. Data represents the mean of triplicate
samples.
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3.4 Discussion of Results
As discussed, the sensitivity of the tumour cell lines, to antagonist G, differed across the
panel with a range of >1 log order (lOpM - >100pM). These differences strongly
suggest that antagonist G inhibits cell growth by some specific mechanism. If
antagonist G acts as a non-specific cytotoxic or cytostatic compound then the observed
differences in sensitivity between cell lines would be unlikely.
IC50 values for 72% of all cell lines tested were near to or below 40pM, which is
approximately the maximum concentration of antagonist G that can be obtained in
patient plasma, without dose limiting toxicity. Tumour cells may well show different
sensitivity to antagonist G in vivo, however, it is still encouraging that significant
growth inhibition can be observed at physiologically relevant concentrations in vitro.
Antagonist G is in clinical trial as a potential therapy for small cell lung cancer. Based
on these results of this screen, it seems that antagonist G could be used therapeutically
against several other tumour types in addition to SCLC. 4/5 SCLC, 2/3 colo-rectal
carcinoma 1/1 non-SCLC and 1/1 ovarian carcinoma cell lines had IC50 values which
were in the range of physiologically obtainable plasma concentrations.
Growth inhibition assays do not provide information as to the nature of the growth
inhibition. Antagonist G could be acting as a cytostatic drug which does not cause cell
death but prevents cells from undergoing mitosis. Alternatively antagonist G may be a
cytotoxic drug which causes one of two mechanisms of cell death, namely necrosis or
apoptosis. Previous studies have shown that substance P analogues can induce
apoptosis and the pro-apoptotic effects of antagonist G were confirmed using three
methods of detection; annexin V binding, caspase 3 activation and observation of
morphological changes which are characteristic of apoptosis. All methods provided
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evidence that antagonist G induces apoptosis in H69 SCLC cells. Using both annexin V
binding and caspase 3 activation assays, antagonist G dose dependently increased the
frequency of apoptosis and at 30pM, antagonist G induced up to 50% increase of basal
rates. Using morphological detection of apoptosis, the same concentration of antagonist
G increased a basal rate of 7% apoptosis to 14% apoptosis. These antagonist G
induced, pro-apoptotic effects are likely to cause marked changes in the overall growth
rate of tumours. It would be interesting to measure antagonist G induced apoptosis in
tumour samples from xenografts in mice in order to confirm this phenomenon in vivo.
In order to confirm that the apoptotic effects of antagonist G were of a cell specific
nature, the non-cancerous, non-neuroendocrine Chinese hamster ovary cells (CHO-K1)
were incubated with high concentration antagonist G (50p,M). Only a small (7%)
increase in apoptosis was seen following antagonist G treatment whereas, in contrast,
there was a 127% increase in apoptosis seen following incubation with the cytotoxic
drug cyclohexamide (Fig 3.17). This result strongly suggests that the pro-apoptotic
effects of antagonist G are of a specific nature. In addition, unpublished observations
from our laboratory show that antagonist G and D do not induce apoptosis in human
neutrophils. If these drugs activate a non-specific apoptotic pathway then it would be
expected that all cell lines would be sensitive to their pro-apoptotic effects. The lack of
responsiveness of CHO cells and neutrophils to antagonist G is encouraging as many
currently used, cytotoxic cancer therapies induce cell death in an non-selective manner
which results in damage to non-cancer cells.
Using the caspase 3 activation assay, it was observed that the co-incubation of H69 cells
with 30pM antagonist G plus a maximal dose of the cytotoxic drug, etoposide, produced
an additive apoptotic effect which was greater than the effect of either drug alone. This
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is an interesting observation because etoposide is currently a drug of choice for the
treatment of SCLC and this experiment suggests that combined treatment with
antagonist G may increase its effectiveness. Further in vitro studies have since been
carried out in our lab, and have shown that antagonist G has synergistic effects on
growth inhibition and apoptosis, when used along-side several cytotoxic agents (in press
MacKinnon et al, Brit Jnl Cancer, Sept 2000). These findings have important
implications for the clinical scheduling of antagonist G.
Studies have been carried out to investigate the in vivo metabolism of antagonist G.
Metabolism studies in mice bearing the H69 SCLC xenograft showed that metabolism
is restricted almost exclusively to the C-terminal of the peptide producing 4 major
products (Fig 3.21). The major pathway of metabolism was peptidase mediated
catabolism and the minor pathway was the oxidation of the C-terminal methionine
residue. Metabolism was initiated by deamidation to produce metabolite 1 followed by
exopeptidase removal of the C-terminal methionine to yield metabolite 2. Both
metabolite 1 and 2 retain growth inhibitory activity in vitro. Further exopeptidase
metabolism at both the C and N terminals produced metabolites 4 and 4b respectively.
Oxidation of antagonist G produced metabolite 3 (before deamidation) and metabolite
3b (after deamidation) (Cummings et al., 1995).
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H-Arg - DTrp - mePhe - D-Trp - Leu - Met - NH2
3a H-Arg - DTrp - meP
OXIDATIOI PEPTIDASE CATABOLISM
1 H-Arg - DTrp - mePhe - DTrp - Leu - Met - OH
I
3b H-Arg - DTrp - mePhe - DTrp - Leu - Met(O) -OH ► 2 H-Arg - DTrp - mePhe - DTrp - Leu - OH
4b H- DTrp - mePhe - DTrp - Leu - OH 4a H-Arg - DTrp - mePhe - DTrp - OH
Fig 3.21 In vivo metabolism of Antagonist G. Data derived from liver and H69 xenograft homogenates
(Cummings et al., 1995).
All of the tissue culture studies in this chapter were carried out in SITA media. The
stability of antagonist G in this media was unknown so HPLC analysis of the stability of
antagonist G in cell free, SITA tissue culture media was carried out. Over a 16 day
period the levels of both intact antagonist G and its metabolites were monitored.
Interestingly, an average of 40% of the starting concentrations of antagonist G were lost
over the first 4 days and then levels were stable for the remaining time period. Part of
this reduction in antagonist G levels can be explained by metabolism of the compound
as there was a concurrent increase in levels of metabolite 2 and 3. However, the
increased presence of these metabolites does not account for the total reduction in the
intact parent peptide. It may well be the case that the unaccountable portion of the
intact antagonist G was stuck to the plastic surface of the tissue culture vessels and was
therefore not detected when the media samples were analysed. Cummings et al
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(Cummings et al., 1995), performed a similar study to analyse the stability of antagonist
G in HITES medium (hydrocortisone, insulin, transferrin, estradiol and sodium selenite)
and found that the levels of intact peptide were not reduced over a 7 day period. There
is a possibility that the presence of the globular protein albumin, in SITA media could
effect the analysis of antagonist G levels and may account for the findings of this study.
This work has only been carried out in a single study and further work will be necessary
to enable final conclusions to be drawn.
In an attempt to discover whether differences in sensitivity to antagonist G were due to
different rates of metabolism of the drug, HPLC analysis of media and cell associated
antagonist G was carried out for two cell lines; the relatively sensitive HT29 colorectal
cell line and the more resistant PANC1 pancreatic carcinoma cell line. There was very
little difference between the levels of antagonist G present in the media of either cell
line and there were no significant changes in the media levels between day 4 and day 7
in either cell line. This suggests that the rates of metabolism of antagonist G by the
sensitive HT29 cell line and the resistant PANC1 cell line, are similar and that
variations in metabolism rates do not account for the differences in sensitivity between
these two cell lines. As in the above study, this experiment has only been performed
once and will need to be repeated before final conclusions can be made.
A study was performed to asses the association of antagonist G with HT29 and PANC1
cells, following short exposures of 24hrs and 4 days in comparison with continuous
exposure. Cell associated antagonist G was measured following 7 days of cell growth
in each case. In both cell lines it was found that a significant level of intact peptide was
still associated with cells on day 7, following a period of 6 days in drug free media
(24hr exposure) and 3 days in drug free media (4 day exposure). The levels of
131
antagonist G following these shorter exposures were lower than levels found after
continuous exposure, however, it is possible that antagonist G present following shorter
exposures may still exert a growth inhibitory effect. Further experiments are required to
determine the growth inhibitory potential of these various exposure times. These
experiments will have important implications in the scheduling of antagonist G
treatment for clinical use. Results of the phase 1 clinical trial have shown that
antagonist G is rapidly cleared from patient plasma but these preliminary results suggest
that continuous infusion of the drug may not be necessary as the drug can remain
associated with tumour cells for some time after administration.
In this section it has been demonstrated that some cancer cell lines are sensitive to
growth inhibition by antagonist G and other cancer cell lines are not. What cellular




Sensitivity to Growth Inhibition by Antagonist G Correlates with
High Expression of Neuropeptide Receptors.
Substance P analogues are able to antagonise the mitogenic effects of neuropeptide
growth factors. They are capable of blocking calcium mobilisation and mitogenesis
induced by bombesin, bradykinin, cholecystokinin, neurotensin, gastrin, galanin,
endothelin and substance P (Woll and Rozengurt, 1988; Woll and Rozengurt, 1990;
Sethi and Rozengurt, 1991; Sethi and Rozengurt, 1992). These antagonists can also
inhibit the binding of neuropeptides bombesin and vasopressin to their receptors
(Seckl et al., 1995). It is likely that substance P analogues can recognise and bind to
some part of either the neuropeptide receptor or to a protein which can regulate
receptor function such as a G protein. However, it is unclear whether or not their
ability to inhibit cell growth in the absence of exogenous neuropeptides, involves
neuropeptide receptors, or some other mechanism.
In order to address this question a panel of tumour cell lines, representing a spectrum
of sensitivity to Antagonist G, were tested for expression of four neuropeptide
receptors; vasopressin (VIA) receptor, gastrin releasing peptide (GRP) receptor,
bradykinin receptor (BK2) receptor and gastrin receptor. Relative levels of these
receptors were determined by semi-quantitative RT-PCR. This technique was
utilised because of its specific nature and its ability to detect receptors expressed at
very low density. Antibodies against these receptors are not commercially available
so detection by western blotting was not possible. Radio-ligand binding was not
used to avoid excessive use of radioactivity and to keep costs minimal. The aim of
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this work was to attempt to compare sensitivity to antagonist G, with the expression
levels of these receptors.
Detection of mRNA by RT-PCR gives an accurate indication of transcription of a
particular gene but gives no solid information regarding the expression levels of
functional proteins, although a tight correlation between transcription and protein
levels would be expected. Regardless, it was decided to confirm the presence of
functional receptors by measuring the ability of the cells to mobilise intracellular
calcium in response to neuropeptide stimulation. This was carried out for all of the
SCLC cell lines in the panel.
4.1 Detection of Neuropeptide Receptors in a Panel of Tumour Cell Lines
Using semi-quantitative RT-PCR, the levels of GRPR, V1AR, BK2R and Gastrin R
were determined in 9 tumour cell lines (Table 4.1).
Table 4.1 Panel of human tumour cell lines for detection of neuropeptide
receptors











Receptors for vasopressin (V1AR) were detected in 4/4 lung cancer cell lines (3
SCLC and 1 NSCLC). The WX330 SCLC cell line was the highest expresser of
V1AR with approximately three times more mRNA detected than in the other three
lung cancer lines. None of the three colo-rectal cancer cell lines expressed any
detectable VIAR and the pancreatic and ovarian cancer lines expressed very low
levels (Fig 4.1).
Receptors for gastrin releasing peptide (GRPR) were detected in 3/4 lung cancer cell
lines (2 SCLC and 1 NSCLC). Both H69 (SCLC) and NX002 (NSCLC) expressed
high levels of GRPR. 3/3 colo-rectal cell lines expressed GRPR. The HT29 cell line
was the highest expresser, whereas the HCT116 cell line showed a very low level of
GRPR expression. The pancreatic cell line PANC1 had a very low expression level.
The PE04 ovarian cancer cell line was the highest expresser of GRPR in the cell
panel. (Fig 4.2)
Receptors for bradykinin (BK2R) were detected in all cells of the cell panel.
WX330, PANC1 and PE04 had relatively low receptor levels in comparison to the
rest of the panel. Other studies have found an almost ubiquitous expression of
bradykinin receptors in human lung cancers (Bunn et al.,1992a,b). Interestingly the
colo-rectal cell lines were high BK2R expressers. (Fig 4.3) There is no published
data implicating bradykinin as a growth factor for such cell lines and further work to
determine the role of bradykinin in colo-rectal cancer would be interesting.
Gastrin receptors were detected in 4/4 lung lines (3 SCLC and 1 NSCLC) and to a
small degree in the ovarian line PE04. The highest expresser was the SCLC cell line
H510. Interestingly, the colo-rectal cell lines did not express gastrin receptors as
may have been expected, bearing in mind the site of origin of these tumours (Fig
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4.4). This finding is confirmed in a study by Reubi et al who found that the gastrin
receptor was rarely expressed in colo-rectal cancer cell lines (Reubi et al., 1997).
The gastrin receptor is more commonly found in other forms of gastric cancer
(discussed in chapter 1).
136
Relative levels of VIA Receptor mRNA
Fig 4.1 V1AR expression in tumour cell panel.
Fig 4.2 GRPR expression in tumour cell panel.
Receptors were detected by RT-PCR and gels were analysed by densitometry.
Results of this analysis are expressed as a ratio of levels of y-actin for the
same cDNA batch. Data represents the mean of 3-6 separate determinations
from at least three different cDNA synthesis reactions. Below the charts are
representative PCR gels for the respective receptors.
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Relative levels ofBK2 Receptor mRNA
Relative levels ofGastrin Receptor mRNA
3-i
G
H69 H510 WX330 NX002 HT29 HCT116 HRT18 PANC1 PE04
220bp^
Fig 4.3 BK2R expression in tumour cell panel.
Fig 4.4 Gastrin R expression in tumour cell panel.
Receptors were detected by RT-PCR and gels were analysed by densitometry.
Results of this analysis are expressed as a ratio of levels of y-actin for the
same cDNA batch. Data represents the mean of 3-6 separate determinations
from at least three different cDNA synthesis reactions. Below the charts are
representative PCR gels for the respective receptor
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4.2 Mobilisation of Intracellular Calcium in Response to Neuropeptide Ligand
Stimulation to Confirm the Presence of Functional Receptors.
The presence of mRNA for a particular neuropeptide receptor does not necessarily
mean that a functional receptor is present on the surface of the cell. In order to
confirm the presence of functional receptors, high concentrations (lOOnM) of
neuropeptide receptor ligands were tested for their ability to induce the mobilisation
of intracellular calcium in the three SCLC cell lines of the cell panel. The four
neuropeptide receptors analysed by RT-PCR (bombesin/GRP, vasopressin,
bradykinin and gastrin) were tested, in addition to galanin and neurotensin.
It was found that the ability of the cell lines to mobilise intracellular calcium in
response to stimulation with neuropeptide ligands, corresponded with high
expression of mRNA for the respective receptor. Cell lines expressing very low
mRNA levels failed to respond to ligand stimulation. None of the three cell lines
mobilised calcium in response to neurotensin and only the H510 cells line showed
any response to galanin.
In this study it was found, in three SCLC cell lines, that neuropeptide receptor
activation results in mobilisation of intracellular calcium. This phenomenon was
adopted as an indication of the presence of functional receptor protein, however, it is
not clear as to the significance of calcium mobilisation in terms of a mitogenic
response. The colo-rectal carcinoma cell line HT29 has been shown in this study and
in others to express high levels of GRP receptors. Stimulation of this cell line with
GRP results in a proliferative response but not in the mobilisation of intracellular
calcium. This may suggest that, in some cell lines at least, the mobilisation of
calcium is not critical for mitogenisis via neuropeptide receptors and that these cell
139


















































Intracellular Calcium Mobilisation in H69 Cells
Time (Sec)
Fig 4.5. Calcium mobilisation in H69 SCLC cell line. Intracellular calcium mobilisation was
measured as described in materials and methods. Neuropeptides were used at lOOnM and were used
in a random order for each determination. Graph represents the mean increase in intracellular calcium
concentration for 4 independent experiments. The trace below is representative of 4 independent
experiments and shows real time increases in calcium concentration upon exposure to lOOnM of the
indicated neuropeptides.













































Intracellular Calcium Mobilisation in H510 Cells
Time (Sec)
Fig 4.6. Calcium mobilisation in H510 SCLC cell line. Intracellular calcium mobilisation was
measured as described in materials and methods. Neuropeptides were used at lOOnM and were used
in a random order for each determination. Graph represents the mean increase in intracellular calcium
concentration for 4 independent experiments. The trace below is representative of 4 independent






































Intracellular Calcium Mobilisation in WX330 Cells
0 300
Time (Sec)
Fig 4.7. Calcium mobilisation in WX330 SCLC cell line. Intracellular calcium mobilisation was
measured as described in materials and methods. Neuropeptides were used at lOOnM and were used
in a random order for each determination. Graph represents the mean increase in intracellular calcium
concentration for 4 independent experiments. The trace below is representative of 4 independent
experiments and shows real time increases in calcium concentration upon exposure to lOOnM of the
indicated neuropeptides.
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4.3 Comparison of Neuropeptide Receptor Levels and Sensitivity to
Antagonist G
In order to determine whether the presence of a single class of neuropeptide receptor
confers sensitivity to antagonist G, the IC50 values of the tumour cells were
compared with the relative levels of GRPR, VIAR, BK2R or Gastrin R (Fig 4.8).
Comparison of GRPR Level and
Sensitivity to Antagonist G
Spearman R = -0.7
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Fig 4.8 Comparison of IC50 value with expression of neuropeptide receptors. The four graphs
show relative levels of GRPR, V1AR, BK2R or gastrin R plotted against the IC50 value for the
corresponding cell line. Correlation between receptor level and IC50 value was analysed by
Spearman- rank analysis using Prism software. Spearman R values are shown; when R= -1 a perfect
negative correlation can be assumed. The Spearman R value for the GRPR/ IC50 correlation is
significant with a P value of <0.05.
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SCLC Colo -Rectal
H69 H510 WX330 HT29 HRT18 HCT116
GRPR
IC50(|iM) 10.5 29 42 18 37 129
Fig 4.9 Representative PCR gels (inverted images) showing GRPR levels in three SCLC cell
lines and three colo-rectal cancer cell lines. In both groups, high GRPR expression correlates with
low IC50 values for growth inhibition by antagonist G. Conversely, the absence of GRPR expression
correlates with increased resistance to growth inhibition by antagonist G. Cell lines with mid-range
expression of GRPR exhibit mid range sensitivity to antagonist G.
The above comparisons of IC50 value and neuropeptide receptor levels highlight the
importance of neuropeptide receptor expression in dictating the sensitivity of tumour
cell lines to growth inhibition by substance P analogues (Figs 4.8 and 4.9). Analysis
of this correlation by a Spearman-rank test shows that increased sensitivity to
antagonist G significantly correlates with increased GRP receptor expression. It is
worth noting that, although not statistically significant, there is also a correlation
between gastrin and vasopressin receptor expression and sensitivity to antagonist G.
To further explore these issues, the substance P analogue sensitivity of Rat-1
fibroblasts, which do not express GRP receptors, were compared to the sensitivity of
Rat-1 fibroblasts stably transfected with the Bombesin/GRP receptor. These results
will be discussed in the following section.
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4.4 Comparison of Sensitivity to Antagonist G in Rat-1 Fibroblasts with and
without transfected Bombesin Receptor.
The apparent importance of neuropeptide receptor status in order for cell lines to be
sensitive to antagonist G was further tested in Rati fibroblasts. The BOR15 cell line
is a Rat-1 fibroblast clone, stably transfected with the bombesin receptor (amphibian
homologue of the gastrin releasing peptide receptor). This transfected cell line has
been shown to respond normally to bombesin stimulation (Charlesworth et al.,
1996)in terms of signal transduction and stimulation of DNA synthesis. The ability
of bombesin to stimulate calcium mobilisation and DNA synthesis in BOR15 cells
was confirmed prior to experimentation with this cell line (Figs 4.10 and 4.11). The
sensitivity to antagonist G, of the bombesin receptor bearing BOR15 cells were
compared with the bombesin receptor negative parent Rat-1 cells. IC50 values for
growth inhibition by antagonist G were determined as described in materials and
methods. It was found that the parent Rat-1 cells were resistant to antagonist G with
an IC50 value of 135pM whereas the BOR15 cells showed increased sensitivity with
an IC50 value of 44pM on day 7 (Fig 4.14). Rat 1 cell growth was inhibited only by
80fiM antagonist G however some growth occurred at this high concentration. In
contrast, BOR15 cell growth was completely inhibited by 80pM AntG and growth
was also reduced by 40pM AntG. (figs 4.12 and 4.13). This work shows that the
presence of the bombesin receptor leads to increased sensitivity to antagonist G.
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Fig 4.10 Incorporation of [3H]Thymidine in BOR15 cells. Measurement of [3H] thymidine
incorporation was performed as described in materials and methods. BOR15 cells were treated with




Fig 4.11 Calcium mobilisation in BOR15 cells. Measurement of intracellular calcium mobilisation
was carried out as described in materials and methods. BORIS cells were stimulated with lOOnM
bombesin.
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Fig4.12. Proliferation ofRATI cells in liquid culture in the presence or absence of antagonist G.
Rati fibroblasts were incubated in the presence of various concentrations of antagonist G. Cell
number was determined using a coulter counter at the time points indicated.
Graphs are representative of two independent experiments. Data points are means of three samples
counted in triplicate.









Fig4.13 Proliferation of BOR15 cells in liquid culture in the presence or absence of antagonist G.
BOR15 cells were incubated in the presence of various concentrations of antagonist G. Cell number
was determined using a coulter counter at the time points indicated.
Graph is representative of two independent experiments. Data points are means of three samples
counted in triplicate
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Sensitivity of RAT-1 and BOR15
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Fig 4.14 IC50 determinations for growth inhibition by antagonist G in Rat-1 and BOR15 cells.
IC50 values were calculated during the exponential growth phase of each cell line (Day7).
Data represents the means of two independent experiments, performed in triplicate.
The IC50 value for Rat-1 cells is 139pM.
The IC50 value for BOR15 cells is 44pM
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4.5 Stable Transfection of Rat-1 Fibroblasts with V1AR and GRPR.
It was apparent that the presence of the bombesin receptor, in Rat-1 fibroblasts,
conferred sensitivity to growth inhibition to antagonist G. It was decided to attempt
to produce Rat-1 derived cell lines which stably expressed the vasopressin (VIA) or
the GRP receptor. This was carried out in order to determine whether the presence
of VIAR could increase sensitivity to antagonist G and to confirm the results
obtained with the BOR15 cell line, in a Rat-1 derived cell line bearing the GRPR,
rather than the bombesin receptor.
Rat-1 fibroblasts were transfected with cDNA encoding the VIAR as described in
materials and methods. The resulting cultures were grown in the presence of
800|Lig/ml G418 for 1 week and then dishes were trypsinised and cell suspensions
transferred to a 96 well plate at a density of lcell/well in the presence of 800pg/ml
G418. Two weeks later, the resulting clones were split then transferred to 100mm
petri dishes and screened for the ability of lOOnM vasopressin to induce mobilisation
of intracellular calcium. Of 24 clones originally chosen for screening only two
showed any response to vasopressin (Fig 4.15). These cell lines were expanded and
stocks frozen in liquid nitrogen.
The same procedure was carried out in order to create a cell line bearing the GRPR.
Resulting clones were screened for the ability of lOOnM GRP to induce the
mobilisation of intracellular calcium. Of 24 clones originally selected 4/24 cells
responded to GRP stimulation. Calcium mobilisation in clone 14 is shown in figure
4.16. These four cell lines were expanded and stocks frozen in liquid nitrogen.
During this period the four GRP responsive cell lines were screened for their ability
to bind radiolabeled [II25]-GRP as described in materials and methods. All four cell
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lines were positive for [l'25]-GRP binding (Fig 4.15). The GRP6 clone was the most
efficient at binding [I125]-GRP, so this cell line was chosen for further examination.
Calcium mobilisation in response to increasing concentrations of GRP was carried
out. The EC50 for calcium mobilisation by GRP in the GRP6 cell line was 2.1nM
(fig 4.17) which is similar to the EC50 for calcium mobilisation by bombesin in the
BOR15 cell line.
All vasopressin or GRP responsive cell lines were maintained in 400|ig/ml G418
while they were being further characterised. Unfortunately during this period the
cells repeatedly failed to respond to stimulation with GRP or VP in terms of
mobilisation of calcium. It was presumed that, over time, the cell lines had lost the
cDNA for their respective receptors. This can occur for various reasons. The
presence of the cDNA or the receptor protein may confer a negative selective
pressure on the cell population. In this situation the cell line quickly evolves into a
population which does not express the protein in question. Secondly, it is possible
for inserted cDNA to fragment and the cells may reject the sequence coding for the
receptor but retain the sequence coding for resistance to G418. This may explain
why the above cell lines were still able to survive in high concentrations of G418
without expressing the GRP or VIA receptors.
151
Changes in [Ca2+]j (nM)
Rat1+V1AR Clone20


















Fig 4.15 Calcium mobilisation in Rat-1 fibroblasts transfected with the V1AR or the GRPR.
Calcium mobilisation was determined as described in materials and methods. Traces are examples of
the effects of stimulation with lOOnM vasopressin (1st trace) or gastrin releasing peptide (2nd trace) in
Rat-1 fibroblasts stably transfected with V1AR or GRPR, respectively.
Binding of [ l125]-GRP to Rat-1















GRPR6 GRPR12 GRPR14 GRPR17
Fig 4.16 Specific binding of [112:,]-GRP to four Rat-1 derived cell lines, stably transfected with
GRPR. Determination of [I ]-GRP binding was performed in four GRP responsive Rat-1 clones, as
described in materials and methods. All cell lines tested were capable of binding [I125]-GRP. Results
represent a single experiment, performed in triplicate.
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Fig 4.17 Calcium mobilisation in Rat-1 clone GRP6. Calcium mobilisation was determined as
described in materials and methods. GRP6 cells (Rat-1 fibroblasts stably transfected with the GRPR)
were exposed to increasing concentrations of gastrin releasing peptide. EC50 for mobilisation of
calcium by GRP6 cells is 2.1nM.
Data represents single determinations.
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4.6 Discussion of Results.
These experiments have shown that cell lines with high expression of receptors for
GRP, vasopressin or gastrin are more likely to be sensitive to growth inhibition by
antagonist G. Within the SCLC lines of the cell panel, detection of mRNA for a
particular receptor correlated well with the ability to mobilise intracellular calcium in
response to ligand stimulation. This showed that the receptors detected by RT-PCR
were functional.
Bradykinin receptors were expressed by all cell lines tested and expression levels did
not relate to sensitivity to antagonist G. The only statistically significant correlation
was between high expression of the GRPR and increased sensitivity to antagonist G.
GRP and GRPR expression are the hallmark of the neuroendocrine phenotype, thus it
is likely that cell lines with high expression of GRPR represent a more
neuroendocrine-like phenotype than other cell lines.
Unfortunately, due to the nature of semi-quantitative RT-PCR, only levels of a single
receptor type can be compared across the cell panel and therefore the levels of one
receptor can not be accurately compared with another receptor type. Ideally, levels
of total neuropeptide receptors should be compared across the cell panel but this
would require either real-time quantitative RT-PCR or binding studies to determine
numbers of each receptor type. Neither of these techniques were available or
practical during this project.
It was apparent that neuropeptide receptor expression is a pre-requisite for cells that
are sensitive to growth inhibition by antagonist G and to further test this hypothesis,
sensitivity to antagonist G was compared between non-neuropeptide receptor
expressing Rat-1 fibroblasts and Rat-1 fibroblasts stably transfected with the
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bombesin receptor (BOR15 cells). The BOR15 fibroblasts showed increased
sensitivity to growth inhibition by antagonist G with a shift in IC50 from 135pM
(wild type) to 44pM (BOR15). This work shows that in Rat-1 cells the presence of
the bombesin receptor confers increased sensitivity to antagonist G and supports the
hypothesis that cell lines which express bombesin/GRP receptors are susceptible to
the growth inhibitory effects of antagonist G.
It is still unclear as to whether the presence of other neuropeptide receptors such as
the vasopressin receptor, confers increased sensitivity to antagonist G. It was
attempted to create a Rat-1 fibroblast derived cell line expressing the VIA receptor
in order to investigate this question. The resulting cell lines initially expressed the
V1AR but soon became unresponsive to vasopressin stimulation and this experiment
was abandoned. It would be interesting to re-attempt these transfections, perhaps
using different techniques to enable higher initial transfection efficiency and quicker,
more robust screening methods such as FACS analysis.
This work has important implications for the therapeutic use of substance P
analogues. Screening tumour biopsy samples for GRPR or other neuropeptide
receptor expression may provide insight into the likelihood of patients to respond to
treatment with substance P analogues.
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Chapter 5
An Investigation into the Effects of Pre-exposure to
Chemotherapeutic Agents on Sensitivity to Substance P Analogues.
Small cell lung cancer is initially sensitive to chemotherapy and radiotherapy but it
almost invariably relapses and is resistant to further treatment. The two year survival
rate for SCLC patients is less than 5%. Little is known about the responsiveness of
SCLC cells to neuropeptide antagonists when the tumour progresses from
chemotherapy sensitive to chemotherapy resistant. It was of interest to discover
whether tumour cells which were resistant to conventional chemotherapy, which
often are cross-resistant to a variety of treatment, showed any differences in their
sensitivity to substance P analogues.
A useful panel of three cell lines have been developed which have been established
from one patient during longitudinal follow-up (Berendsen et al., 1988). During this
period the tumour changed from sensitive to resistant to chemotherapy and the in
vitro sensitivity to chemotherapeutic agents of the cells reflected the clinical
resistance to treatment (de Vries et al., 1989). These cell lines (GLC14, 16 and 19)
represent an in vitro model in which to study the in vivo development of drug
resistance in SCLC. Another pair of cell lines LS274 and LS310 were established
from a similar clinical follow-up of a single patient, prior to chemotherapy and
following the onset of chemotherapy resistance (provided by J.Plumb, CRC).
In addition to the above panels of cell lines with in vivo derived resistance to
chemotherapy, two other pairs of cell lines (SCLC cell lines GLC4 and H69) were
used in which chemotherapy resistance was derived in vitro to create the cell lines
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GLC4(ADR) and H69(LX4) respectively (Reeve et al., 1989; Zijlstra et al., 1987).
Together these cell lines provide a model for analysis of the effects of pre-exposure
to chemotherapy, on the sensitivity of the cell lines to substance P analogue induced
growth inhibition.
To assess the sensitivity of the above panels of cell lines to antagonist D and G
induced growth inhibition, growth was measured using two assays; measurement of
cell proliferation in liquid culture media (SITA) and measurement of colony
formation in semi-solid media (SITA / agarose).
5.1 Sensitivity of GLC16 and GLC19 SCLC cells to Antagonist G and
Antagonist D.
The GLC14 cell line was derived before treatment, from a supraclavicular lymph
node. After chemotherapy, the patient was in complete remission. After four months
she relapsed, further chemotherapy resulted in a partial response and the GLC16 cell
line was established from a recurrence in the lung. After further therapy, the lung
appeared free from tumour however, three months later the tumour recurred in the
lung, from which the GLC19 cell line was derived, this was resistant to further
treatment and the patient died two months later.
Ideally this work should have been carried out using the GLC14 and 19 cell lines to
compare before and after chemotherapy, however stocks of the GLC14 cell line were
suspected to be contaminated with mycoplasma so the GLC16 and 19 cell lines were
compared as an alternative.
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In the presence of 0-80pM antagonist D or G, proliferation of cells in liquid SITA
media were measured using a coulter counter. Cell number was determined on day
7. The GLC19 cell line showed increased sensitivity to both antagonist D and
antagonist G when compared to the sensitivity of the GLC16 cell line (Fig 5.1). The
IC50 values for growth inhibition by antagonist G for GLC16 and 19 were 38pM and
llpM respectively. The IC50 values for growth inhibition by antagonist D for the
GLC16 and 19 were 39pM and 7.5pM respectively.
In addition to measuring growth inhibition in liquid culture, prevention of cell
growth was measured in semi-solid media containing 0-100p.M antagonists G or D.
This assay measures the ability of single cells to form visible colonies which were
counted 7 days after seeding. Again the GLC19 cell line showed increased
sensitivity to both antagonist D and G with IC50 values for colony inhibition of 2fxM
and 2.6pM respectively. In comparison the IC50 values for colony inhibition in
GLC16 cells, by antagonists D and G, were 18p,M and 33p,M respectively (Fig 5.2)
























Fig 5.1 Proliferation of SCLC cell lines GLC16 and GLC19 in Liquid Culture.
Cells were grown in SITA media in the presence or absence of the indicated concentrations of
antagonist G (top) and antagonist D (bottom). Cell number was determined using a coulter counter
following 7 days of growth. Graphs represent the mean of two independent experiments performed in
triplicate. Curve fitting was carried out using non-linear regression curve fitting in Prism software.
159









-7 -6 -5 -4 -3
Log [Antagonist D]M













Fig 5.2 Proliferation of SCLC cell lines GLC16 and GLC19 in Semi-Solid Media.
Cells were grown in SITA/agarose media in the presence or absence of the indicated concentrations of
antagonist D (top) and antagonist G (bottom). Colony number was determined following 7 days of
growth. Graphs represent the mean of two independent experiments performed in triplicate. Curve
fitting was carried out using non-linear regression curve fitting in Prism software.
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5.2. Sensitivity of LS274 and LS310 SCLC cells to antagonist G and D.
The LS274 and LS310 SCLC cell lines were established from a single SCLC patient,
before and after chemotherapy respectively.
As in the previous panel of cell lines, sensitivity to growth inhibition by substance P
analogues was determined using both liquid growth assays and colony assays in
semi-solid media.
In contrast to the GLC16 and GLC19 cell lines, when the LS274 and LS310 cells
were exposed to antagonist G in liquid culture their growth was inhibited to a similar
degree. The IC50 values for growth inhibition by antagonist G in liquid culture for
the LS274 and LS310 cell were 19pM and 18pM respectively. The dose response
curves for these two cell lines were superimposable. Growth inhibition by antagonist
D also occurred to a similar degree in these two cell lines. The IC50 values for
growth inhibition by antagonist D in liquid culture for the LS274 and LS310 cell
were 7.5pM and 7pM respectively (Fig 5.3). When the inhibition of colony
formation was measured in the LS274 and LS310 cell lines, again both cell lines
were similarly sensitive. The IC50 values for colony inhibition by antagonist G were
7pM for the LS274 cells and 4pM for the LS310 cells. For antagonist D mediated
colony inhibition, the IC50 values were 4.2jxM for the LS274 cell line and 2pM for
the LS310 cell line (Fig 5.4).
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Fig 5.3 Proliferation of SCLC cell lines LS274 and LS310 in Liquid Culture.
Cells were grown in SITA media in the presence or absence of the indicated concentrations of
antagonist D (top) and antagonist G (bottom). Cell number was determined using a coulter counter
following 7 days of growth. Graphs represent the mean of two independent experiments performed in
triplicate. Curve fitting was carried out using non-linear regression curve fitting in Prism software.
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Fig 5.4 Proliferation of LS274 and LS310 SCLC cell lines in semi-solid media.
Cells were grown in SITA/agarose media in the presence of the indicated concentrations of antagonist
D (top) and antagonist G (bottom). Colony number was determined following 7 days of growth.
Graphs represent the mean of two independent experiments performed in triplicate. Curve fitting was
carried out using non-linear regression curve fitting in Prism software.
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5.3 Sensitivity of the SCLC Cell Lines GLC4 and GLC4ADR to Growth
Inhibition by Antagonist G
The GLC 4 cell line was derived from a pleural effusion of a patient with SCLC. It
was characterised as a variant SCLC cell line (Carney et al., 1985). The GLC4ADR
cell line was derived by culturing GLC4 cells in 18nM adriamycin until a resistant
cell line was obtained. The resulting cell line was multi-drug resistant with a 40-fold
increase in IC50 for adriamycin induced growth inhibition (Zijlstra et al., 1987).
The sensitivity of the GLC4 and GLC4ADR cell lines to antagonist G were
compared by liquid growth assay. The IC50 values for the two cell lines were not
significantly different although the GLC4ADR cell line was marginally more
resistant with an IC50 value of 26pM compared to an IC50 value of 18(iM for the
parent cell line (Fig 5.5).
5.4 Sensitivity of the SCLC Cell Lines H69 and H69LX4 to Growth
Inhibition by Antagonist G
The H69 cell line and its multidrug resistant partner, H69LX4 were provided by
P.Twentyman (MRC). The H69LX4 cell line has been show to express the mutidrug
resistance glycoprotein pl80 (Reeve et al., 1989).
The sensitivity of the H69 and H69LX4 cells to antagonist G, were compared by
liquid growth assay. The IC50 value for growth inhibition for the H69 cells was
6pM and the IC50 for the H69LX4 cells was 16|U,M although this difference was not
significant.
164





Log [Antagonist G] M
Fig 5.5. Proliferation of the GLC4 and GLC4ADR SCLC cell lines in liquid culture.
Cells were grown in SITA media in the presence or absence of the indicated concentrations of
antagonist G. Cell number was determined using a coulter counter following 7 days of growth.
Graphs represent the mean of two independent experiments performed in triplicate. Curve fitting was
carried out using non-linear regression curve fitting in Prism software.
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Fig5.6. Proliferation of the H69 and H69LX4 SCLC cell lines in liquid culture.
Cells were grown in SITA media in the presence or absence of the indicated concentrations of
antagonist G. Cell number was determined using a coulter counter following 7 days of growth.
Graphs represent the mean of two independent experiments performed in triplicate. Curve fitting was
carried out using non-linear regression curve fitting in Prism software.
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5.5 Chemotherapy Resistant SCLC Cells with Increased Responsiveness to
Substance P Analogues, also Show Increased Responsiveness to
Bombesin/GRP.
In view of the findings of the previous chapter, which suggested that cell lines that
were sensitive to growth inhibition by antagonist G exhibited increased expression of
Bombesin/GRP receptors, it was decided to compare the responsiveness of the SCLC
cell lines GLC16 and GLC19, to bombesin/GRP.
The mobilisation of intracellular calcium bylOOnM bombesin was used as an
indicator of bombesin responsiveness. The GLC16 cell line showed very little
response to stimulation with supra-maximal concentrations of bombesin with a
change in intracellular calcium levels of <10nM. FCS was used as a positive control
and stimulated the mobilisation of >200nM intracellular calcium, indicating that
defects in the mechanisms of calcium mobilisation did not account for this lack of
responsiveness to bombesin. The GLC19 cell line, which showed increased
sensitivity to growth inhibition by substance P analogues, exhibited a much greater
response to stimulation with lOOnM bombesin. In this cell line, supra-maximal
concentrations of bombesin stimulated the mobilisation of 150nM intracellular
calcium. (Fig 5.7). Other members of our group have shown that the GLC19 cell
line can be stimulated by bombesin, to form colonies in semi-solid media to a
significantly greater degree than the GLC16 cell line (data not shown). The above
data is in accordance with the data presented in chapter 4 and supports the hypothesis
that cell lines which are sensitive to growth inhibition by substance P analogues
show relatively higher expression of GRP/Bombesin receptors.
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Fig 5.7. Calcium Mobilisation in SCLC GLC16 and GLC19 Cells in Response to Stimulation
with Bombesin. Calcium mobilisation was detected as described in materials and methods. SCLC
cells, grown in SITA media, were loaded with the calcium indicator FURA2-AM then exposed to
lOOnM bombesin or 1%FCS as indicated. Traces are representative of three independent experiments.
5.6 Discussion of Results
This work was carried out in order to investigate the effect of pre-exposure to
conventional chemotherapy on the sensitivity of SCLC cell lines to growth inhibition
by substance P analogues. Four pairs of cell lines were used for this study. The
GLC16 cell line was derived from a SCLC recurrence in the lung and its partner, the
GLC19 cell line was derived from the same tumour following the onset of
chemotherapy resistance. The LS274 and LS310 SCLC cell lines were obtained in
similar circumstances with the LS310 cell line being resistant to further
chemotherapy treatment. The GLC4ADR and the H69LX4 SCLC cell lines had been
exposed to chemotherapeutic compounds in vitro in order to create multi-drug
resistant cell lines which were compared to their parent cell lines.
The GLC19 cell line showed increased sensitivity to both antagonist G and D when
compared to the GLC16 cell line. In accordance with data presented in chapter 4, the
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GLC19 cell line showed increased responsiveness to bombesin, as measured by the
mobilisation of intracellular calcium.
The second pair of SCLC cell lines were the LS274 and LS310 cells, the LS310 cells
being a model of in vivo derived chemotherapy resistance. Both of these cell lines
displayed similar sensitivities to both antagonist G and D induced growth inhibition.
There was also no significant correlation between sensitivity to chemotherapy and
sensitivity to substance P analogues in the two pairs of cell lines used as models of in
vitro derived chemotherapy resistance (GLC4/GLC4ADR and H69/H69LX4).
Taken together, these results suggest that cell lines which have been exposed to
conventional chemotherapy and have developed resistance to such treatments, are not
more resistant to growth inhibition by substance P analogues. This implies that
patients bearing tumours with multi-drug resistant phenotypes may be benefited by
treatment with substance P analogues, either as an adjunct to conventional treatments
or during such times when further chemotherapy will have no therapeutic effect.
SCLC growth is sustained by multiple paracrine and autocrine loops involving a
variety of neuropeptide growth factors (Woll and Rozengurt, 1989; Sethi and
Rozengurt, 1992). A plausible extension of this hypothesis is that the clinically
aggressive, drug resistant, SCLC cells that emerge after chemotherapy might have a
more extensive network of neuropeptide regulation and therefore may display
increased sensitivity to neuropeptide antagonists. In support of this theory, the
GLC19 cell line, which displayed increased sensitivity to substance P analogues, also
showed increased responsiveness to bombesin.
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Due to the lack of available cell lines derived from longitudinal follow ups from
single patients, it is difficult to draw conclusions from these observations and it will
be necessary to further investigate this topic in order to clarify the situation.
Chapter 6
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An Investigation into the Agonist Activity of Substance P Analogues
The precise mechanism of action of substance P analogues is more complex than was
previously appreciated. It has been clearly demonstrated that these compounds can
inhibit many neuropeptide stimulated signalling events such as neuropeptide receptor
binding (Woll and Rozengurt, 1988; Bepler et al., 1988), calcium mobilisation (Sethi
and Rozengurt, 1991; Bunn et ah, 1994; Sethi and Rozengurt, 1992), and MAPK
activation (Mitchell et al., 1995; Seckl et al., 1996). The inhibition of these
neuropeptide stimulated events can be reversed by the addition of high
concentrations of neuropeptides which suggests that substance P analogues are
competitive antagonists of neuropeptide signalling (Seckl et al., 1996). It has
recently been hypothesised that substance P analogues induce apoptosis and growth
inhibition via a mechanism which is independent of competitive neuropeptide
antagonism. This is demonstrated by the fact that high concentrations of
neuropeptides are not capable of reversing the pro-apoptotic and growth inhibitory
effects of substance P analogues (MacKinnon et al., 1999). In a study by Bunn et al
it was found that substance P analogues were capable of inhibiting SCLC cell growth
whereas a range of specific neuropeptide antagonists did not inhibit cell growth
(Bunn et al., 1994). This suggests that the mechanism of growth inhibition by
substance P analogues involve some activity distinct from, or in addition to,
competitive neuropeptide antagonism.
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Studies in this lab, and others, have demonstrated that antagonists D and G are
capable of activating c-Jun N-terminal Kinase (JNK) in both SCLC cells and in
fibroblasts and that this is a neuropeptide receptor mediated event (MacKinnon et ah,
1999; Jarpe et ah, 1998). Thus, in addition to acting as classical receptor antagonists,
antagonists G and D are capable of initiating cellular events which are independent
of neuropeptide antagonism. Activation of JNK may play an important role in
stimulating apoptosis in SCLC cells (Xia et ah, 1995) and in this lab it has previously
been shown that antagonist G induced JNK activation is dependant upon the
generation of reactive oxygen species and that antagonist G induced apoptosis is
inhibited by hypoxic conditions (MacKinnon et al., 1999).
Thus, it is apparent that substance P analogues have agonist activities in addition to
classical antagonist activity. In a recent paper by Jarpe et al (Jarpe et ah, 1998), both
bombesin and antagonist D were shown to activate JNK however, calcium
mobilisation was stimulated by bombesin but not antagonist D. This led the authors
to speculate that antagonist D was activating the bombesin receptor but it was
activating some available downstream pathways and not others. Bombesin behaves
as a classical agonist, so the term "biased agonist" was introduced as a way of
explaining the behaviour of antagonist D (Fig 6.1). The biased agonist theory
suggests that antagonist D favours association with R*2 over R*l. This model can
be extended to include as many activation states of the receptor as there are available
G protein-coupling states. The data published by Jarpe et al suggests that antagonist
D may cause neuropeptide receptors to couple to G12 but not to Gq. This hypothesis
is based on the data of other groups who show that JNK activation, via G protein
coupled receptors, can be through activation of G12 family of G proteins (Prasad et
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al., 1995). Jarpe et al also show that antagonist D induces cytoskeletal reorganisation
in Swiss 3T3 cells via a Rho dependant pathway. This pathway has previously been
shown to be via the activation of G12(Buhl et al., 1995).
IA BA
R*7., R , —* R*1 R*9 , R , R*1
Fig 6.1 Biased agonist hypothesis for the activation of receptors by antagonist D A receptor, R,
is capable of spontaneously cycling between two or more active conformational states, here shown as
R*1 and R*2, and one energetically favoured inactive state, R.
R*1 represents the conformation of GRPR that activates Gaq and R*2 represents the conformational
state of the GRPR that activates Gal2 An agonist (A) binds to and stabilises both active states of the
receptor. An antagonist (AA) binds to all three states, competing with the agonist. It may or may not
stabilise the active states. If an antagonist stabilises an active state of the receptor it is termed a partial
agonist. An inverse agonist (IA) binds to and further stabilises the inactive state of the receptor. A
biased agonist (BA) binds preferentially to one of the active states and stabilises it, thus initiating one
set of signal transduction events downstream of the receptor, without activating others.
(adapted from (Jarpe et al., 1998))
Binding of a biased agonist to the receptor inhibits the binding of full agonists so
when bombesin stimulated Gq events such as calcium mobilisation are measured, it
appears that antagonist D is acting as a competitive receptor antagonist. This theory
fits previous experimental data by other groups but so far there is no direct evidence
of this biased agonist activity.
For this reason it was decided to further investigate the agonist activities of
antagonist D in fibroblast models. Firstly, it was necessary to confirm that the
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agonist activity of antagonist D was, indeed, via neuropeptide receptors and not via
another mechanism. It was intended to compare agonist signalling events, such as
the activation of JNK by antagonist D, in the Rat-1 fibroblasts and the BOR15 cell
line (Rat-1 fibroblasts stably expressing the bombesin receptor). The agonist effects
were also investigated in a panel of Balb 3T3 rat fibroblasts which were stably
transfected with either wild type GRPR or with various GRPR mutants. Secondly,
the signal transduction pathways involved in the agonist activity of antagonist D
were compared to those of the full agonist, bombesin. Lastly, the physiological
relevance of the agonist effects of antagonist D were investigated, in terms of the
growth inhibitory effects of this class of compounds.
This work was initiated in order to look at JNK activation by antagonist D, however,
it soon became clear that antagonist D also had profound stimulatory effects on
MAPK signalling. It was decided to focus on the activation of MAPK by antagonist
D in an attempt to fit this phenomenon into the biased agonist theory and to
determine its physiological relevance.
6.1 Antagonist D, Antagonist G and Bombesin activate MAPK
Interestingly, in addition to the activation of JNK, it became apparent that
antagonists G and D were potent activators of MAPK (Fig 6.2). Using SDS-PAGE
and western blotting followed by detection of phosphorylated ERK1 and ERK2, it
was found that relatively low concentrations (10|iM) of antagonists G and D,
produced a potent stimulation of MAPK phosphorylation. This phosphorylation was
comparable to the degree of phosphorylation found with maximal concentrations
(3nM) of bombesin.
CON 10|liM 10|liM 3nM
Ant G Ant D Bn
Fig 6.2. Antagonist G, Antagonist D and Bombesin activate MAPK in BOR15 cells. Confluent,
quiescent cultures of BOR15 cells were incubated with the indicated treatments for 5 minutes.
Samples were prepared as described in materials and methods and proteins were separated using SDS-
PAGE. Western blots were probed with anti-phospho ERK1 and 2 (p44,p42) primary antibody and
then an anti-mouse-EIRP secondary antibody. Proteins were visualised using ECL detection. Blot is
representative of three independent experiments.
6.2 Activation of MAPK by antagonist D in BOR15 cells is via the
Bombesin/GRP Receptor.
It was unclear whether the observed MAPK activation by substance P analogues
occurs via the activation of neuropeptide receptors, or by some other mechanism. To
address this question, the extent of MAPK activation by antagonist D was analysed
in the bombesin receptor expressing, BOR15 cell line, and compared to MAPK
activation in the parent Rat-1 fibroblasts.
Firstly, the expression of bombesin receptors and other neuropeptide receptors were
analysed in these two cell lines. By detecting the mobilisation of intracellular
calcium in response to bombesin and other neuropeptides, the neuropeptide receptor
status of these cell lines could be determined. This served the purpose of confirming
the presence of the bombesin receptor in the BOR15 cells and also determining
which other neuropeptide receptors may be present on the cell lines (Fig 6.2). Using
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high concentrations of a range of neuropeptides (lOOnM) it was found that the Rati
cells had no large responses to any neuropeptide tested. There was a small but
reproducible response to lOOnM bradykinin in these cells. The BOR15 cells
responded to stimulation with lOOnM bombesin and showed an increase in
intracellular calcium concentration of 400nM. As in the BOR15 cells, the Rat-1 cells
responded to no other neuropeptide tested, other than with a small response to
bradykinin.
This lack of neuropeptide receptors in the Rat-1 cells was confirmed by testing the
ability of a range of neuropeptides (lOOnM) to induce the phosphorylation of ERK1
and ERK2 (Fig 6.4). In accordance with the above data, only bradykinin and FCS
stimulated any significant increase in MAPK phosphorylation. These data show that,
apart from low levels of bradykinin receptor, the Rat-1 fibroblast cell line does not
normally express any of the tested neuropeptide receptors and that transfection of the
bombesin receptor into these cells creates a cell line that is able to respond to
stimulation with bombesin.
Secondly, the extent of MAPK activation by antagonist D and bombesin was
compared between the Rat-1 fibroblasts and BOR15 cells. This work was carried out
using a kinase assay which measures the ability of immuno-precipitated p42ERK2,
33
to phosphorylate myelin basic protein in the presence of radio-labelled [ P]ATP.
This method of measuring MAPK activation is quantitative and allowed direct
comparisons of MAPK activity between the two cell lines. The cells were treated
with increasing concentrations of either antagonist D or bombesin and the activation
state of ERK2 was determined (Fig 6.5). It was found that bombesin stimulated a
dose dependant increase in MAPK activity in the bombesin receptor expressing
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B0R15 cells (EC50 0.59 +/- 0.18nM) but not in the parent Rat-1 cell line. Antagonist
D stimulated a dose dependant increase in MAPK activity in both cell lines however,
this activity was much greater in the bombesin receptor expressing BOR15 cells
(EC50 4.19 +/- 0.6pM) than in the Rat-1 cells (EC50 22.5 +/- 2.6(iM). This data
suggested that the presence of the bombesin receptor potentiates MAPK activation
by antagonist D.
To confirm this observation, MAPK activity and phosphorylation were measured, in
the presence or absence of the specific bombesin antagonist RC3940-II
(Hca6,Leu13\|/[CH2N]Tac14-BN(6-ll)) (Koppan et al., 1998). It was found that lpM
RC3940-II inhibited MAPK activity and phosphorylation by both antagonist D and
bombesin (Fig 6.6). This data confirms that MAPK activation by antagonist D is at
least partly via the bombesin receptor in BOR15 cells.
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Fig 6.3. Calcium mobilisation in Rat-1 and BOR15 cells in response to stimulation with
neuropeptides. Calcium mobilisation was detected as described in materials and methods.
Confluent, quiesced cultures of Rat-1 or BOR15 cells were loaded with the calcium indicator FURA2-
AM then exposed to the indicated neuropeptides. Neuropeptides were used at lOOnM. 1% FCS was
used as a positive control. Results are representative of three independent experiments.
P44
P42
Con Bb GRP NT BK Gal Gas CCK VP FCS
Fig 6.4. Phosphorylation of ERK1 and ERK2 in RATI cells in response to stimulation with
neuropeptides. Confluent, quiescent cultures of BOR15 cells were incubated with the indicated
treatments (lOOnM neuropeptides or 1%FCS) for 5 minutes. Samples were prepared as described in
materials and methods and proteins were separated using SDS-PAGE. Western blots were probed
with anti-phospho ERK1 and ERK2 (p44,p42) primary antibody and then an anti-mouse-HRP
secondary antibody. Proteins were visualised using ECL detection. Blot is representative of three
independent experiments.
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Fig 6.5. ERK2 activity stimulated by bombesin or antagonist D in Rat-1 fibroblasts and BOR15
cells. MAPK activity was assessed as described in materials and methods. Bombesin stimulates a
dose dependant increase in MAPK activity in the BOR15 cells but not in Rat-1 cells (top). Antagonist
D stimulates a dose dependant increase in MAPK activity in both cell lines but this increase is
potentiated in the BOR15 cells (bottom). Data represents the means of 3-4 independent experiments,
each performed in duplicate.
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Fig 6.6. ERK2 Activity in BOR15 cell is attenuated by the bombesin receptor antagonist
RC3940-II. MAPK activity was determined as described in materials and methods. Confluent,
quiescent cultures of BOR15 cells were incubated for 5 minutes with the indicated concentrations of
antagonist D or bombesin, with or without lpM RC3940-II. The increase in ERK2 activity seen with
antagonist D and bombesin was markedly attenuated in the presence of RC3904-II. (top). Data
represents the means of 3 independent experiments.
Representative western blot probed with anti-phospho ERK1 /ERK2 antibody, showing inhibition of
antagonist D and bombesin stimulated MAPK phosphorylation in the presence of RC3940-II.
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6.2.1 MAPK activation by antagonist D is inhibited in balb3T3 fibroblasts
expressing mutant GRP receptors.
In order to confirm that the MAPK activation by antagonist D is via bombesin / GRP
receptors, MAPK activation by antagonist D was measured in two, balb3T3
fibroblast derived, cell lines. The 5ET4 cell line was provided stably transfected
with the wild type mouse GRP receptor. The R288H cell line was provided stably
transfected with a mutated mouse GRP receptor. The mutations in the cDNA
encoding the R288H GRP receptor were created by site-directed mutagenisis.
Amino acid residues in the wild type GRP receptor were swapped for corresponding
residues from the bombesin receptor subtype-3 (BRS-3) which has low affinity for
bombesin. The resulting receptor has a 1000 fold reduction in bombesin affinity and
a 100 fold reduction in bombesin stimulated inositol phosphate hydrolysis (Akeson et
al., 1997). The neuropeptide receptor status of the parent balb3T3 cell line was
determined by measuring the phosphorylation of ERK1 and ERK2 in response to
high concentrations of various neuropeptides (lOOnM). It was found that there was
no large responses to any neuropeptide tested but lOOnM bombesin, GRP and
galanin produced small increases in MAPK phosphorylation (Fig 6.7). It may well
be the case that using such high concentrations of agonist produced non-specific
effects.
ERK2 activity was compared in the 5ET4 GRPR expressing cell line and the R288H,
mutant GRPR expressing cell line. It was found that in the 5ET4 cells, antagonist D
produced a dose dependant increase in ERK2 activity whereas in the R288H cells
antagonist D was unable to produce a response (Fig 6.8). Antagonist D induced
phosphorylation of ERK1 and ERK2 was also measured in these two cell lines (Fig
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6.9). Again in the 5ET4 cells, antagonist D produced a dose dependant increase in
ERK1 and ERK2 phosphorylation whereas in the R288H cell line there was no
increased phosphorylation except with 60pM antagonist D. There is a slight
inconsistency between the results of the kinase (ERK2 activation) assay and the
phospho ERK1 and ERK2 detection. At 60pM, antagonist D did not cause any
ERK2 activation in the R288H cells, as measured by the kinase assay, but did
produce an increase in ERK1 and ERK2 phosphorylation as measured by western
blotting. In any case, both experiments show that there is no dose dependant
increase in MAPK activation by antagonist D in cells expressing mutant GRPR but
there is a dose dependant increase in MAPK activation in cells expressing wild type
GRPR.
These experiments confirm findings in the previous section and lend support to the
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Fig 6.7 MAPK phosphorylation in balb3T3 cells, phosphorylated ERK1 (p44) and ERK2 (p42)
were detected as described in materials and methods. Confluent, quiescent cultures of balb3T3 cells
were exposed to either lOOnM of the indicated neuropeptides, 1%FCS or lOpM LPA for 5 min at
37°C. The balb3T3 cells were slightly responsive to lOOnM bombesin, GRP and galanin. FCS and
LPA were included as positive controls and both stimulated the phosphorylation of ERK1 and ERK2.
Blot is representative of three independent experiments.
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Fig 6.8 ERK2 activity in 5ET4 cells and R288H cells. ERK2 activity was measured as described
in materials and methods. Confluent, quiescent cultures of 5ET4 cells (balb3T3 cells expressing wild
type GRPR) or R288H cells (balb3T3 cells expressing mutant GRPR) were exposed to increasing
concentrations of antagonist D (l-60pM) for 5 min at 37°C. Antagonist D stimulated a dose
dependant increase in ERK1 and ERK2 phosphorylation in the 5ET4 cells. The R288H cells were
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Fig 6.9 MAPK phosphorylation in 5ET4 and R288H cells. Phosphorylated ERK1 (p44) and
ERK2 (p42) were detected as described in materials and methods. Confluent, quiescent cultures of
5ET4 cells (balb3T3 cells expressing wild type GRPR) or R288H cells (balb3T3 cells expressing
mutant GRPR) were exposed to increasing concentrations of antagonist D (0.3-60|iM) or 3nM
bombesin for 5 min at 37°C. The 5ET4 cells were responsive to bombesin and antagonist D
stimulated a dose dependant increase in ERK1 and ERK2 phosphorylation. The R288H cells were
unable to respond to bombesin and antagonist D did not cause phosphorylation of ERK1 and ERK2
except at 60pM. Blots are representative of three independent experiments.
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6.3 Antagonist D activates MAPK in the absence of calcium mobilisation and
can inhibit bombesin stimulated calcium mobilisation in BOR15 cells.
It is apparent that both bombesin and antagonist D activate MAPK via the bombesin
receptor. It is accepted that bombesin can activate MAPK via the mobilisation of
intracellular calcium and the activation of PKC (Zugaza et al., 1997; Herget and
Rozengurt, 1994) but it was unclear whether antagonist D utilised the same
mechanism. The ability of both bombesin and antagonist D, to stimulate the
mobilisation of intracellular calcium, was assessed in the BOR15 cells using the
previously described method. Bombesin (lOnM) stimulated an increase of
intracellular calcium concentration of ~400nM whereas high concentrations (30pM)
of antagonist D failed to elicit a response. (Fig 6.10).
The inhibition of neuropeptide stimulated calcium mobilisation by substance P
analogues, has been well characterised in both SCLC cells and in swiss3T3
fibroblasts (see introduction for review). In order to confirm that antagonist D was
capable of inhibiting calcium mobilisation in BOR15 cells, dose response curves for
calcium mobilisation by bombesin in the presence or absence of antagonist D were
carried out (Fig 6.11). Bombesin stimulated a dose dependant increase in calcium
mobilisation (EC50 1.5nM) which was inhibited by 30pM antagonist D (EC50
10.4nM). These results show that antagonist D activates MAPK via a non-calcium
dependant pathway and can inhibit calcium mobilisation stimulated by bombesin.
Changes in [Ca2+]i in B0R15

























Fig 6.10 Bombesin but not antagonist D stimulates mobilisation of intracellular calcium in
BOR15 cells.
Measurement of intracellular calcium was carried out as described in materials and methods. 30|xM
antagonist D does not stimulate mobilisation of calcium. Bombesin stimulated an increase of
~400nM. Data is representative of three independent experiments.
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Fig 6.11 Antagonist D inhibits bombesin induced calcium mobilisation in BOR15 cells. Calcium
mobilisation was carried out as described in materials and methods. Cell suspensions were treated
with increasing concentrations of bombesin in the presence or absence of 30p.M antagonist D. Data
represents the mean of three independent experiments.
Below are representative calcium traces showing real time calcium mobilisation in response to lOnM
bombesin (left) and lOnM bombesin in the presence of 30pM antagonist D (right).
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6.4 Antagonist D does not activate MAPK via a PKC dependant pathway.
It has previously been established that, in some cell lines bombesin activates MAPK
via a calcium mediated, PKC dependant pathway (Zugaza et al., 1997; Herget and
Rozengurt, 1994). The above data show that the activation of MAPK by both
bombesin and antagonist D is via signalling from the GRPR but that MAPK
activation by antagonist D is independent of intracellular calcium mobilisation. To
investigate the involvement of PKC in antagonist D and bombesin induced MAPK
activation in BOR15 cells, the PKC antagonist GF109203-X was used. This
antagonist is a bisindolyalemide which acts as a competitive inhibitor of ATP
binding and is specific against PKC (Toullec et al., 1991). GF109203-X treatment
alone, increased basal MAPK phosphorylation. This may have masked some of the
potential inhibitory effects against antagonist D or bombesin stimulated MAPK
phosphorylation. It appeared that GF109203-X only partially inhibited the
phosphorylation of ERK1 and ERK2 by bombesin but had no effect upon the
phosphorylation induced by antagonist D (Fig 6.12). These results suggest that while
bombesin stimulated MAPK activity may be partially dependent upon PKC
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Fig 6.12 Antagonist D activates MAPK via a PKC independent pathway. SDS PAGE and
western blotting was carried out as described in materials and methods. Confluent, quiescent cultures
of BOR15 cells were incubated for 5 min at 37°C, with either 30gM antagonist D or 3nM bombesin in
the presence (*) or absence of 5pM GF109203-X. Blot is probed with anti-phospho ERK1 and ERK2
primary antibody and an anti-mouse HRP secondary antibody. Blot is representative of three
independent experiments.
6.5 Bombesin and antagonist D both activate MAPK via the bombesin receptor
but via differential activation of G-proteins.
Bombesin stimulation of phospholipase C (PLC) which leads to calcium
mobilisation, PKC activation and MAPK activation has been previously shown to be
via the Gq family of G-proteins (Offermans et ah, 1994; Wang et ah, 1996; Piiper et
ah, 1997). The above data shows that antagonist D, unlike bombesin, activates
MAPK via a mechanism that is independent of intracellular calcium mobilisation.
Antagonist D induced MAPK activation is also independent of PKC whereas
bombesin stimulated MAPK activation may be partially dependent upon PKC
activation in BOR15 cells. It was likely therefore, that antagonist D stimulates a
pathway downstream of the bombesin receptor that does not involve the Gq family of
G-proteins. Several reports have shown that MAPK activation by G-protein coupled
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receptors can be via Gi family of G-proteins and this stimulation of MAPK does not
involve either calcium flux or PKC activation (Faure et ah, 1994; Mochizuki et ah,
1999). It has also been shown that the bombesin receptor is capable of coupling to
Gi G-proteins, in addition to Gq G-proteins (Profrock et ah, 1992; Letterio et al.,
1986). Hence, it was decided to determine whether MAPK activation by antagonist
D was sensitive to treatment with pertussis toxin, a bacterial toxin which inhibits the
activation of Gi/0 G-proteins by ADP ribosylation of the a subunits. Using ERK2
activity and ERK1 and ERK2 phosphorylation, as indicators of GRPR activation by
bombesin and antagonist D, it was attempted to block receptor signalling by
stimulating BOR15 cells in the presence or absence of lOOng/ml of pertussis toxin
(activated by incubation with an equal volume of lOOmM DDT at room temperature
for lhr). It was found that antagonist D stimulated MAPK phosphorylation and
activity were attenuated in the presence of pertussis toxin whereas the effects of
bombesin were not significantly affected (Figs 6.13 and 6.14).
This work shows that antagonist D-induced MAPK activation occurs partially via G-
proteins of the Gi/0 subtype.
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Con Con 3D 3D 10D 10D 30D 30D LPA LPA
PTX PTX PTX PTX PTX
Fig 6.13 ERK1 and ERK2 phosphorylation by antagonist D is inhibited by pertussis toxin.
SDS PAGE and western blotting was carried out as described in materials and methods. Confluent,
quiescent cultures of BOR15 cells were pre-incubated for 18hrs with lOOng/ml activated pertussis
toxin (PTX) then PTX treated or untreated cells were incubated for 5 min at 37°C, with either
indicated concentrations of antagonist D or lOpM LPA. Blot is probed with anti-phospho ERK1 and
ERK2 primary antibody and an anti-mouse HRP secondary antibody. Blot is representative of three
independent experiments.
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Fig 6.14 ERK2 activation by antagonist D is inhibited by pertussis toxin. ERK2 activation was
measured as described in materials and methods. Confluent quiescent cultures of BOR15 cells were
pre-treated for 18hrs with lOOng/ml activated PTX. PTX treated and untreated cells were incubated
for 5 minutes at 37°C with either 50nM bombesin or 50pM antagonist D. Data is the mean of three
independent experiments performed in duplicate. (* AntD + PTX treated group is significantly
different from Ant D treated group, P<0.05)
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6.6 MAPK activation by bombesin and antagonist D involves differential
activation of tyrosine kinases.
In addition to PKC/calcium mediated MAPK activation, the MAPK cascade can also
be activated via pathways involving various tyrosine kinases. MAPK activation by
both pertussis toxin sensitive and pertussis toxin insensitive G proteins has been
shown to utilise the tyrosine kinase Src. This Src activation is thought to be
mediated by G protein (3/y subunits and does not involve the activation of PKC or the
mobilisation of intracellular calcium (Igishi and Gutkind, 1998; Delia Rocca et al.,
1999b). The activation of Src family tyrosine kinases can be downstream of several
pathways but seems to follow the recruitment of Ras-GTP exchange factors to the
membrane in most cases. The recruitment of Ras is dependent upon the formation of
a Ras activation complex, which consists of tyrosine phosphorylated adapter proteins
such as She and Gabl and involves the recruitment of Grb-2 and Sos. It has been
proposed that GPCR mediated activation of the MAPK cascade by Ras is catalysed
by either transactivation of tyrosine kinase receptors such as the EGF receptor to
provide a scaffold for Src interaction with the Ras activation complex, or by the
activation of focal adhesion components such as FAK which then mediate Src
interaction with the Ras activation complex. The preferred scaffold seems to be
determined by cellular context in which the receptor in question is expressed (Delia
Rocca et al., 1999b).
With this in mind it was decided to investigate the involvement of Src kinases, Ras
and the tyrosine kinase EGF receptor in MAPK activation by antagonist D and
bombesin in the BOR15 cells. Using the prazolopyramidine Src kinase inhibitor
PP2, it was attempted to inhibit the activation of MAPK by both antagonist D and
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bombesin. Figure 6.15 shows that bombesin stimulated MAPK phosphorylation is
blocked by pre-treatment with 5pM PP2. Antagonist D stimulated MAPK
phosphorylation was also inhibited by PP2, indicating that both compounds stimulate
MAPK activity using pathways involving Src family tyrosine kinases.
Src activation can be involved in MAPK activation via both receptor tyrosine kinase
scaffolds and focal adhesion scaffolds. As both bombesin and antagonist D
activation of MAPK appeared to be dependant upon the activation of Src kinases it
was of interest to determine whether both compounds used Src kinases in the same
signalling context. It has been shown that Bombesin can stimulate the activation of
FAK but it has not been demonstrated that MAPK activation stimulated by bombesin
is mediated via this focal adhesion event (Seufferlein et ah, 1996b). Thus, MAPK
activation by bombesin may be regulated by another tyrosine kinase pathway. The
role of receptor tyrosine kinases were a likely starting point for investigation.
BOR15 cells were treated with the EGF receptor specific tyrosine kinase inhibitor
AG1478 prior to incubation with either antagonist D or bombesin. It was found that
MAPK activation by bombesin but not antagonist D was inhibited by AG1478 (Fig
6.16). This suggests that the MAPK activation by bombesin involves transactivation
of the EGFR whereas MAPK activation by antagonist D employs some other
mechanism involving Src kinase activation.
The activation of Ras follows the activation of Src kinase by GPCRs. It has
previously been shown that stimulation of BOR15 cells with bombesin results in the
activation of Ras and activates MAPK via Ras mediated Raf activation
(Charlesworth and Rozengurt, 1997). In order to determine whether antagonist D
utilised Ras in order to activate MAPK, ERK2 activity was measured in the presence
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or absence of the ras antagonist, S-farnesylthiosiacyclic acid (FTS), which prevents
Ras membrane association and the subsequent activation of Raf-1 and MAPK (Gana-
Weisz et al., 1997). As expected, it was found that 50p.M FTS inhibited ERK2
activation by both bombesin and antagonist D (Fig 6.17) indicating that both activate
the MEK/MAPK cascade via Ras in BOR15 cells.
Further studies to confirm these findings were carried out using a GST fusion protein
containing the ras binding domain of c-raf in order to pull out activated Ras from cell
lysates (see materials and methods). Unfortunately, these experiments were
inconclusive due to problems which were encountered with anti-pan-Ras and anti-H-
Ras antibodies (data not shown).
These results suggest that although both bombesin and antagonist D stimulate MAPK
activation via the GRP/bombesin receptor, both compounds differentially utilise
tyrosine kinase scaffolds in order to activate Src and Ras, upstream of MAPK
activation. These findings support previous data which show that antagonist D and
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Fig 6.15 ERK1 and ERK2 phosphorylation by antagonist D and bombesin involves Src family
kinases. SDS PAGE and western blotting was carried out as described in materials and methods.
Confluent, quiescent cultures of BOR15 cells were pre-incubated for 20min with the Src inhibitor
PP2. PP2 treated or untreated cells were incubated for 5 min at 37°C, with either 3 or 30|iM
antagonist D or 3nM bombesin. Blot is probed with anti-phospho ERK1 and ERK2 primary antibody
and an anti-mouse HRP secondary antibody. Blot is representative of three independent experiments.
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Fig 6.16 ERK2 activity in BOR 15 cells. ERK2 activity was measured as described in materials and
methods. Untreated or AG1478 (5pM) treated confluent quiesced cultures of BOR15 cells were
treated with 30pM antagonist D or 3nM bombesin. Results are representative of three independent
experiments performed in duplicate.
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Fig 6.17 ERK2 activity in BOR 15 cells. ERK2 activity was measured as described in materials and
methods. Untreated or FTS treated (for 18hrs) confluent quiesced cultures of BOR15 cells were
treated with 10pM antagonist D or InM bombesin. Results are representative of three independent
experiments performed in triplicate.
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6.7 Antagonist D does not alter the expression of cell cycle inhibitors P27KIPand
P21waf via sustained activation ofMAPK.
So far it has been established that antagonist D is a potent stimulator of MAPK. This
MAPK activation is via stimulation of Gi dependant pathways downstream of the
bombesin receptor. It was of importance to investigate the relevance of this MAPK
activation in terms of the mechanism of growth inhibition by antagonist D. Several
publications have highlighted the fact that inappropriate activation of the Ras/MAPK
pathway in SCLC cells can result in the upregulation of cell cycle inhibitors (Ravi et
al., 1998; Ravi et al., 1999) and that sustained activation of the Ras/MAPK signalling
cascade can have adverse effects on cell growth in several other cell types (Pumiglia
and Decker, 1997). In light of these findings a time course of MAPK
phosphorylation by both antagonist D and bombesin was carried out in order to
highlight any differences in MAPK activation kinetics by these two compounds.
Ravi et al show that in SCLC cells activation of MAPK by constituitively active Ras
protein results in the upregulation of various cell cycle inhibitor protein levels
including P27K" and P21WAF. Using BOR15 cells, stimulated with antagonist D over
a 4hr time course, the levels of P27kip and P21WAF were analysed by SDS PAGE and
western blotting.
The time course of MAPK phosphorylation by antagonist D and bombesin were very
similar over the four hour period (Fig 6.18). In addition, there were no apparent
differences in the levels of the p27KIP cell cycle inhibitor (Fig 6.19) or the p21WAF
cell cycle inhibitor (data not shown) during this time period. These results indicate
that in BOR15 cells antagonist D does not influence cell growth via transcriptional
regulation of P27K" and P21WAF resulting from sustained activation of MAPK.
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Fig 6.18 Timecourse of MAPK phosphorylation by Antagonist D and Bombesin. Confluent,
quiesced cultures of BOR15 cells were exposed to either 30pM antagonist D (top) or 3nM bombesin
(bottom). SDS PAGE and western blotting was carried out as described in materials and methods.
Blot is probed with anti-phospho ERK1 and ERK2 primary antibody and an anti-mouse HRP
secondary antibody. Blot is representative of three independent experiments.
Antagonist D Does Not Increase p27(Kip) Expression
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Fig 6.19 Antagonist D does not increase expression of P27KI1 in BOR15 cells.
Confluent, quiesced cultures of BOR15 cells were exposed to 30pM antagonist D over a four hour
time course. SDS PAGE and western blotting was carried out as described in materials and methods.
Blot is probed for P27(KIP). Blot is representative of three independent experiments
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6.8 MAPK activation by antagonist D is integral in its pro-apoptotic effects.
It has been shown that antagonist D can stimulate apoptosis in SCLC cells (see
chapter 3). To investigate the involvement of MAPK activation by substance P
analogues it was decided to look at the effects of blocking MAPK activation on the
ability of these compounds to induce apoptosis. Using annexin V binding as an
indicator of apoptosis, the pro-apoptotic effects of antagonist D in BOR15 cells was
investigated in the presence or absence of the MEK inhibitor PD098059. It was
found that antagonist D stimulated apoptosis in BOR15 cells and the apoptosis was
partially inhibited by PD098059. This experiment shows that the activation of the
MAPK cascade by antagonist D, is somehow related to its ability to induce
apoptosis. Our group have also shown that PD098059 inhibits antagonist D and G
induced apoptosis in the SCLC cell line, H69 (data not shown). As the time course
of MAPK activation by antagonist D and bombesin are similar, it is most probably
the cellular context of other signalling events that change the activation of MAPK
from a proliferative signal into an inhibitory signal. The antagonist D induced,
activation of JNK and the inhibition of calcium flux, are likely candidates that alter
the normal cellular context of MAPK activity.
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Fig 6.20 MEK inhibitor PD098059 inhibits antagonist D induced apoptosis. Annexin binding
was carried out as described in materials and methods. Confluent, quiescent cultures of BOR15 cells
were incubated for 30min with lOpM PD098059 then either PD098059 treated or untreated cells were
incubated for 24hrs with the indicated concentrations of antagonist D. Data represents the mean of
two independent experiments performed in triplicate.
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6.9 Discussion of Results.
The data presented in this chapter show that antagonist D and G both activate MAPK
in SCLC and Rat-1 fibroblasts. The activation of MAPK in Rat-1 fibroblasts is
potentiated by the presence of the bombesin/GRP receptor indicating that antagonist
D can activate these receptors. Some antagonist D induced MAPK activation
occurred in the parent Rat-1 cell line. This is likely to be due to the broad-spectrum
activity of antagonist D upon the bradykinin receptor which is present in this cell
line. Rat-1 cells have been shown to express relatively high levels of endothelin
receptors (Ambar and Sokolovsky, 1993; Cadwallader et al., 1997). Substance P
analogues are able to inhibit binding of endothelin to its receptor and also block
calcium mobilisation via endothelin receptors (Fabregat and Rozengurt, 1990) so it is
possible that some of the MAPK activation by antagonist D is via activity at these
receptors. The MAPK activation via the GRP receptor is sensitive to partial
inhibition by the specific bombesin antagonist RC3940-II. Again, the lack of
complete inhibition of MAPK activation may be due to some of the total MAPK
activity being stimulated via other receptor types or via another mechanism. Further
experiments in our group have shown that the MAPK activation by antagonist D is
also sensitive to inhibition by another specific bombesin antagonist
[Leu'V(CH2NF[)-Leu14]-Bombesin (data not shown). Conformation of the
hypothesis that antagonist D activates MAPK via the GRPR, is provided by the fact
that MAPK activation by antagonist D occurs in balb3T3 fibroblasts stably
transfected with the human GRP receptor and this activation is markedly attenuated
in balb3T3 cells transfected with the human GRP receptor with a mutated ligand
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binding site. This cell line bearing the GRP receptor with a mutant ligand binding
site is also unable to respond to bombesin.
As discussed previously, bombesin acts upon the bombesin/GRP receptor resulting in
MAPK activation via the activation of Gq family of G-proteins, stimulating PLC
mediated mobilisation of intracellular calcium and the activation of PKC. This work
has shown that antagonist D activates the same receptor as bombesin but initiates a
different signalling cascade resulting in MAPK activation, which does not involve
the mobilisation of calcium or the activation of PKC. Antagonist D, unlike
bombesin, stimulates the activation of the Gi/0 family of G-proteins as determined by
the sensitivity of antagonist D induced MAPK activation to pertussis toxin treatment.
It is likely that the G-protein involved is Gi and not GO as the bombesin receptor has
been shown to functionally couple to Gi (Profrock et ah, 1992; Letterio et ah, 1986).
It is thought that this Gi stimulated MAPK activation is via Gi (3/y subunits and may
involve the activation of p21 Ras (Koch et ah, 1994).
In accordance with experimental data in this chapter, the activation of MAPK via Gi
has been shown to be independent of PKC activation. Activation of MAPK via Gq
has been shown in many cases to be PKC dependent (Hawes et ah, 1995). This
current work has shown that, in Rat-1 cells, MAPK activation by bombesin is, at
most, partially dependent upon PKC as the phosphorylation of ERK1 and ERK2 was
only slightly inhibited by the PKC inhibitor GF109203X. It has previously been
shown that bombesin stimulation of MAPK in Rat-1 cells, is independent of PKC
activation (Charlesworth and Rozengurt, 1997) whereas in swiss3T3 cells bombesin
stimulated MAPK activation is PKC dependent (Seufferlein and Rozengurt, 1996a).
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The investigation into the involvement of p21 Ras in the MAPK activation by
antagonist D and bombesin showed that MAPK activity was inhibited in both cases,
by the Ras antagonist FTS. It has previously been demonstrated that bombesin
stimulates the GTP-loading of p21 Ras in BOR15 cells (Charlesworth and
Rozengurt, 1997), however in swiss3T3 cells bombesin stimulation of MAPK is
completely dependent upon PKC and independent of Ras activation (Seufferlein et
al., 1996b; Mitchell et al., 1995). These findings stress the importance of cell context
when defining the signal transduction pathways which activate MAPK and indicate
that the involvement of PKC and Ras in signal transduction pathways is very much
determined by cell type and not completely by the nature of the agonist.
The ras dependent activation of MAPK by GPCRs appear to involve a scaffold
which provide docking sites whereby ras can interact with other proteins of the ras
activation complex, mSOS and Grb2 (Luttrell et al., 1997; Delia Rocca et al., 1999a).
These sites have been shown to be provided by both integrin-based focal adhesion
complexes and receptor tyrosine kinases, again, depending on cell type. It appears
that Src family of non-receptor tyrosine kinases present a point of convergence for
signals originating from either scaffold. The data presented in this chapter shows
that MAPK activation by both bombesin and antagonist D is partially inhibited by
the Src kinase inhibitor PP2.
It has been proposed that MAPK activation via Gq coupled receptors occurs by the
activation of one or both, tyrosine kinase independent pathways (PKC mediated) and
the activation of receptor tyrosine kinases such as the EGF receptor (Delia Rocca et
al., 1999a). In the present study, MAPK activation by bombesin was inhibited by the
EGF receptor specific, tyrosine kinase antagonist, AG1478. Delia Roca et al propose
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that Gi mediated MAPK activation can be dependant upon the formation of focal
adhesions as a scaffold for MAPK activation. It has been show that in several cell
types, bombesin can activate FAK (Rodriguez-Fernandez and Rozengurt, 1998;
Salazar and Rozengurt, 1999) but that the activation of MAPK by bombesin is not
dependant upon this event (Luttrell et al., 1999). It can therefore be suggested that,
in BOR15 cells, antagonist D may stimulate Gi mediated MAPK activation via a
focal adhesion scaffold whereas bombesin stimulated MAPK activation involves the
Gq mediated transactivation of the EGF receptor scaffold and in addition, the
activation of a non-receptor tyrosine kinase pathway involving calcium mobilisation
and the activation of PKC. Both Gi and Gq mediated tyrosine kinase pathways
involve the activation of Src and result in the activation of Ras.
It is therefore apparent that the signal transduction pathways which are stimulated by
antagonist D are mostly in accordance with the biased agonist mechanism of action
proposed by Jarpe et al. Antagonist D activates Gi mediated signalling pathways in
favour of the Gq mediated pathways which are stimulated by bombesin. However,
according to the biased agonist theory, the full agonist bombesin should activate all
available, receptor-G-protein coupling states. Although bombesin stimulated MAPK
activation in BOR15 cells is independent of Gi, there are several publications which
suggest that mitogenic signalling and DNA synthesis by bombesin partly involve Gi
family of G-proteins. It has been shown that pertussis toxin inhibits bombesin
stimulation of DNA synthesis in Swiss 3T3 cells, but does not effect the mobilisation
of intracellular calcium or the activation of PLC (Zachary et al., 1987). However
there is contradictory evidence which suggests that Gi does not play a major role in
transducing mitogenic signals from the bombesin receptor (Taylor et al., 1988). It
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has been proposed that a pertussis toxin sensitive G-protein may mediate cross talk
between transmembrane signalling pathways in response to bombesin stimulation
(Rozengurt et al., 1990). It is apparent that the role of Gi in mitogenic signalling by
bombesin deserves more focused attention in future studies.
Similar examples of receptor promiscuity of G-protein coupling leading to activation
of multiple second messenger pathways have been described before where both or
just one of these can be blocked by an inverse agonist (Perez et al., 1996). However
antagonist D is the first compound shown to be capable of simultaneously activating
and inactivating different arms of the signal transduction pathways normally
activated by an agonist.
It has recently been shown by our group that JNK activation by antagonist D is via
the G12 family of G-proteins. JNK activation by antagonist D in COS7 cells is
inhibited by the transient transfection of dominant negative G12 (unpublished results
from our laboratory). Thus the mechanistic model for antagonist D can be extended
to include the activation of both Gi and G12 and the inhibition of Gq receptor
coupling.
The physiological relevance of the signalling events triggered by antagonist D was
investigated. In a recent paper it was shown that the stimulation of the endothelin
receptor with endothelin-1 in Rat-1 cells results in the activation of both MAPK and
JNK. It was demonstrated that the inhibition of either PKC activation or intracellular
calcium mobilisation results in potentiated and sustained activation of JNK by
endothelin (Cadwallader et al., 1997). These findings may be applicable to the
mechanism of JNK activation by antagonist D. Stimulation of the bombesin receptor
with bombesin results in the mobilisation of calcium, the activation of PKC and the
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activation of JNK. Antagonist D stimulation of the bombesin receptor results in the
inhibition of calcium mobilisation and PKC and the sustained activation of JNK.
Thus, by inhibiting the mobilisation of intracellular calcium, antagonist D may cause
discordant activation of other pathways downstream of the receptor.
Several studies have shown that in SCLC cells and some fibroblasts, activation of
elements of the MAPK signalling pathway can produce a growth inhibitory effect
(Ravi et al., 1998; Ravi et ah, 1999; Serrano et ah, 1997). SCLC cells very rarely
have oncogenic Ras mutations and the authors show that in SCLC cells, constitutive
or sustained activation of proliferation signals involving Ras, activates dormant
tumour suppressor pathways involving upregulation of cell cycle inhibitor proteins
including P161NK' P27KIPand P21WAF. With these findings in mind, a time course of
MAPK activation by antagonist D and bombesin was carried out to determine
whether antagonist D induced MAPK activation was sustained in comparison to
bombesin induced MAPK activation. It was found that both time courses were
similar which indicated that sustained MAPK activation was not responsible for the
growth inhibitory effects of antagonist D. Antagonist D induced upregulation of
P27K1Pand P21WAF was also investigated over the same time period. No changes in
protein levels were detected following antagonist D treatment. It would be of
interest to repeat these experiments in SCLC cells as it is possible that the activation
of Ras signalling pathways in SCLC cells will have different consequences than
those observed in Rat-1 fibroblasts.
Both the activation of MAPK and JNK are likely to be important in the growth
inhibitory effects of substance P analogues. There has been considerable research
implicating JNK in the onset of apoptosis in a variety of cell types including SCLC
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(Butterfield et al., 1997), see (Chen and Tan, 2000; Leppa and Bohmann, 1999) for
review. Our group have shown that the JNK activation by antagonist D is sustained
in comparison with the JNK activation by bombesin (Mackinnon et al., 2000) and
this may be pivotal in the pro-apoptotic effects of this class of compound. In the
current study, it has been shown that the activation of MAPK is also partially
required for the pro-apoptotic effects of antagonist D. The dose dependant increase
in antagonist D induced apoptosis, in BOR15 cells, is partially inhibited by the MEK
inhibitor PD098059. Our group has also shown this to be the case in the SCLC cell
line H69 (data not shown).
In summary, it is likely that the combined effects of sustained JNK activation and the
discordant activation of MAPK, alongside the inhibition of neuropeptide stimulated
calcium mobilisation, produce a growth inhibitory / pro-apoptotic effect (Fig 6.21). It
can be hypothesised that cells presenting a neuroendocrine phenotype are sensitive to
the biased agonist activation of signalling pathways by antagonist D and are thus




Fig6.21 Proposed model for the modulation of signal transduction pathways by antagonist D in
comparison to bombesin. Both antagonist D and bombesin activate the GRP/bombesin receptor.
Bombesin stimulates the activation of Gq mediated signal transduction pathways whereas antagonist
D inhibits the activation of Gq mediated pathways. These bombesin stimulated pathways result in the
mobilisation of intracellular calcium and the activation of PKC and in addition, bombesin stimulates
the trans-activation of the EGFR, the activation of Src and Ras, all of which are upstream of the
activation of MAPK. Antagonist D also activates MAPK kinase but rather than via Gq mediated
signals, it stimulates the activation of Gi. Upstream of MAPK activation by antagonist D is the
activation of Src and Ras. This is via a tyrosine kinase scaffold other than the EGFR and may involve
focal adhesions or another receptor tyrosine kinase. Both antagonist D and bombesin stimulate the
activation of JNK, most likely via the activation of G12 G proteins and possibly involving the small
GTP binding Rho (further experiments in progress in our lab). However, the JNK activation by
antagonist D is of greater magnitude and duration than the activation by bombesin.
Taken together it is likely that the differential activation of G proteins coupled to the GRPR, results in
discordant activation of MAPK and JNK and the inhibition of calcium mobilisation. This shift from
the normal signalling of the full agonist bombesin results in growth inhibition or apoptosis.
Chapter 7
General Discussion and Suggestions for Future Work
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This project was designed to address several issues that can be loosely divided into
two categories - pre-clinical studies and mechanistic studies. The pre-clinical
studies investigated the range of tumour types which are sensitive to growth
inhibition by substance P analogues, looked for the expression of neuropeptide
receptors which may confer sensitivity and addressed the question of whether
resistance to conventional chemotherapy alters the effectiveness of treatment with
substance P analogues. The mechanistic studies focussed on the nature of the
interaction of substance P analogues with cells and explored the effects that these
compounds have on signal transduction pathways. These studies also addressed the
physiological relevance of the observed cellular effects, in terms of growth inhibition
and apoptosis.
A panel of tumour cell lines of various origins was used to investigate the range of
sensitivity to antagonist G. It was found that in addition to SCLC cell lines, a non-
SCLC cell line, two colo-rectal cancer cell lines and an ovarian cell line were
sensitive to growth inhibition by pharmacologically achievable concentrations of
antagonist G (<40pM). Several cell lines in the cell panel (a colo-rectal cancer cell
line, a pancreatic cancer cell line and a SCLC cell line) showed marked resistance to
growth inhibition by antagonist G which indicated that this compound acts via some
specific mechanism rather than non-specifically disrupting cell growth. RT-PCR
studies on the tumour cell panel, and experiments using GRPR/bombesin receptor
bearing fibroblast models, showed that high expression of the gastrin releasing
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peptide receptor confers increased sensitivity to antagonist G. Other tumour types
such as breast cancer (Halmos et al., 1995) and prostate cancer (Bologna et al., 1989;
Aprikian et al., 1996) have also been shown to express GRP receptors. It would be
of interest to test the sensitivity of cell lines from other GRP receptor expressing
tumours to fully explore the range of cancers which may be treatable with substance
P analogues. The presence of the GRP receptor may be a reflection of the general
neuroendocrine phenotype of the cancer cells or it may be the case that the
interaction of substance P analogues with the GRPR initiates a growth inhibitory
signal which does not occur upon interaction with other neuropeptide receptors.
These findings have important implications for the clinical use of substance P
analogues. Antagonist G is currently entering a phase two clinical trial where its
effectiveness will be tested in SCLC patients, but ultimately, compounds of this type
may also be suitable for the treatment of other tumour types. Detecting expression of
the GRP receptor from biopsy samples may be a useful indicator to identify patients
for whom such treatment may be effective, therefore, it is important to further clarify
this situation. It would be of interest to re-attempt the transfection of Rat-1
fibroblasts with other neuropeptide receptors such as the vasopressin receptor and
look for effects on sensitivity to substance P analogues. In addition to using a Rat-1
fibroblast model, these findings should be confirmed using GRP receptor non-
expressing neuroendocrine cancer cell lines as recipients for the transfection of GPR
receptors. Also, anti-sense molecules could be designed to knock out the GRP
receptor on a cell line which naturally expresses high levels of GRP-R in an attempt
to create a more resistant cell line. In addition to this work, it would be useful to
confirm the correlation between sensitivity to antagonist G and GRP receptor
209
expression in murine xenograft models. Several of the cell lines used in this study
are already available in our lab as xenografts so this investigation would be feasible.
The final question which was investigated as part of the pre-clinical aspect of this
project, was whether or not cell lines which had been exposed to conventional
chemotherapy and subsequently developed resistance to these treatments, displayed
any differences in sensitivity to substance P analogues. This work was initiated in
order to help define the clinical setting of these compounds. Should they be used in
addition to standard chemotherapy or would they be more effective when used after
tumours have relapsed and cells are resistant to currently available treatments? A
panel containing pairs of SCLC cell lines derived before and after the onset of
chemotherapy resistance were tested for sensitivity to antagonist G. A major
drawback in this work was the unavailability of paired cell lines which had been
created before and after exposure to chemotherapy in vivo. As a result two of the
four pairs of cell lines used, were models of in vitro derived resistance. It is not
known whether the mechanisms of drug resistance derived in vitro, accurately
represent chemotherapy resistance as it occurs in an in vivo tumour environment.
The results of this work did not confirm the hypothesis which suggested that tumours
which are resistant to chemotherapy display increased neuropeptide responsiveness
and increased sensitivity to substance P analogues, however, this theory did hold true
in one of the two in vivo derived resistance models. None of the chemotherapy
resistant cell lines tested showed increased resistance to antagonist G or D. This
finding is encouraging as many chemotherapy resistant cell lines show cross
resistance to multiple treatments. It is therefore likely that tumours which show
resistance to conventional therapies may be treatable with substance P analogues.
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Access to more cell lines from longitudinal patient follow ups would allow further
work to be carried out on this matter. It would also be of interest to create in vivo
derived chemotherapy resistant cell lines in murine xenograft models. These cell
lines would be more representative of the situation found in cancer patients. Finally,
it is not known whether prolonged treatment with substance P analogues will result
in the development of resistance to these compounds. It would be of interest to try
and derive resistance to substance P analogues, and attempt to identify any resistance
mechanisms involved. Techniques which analyse differences in RNA species
between two cell lines (differential display) could be employed to detect changes
between the parent cell line and the resistance cell line. It is unknown whether
substance P analogues are substrates for the pi80 membrane pump which is
responsible for much of the multi-drug resistant (MDR) phenotypes which are
common in SCLC tumours. Further work in this area would be useful.
The second part of this project involved studies in order to increase the
understanding of the mechanism of action of substance P analogues. Several lines of
evidence had shown that substance P analogues may not simply act as a competitive
neuropeptide antagonists and that in addition to blocking neuropeptide signalling,
antagonists D and G had agonist effects which resulted in the activation of c-Jun-N-
terminal Kinase (JNK) (MacKinnon et ah, 1999). The pre-clinical studies had
highlighted the GRP/bombesin receptor as candidate factor in the mechanism of
growth inhibition and for this reason it was decided to investigate the nature of the
interaction of antagonist D with GRP/bombesin receptor expressing fibroblast
models. Studies were initiated to investigate the agonist effects of substance P
analogues. It was discovered that both peptides were potent activators of MAPK and
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it was decided to focus on this novel observation. It was unclear whether the
activation of MAPK was receptor mediated or via some other mechanism and the
signal transduction pathways involved were unknown. It was found that the
activation of MAPK by antagonist D was indeed, via the GRP/bombesin receptor as
shown by increased MAPK activity in the bombesin receptor expressing BOR15
cells compared to the parent cell line, the inhibition of this MAPK activity by
specific bombesin antagonists and the inability of antagonist D to activate MAPK in
fibroblasts expressing GRP receptors with mutated ligand binding sites.
Investigations into the signal transduction pathways employed by both bombesin and
antagonist D showed that bombesin stimulated the mobilisation of intracellular
calcium whereas antagonist D did not. In fact antagonist D inhibited calcium
mobilisation by bombesin. Bombesin activation of MAPK was shown to be via a
pathway which involves the transactivation of the EGF receptor and the activation of
Ras and Src. Subsequent studies showed that the activation of MAPK by antagonist
D, also involves the activation of Ras and Src but not the transactivation of the EGF
receptor. Further experiments to determine how antagonist D stimulates MAPK
should be carried out. The use of agents such as cytochalasin D, which prevent
activation of tyrosine kinases via focal adhesions by disrupting the actin
cytoskeleton, may be useful in determining whether or not MAPK activation occurs
via focal adhesion associated proteins. Also immuno-precipitation of tyrosine
phosphorylated proteins and subsequent probing for transactivated receptor tyrosine
kinases may be necessary to find out if antagonist D induced MAPK activation
involves a receptor tyrosine kinase scaffold other than the EGF receptor.
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MAPK activation by antagonist D was shown to be via a pertussis toxin sensitive G
protein, most likely of the Gi class. This contrasted with the natural receptor agonist,
bombesin, which activates MAPK via the Gq family of G proteins. It was apparent,
therefore, that antagonist D and bombesin both activate different signal transduction
pathways from the same receptor by the differential activation of G-proteins. Our
group has also shown that antagonist D and G activate JNK via the G12 family of G
proteins and that this JNK activation is of greater magnitude and duration that JNK
activation by bombesin. It is likely that this discordant activation of MAPK and JNK
and the inhibition of Gq mediated signals, such as the mobilisation of calcium, is
responsible for the growth inhibitory effects of substance P analogues. Further work
to characterise the differential signalling by neuropeptides and substance P analogues
is now necessary, to determine which of several aspects are integral in the growth
inhibitory / pro-apoptotic effects of this family of peptides. In this study it is shown
that inhibition of antagonist D induced MAPK activation results in a reduction in the
ability of antagonist D to induce apoptosis. It is of great interest to determine the
exact mechanism by which this activation of MAPK creates an inhibitory signal. Is
it dependent upon the concurrent activation of JNK and/or the inhibition of
intracellular calcium? Experiments using dominant negative JNK expression to
block JNK activation or constituitively active Gq to prevent the inhibition of calcium
mobilisation, could be carried out to further investigate this issue.
It is not clear as to whether these receptor effects are unique to the GRP receptor
(which would explain the correlation between sensitivity to antagonist G and GRP
receptor expression) or whether substance P analogues have the same "biased
agonist" activity at other neuropeptide receptors. There is evidence to suggest that
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the signal transduction pathways downstream of the GRP/bombesin receptor may be
slightly different than those stimulated by other neuropeptide growth factor
receptors. In order for SCLC cells to proliferate in response to neuropeptide growth
factors they require stimulation with an additional growth factor such as insulin.
Bombesin/GRP differs in this respect in that it is the only neuropeptide that can act
as a sole mitogen for SCLC cells. It may be useful to further explore these ideas if it
is shown that the mechanism of growth inhibition by substance P analogues is solely
dependent upon their biased agonist effects on the GRP/bombesin receptor.
Interestingly, it has been shown that antagonist D has highest affinity for the
GRP/bombesin receptor whereas antagonist G has higher affinity for the vasopressin
receptor and in terms of growth inhibition and pro-apoptotic effects, antagonist D is
more potent than antagonist G. It would be interesting to compare the growth
inhibitory potency of the complete range of substance P analogues with their affinity
for the GRP/bombesin receptor. It is of vital importance to this line of drug
development to answer these questions, as it may be the case that the broad spectrum
activity of substance P analogues is not as important as their relative affinity to the
GRP/bombesin receptor. This will undoubtedly influence future drug design.
The current study has highlighted the fact that the mechanism of action of substance
P analogues is more complex than was previously appreciated. The novel
mechanism of "biased agonism" resulting in differential activation of signal
transduction pathways, is worthy of further characterisation and it must be
determined whether this aspect of receptor pharmacology can be exploited by other
types of compound.
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The potential clinical setting for substance P analogues needs to be defined. The
current range of substance P analogues may not be an immediate clinical success due
to their relatively low potency (pM range) and high cost of production, however the
ongoing drug development programme to search for more potent analogues may find
more hopeful candidate compounds. Further research to pinpoint the exact
mechanism of action by which substance P analogues inhibit the growth of cancer
cells will allow drug structure / function relationships to be investigated, perhaps
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